Biodegradable oligomers and polymers for oligonucleotide and gene delivery

Biodegradable cationic polymers with tunable properties address the limitations of existing non-viral vectors by enabling efficient and targeted nucleic acid delivery, enhancing the safety and efficacy of gene therapy.

WO2024233985A1PCT designated stage expired Publication Date: 2024-11-14N1 LIFE INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028990
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-10
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current non-viral gene vectors for nucleic acid delivery face challenges such as cytotoxicity, immune responses, and lack of organ targeting specificity due to high molecular weight and non-degradable bonds, limiting their clinical application.

Method used

Development of cationic biodegradable polymers with tunable molecular weight and hydrophobicity, composed of specific repeating units, which form complexes with nucleic acids for targeted and safe delivery.

Benefits of technology

The polymers enable efficient, biocompatible, and targeted delivery of nucleic acids with reduced cytotoxicity and immune responses, improving the efficacy and safety of gene therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024028990_14112024_PF_FP_ABST
    Figure US2024028990_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed herein are a series of biodegradable polymeric materials, synthesis method thereof, and use thereof in gene delivery. The polymeric materials described herein allow for highly effective complexation, protection, intracellular and target delivery and release of biological molecules such as oligonucleotides and nucleic acids in cells, tissues and organs both in vitro and in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Ref.28767-20004.40 BIODEGRADABLE OLIGOMERS AND POLYMERS FOR OLIGONUCLEOTIDE AND GENE DELIVERY CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority benefit of United States Provisional Patent Application No.63 / 501,613, filed May 11, 2023, the content of which is incorporated herein by reference in their entirety. REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0002] The content of the electronic sequence listing (287672000440seqlist.xml; Size: 2,834 bytes; and Date of Creation: May 7, 2024) is incorporated herein by reference in its entirety. FIELD

[0003] The present disclosure in some aspects relates generally to compositions for delivery of a biological molecule (e.g., oligonucleotide or nucleic acid) and method for such a delivery. The present disclosure in some aspects relates generally to a series of cationic and biodegradable polymeric materials, synthesis method thereof, and use thereof in gene delivery. These polymers have tunable molecular weight, water solubility, polydispersity, and hydrophobicity which enables highly effective protection and target delivery and release of biological molecules (e.g., oligonucleotides, nucleic acids, or a mixture of gene cargos) in tissues and organs both in vitro and in vivo. BACKGROUND

[0004] Nucleic acid-based gene therapy is a rapidly growing field with great potential for the treatment of persistent and fatal diseases such as cancer and genetic disorders. The success of gene therapy depends on the successful delivery of nucleic acids to target cells, a process that is typically hampered by renal clearance, phagocytosis, enzymatic degradation, protein uptake, and cellular internalization. Naked nucleic acids are considered as foreign genetic materials when introduced into the body and are rapidly cleared by the reticuloendothelial system or degraded by nucleases, rarely reaching the site of action. Therefore, gene vectors are needed to load nucleic acid molecules, deliver them into target cells, tissues, or organs, and express them successfully. 1ny-2728093Attorney Ref.28767-20004.40

[0005] Gene vector materials can usually be divided into two categories, viral vectors and non-viral vectors, each with its own advantages and disadvantages. Viral vectors have the advantages of high transfection efficiency, but their disadvantages such as high immunogenicity, high oncogenic risk and low gene loading capacity seriously limit their applications and developments in the pharmaceutical field. Based on this, non-viral gene vectors are gradually gaining attention and development. Compared with viral vectors, non- viral vectors have many advantages, such as significant improvements in efficacy and safety, reduced pathogenicity, reduced insertional mutagenicity, and easy large-scale preparation.

[0006] Commonly used non-viral gene vectors include cationic lipids and cationic polymers, which are capable of binding negatively charged nucleic acids through electrostatic interactions and can deliver nucleic acid molecules into target cells with relatively high delivery efficiency. However, cationic liposomes carry a large number of positive charges on their surface and interact electrostatically with negatively charged polysaccharide protein complexes on the cell surface or in the blood, which often leads to adverse effects such as cell membrane toxicity and limits their clinical applications. In terms of cationic polymers, promising cationic polymers such as poly(ethyleneimine) (pEI), poly(2-dimethylaminoethyl methacrylate) (pDMAEMA), and poly-L-lysine (pLL) have been more studied for their efficient gene delivery and good transfection properties in vitro and in vivo. These cationic polymers are mixed with nucleic acids to form nanocomplexes, which are usually more stable than lipid complexes formed from cationic lipids. However, these cationic polymers with high molecular weight and non-degradable bonds may accumulate in normal cells, which could induce cytotoxicity and immune responses, and thus limiting their clinical usage. Furthermore, these cationic polymers are lack of organ targeting specificity with respect to gene delivery.

[0007] Therefore, there is an unmet need in the field to develop novel polymeric transporters that not only have the advantages of biocompatibility, low cytotoxicity, and high transfection efficiency, but also require a convenient, effective, and safe preparation process, and can achieve more targeted delivery of the nucleic acid. SUMMARY

[0008] In one aspect, provided herein is a cationic polymer comprising n unit(s) of a first repeating unit of Formula (Ia) and m unit(s) of a second repeating unit of Formula (IIa): 2ny-2728093Attorney Ref.28767-20004.40or a salt thereof, wherein L1, L2, L3, L4, L5, L6, L7 and L8 are each independently -O-, -NH-, optionally substituted C1-C12alkylene, optionally substituted C2-C12alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H, optionally substituted C1-C12 alkyl, or a protecting group; R6is optionally substituted C3-C20alkyl or optionally substituted C3-C20alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end-capped by at least one capping group selected from the group consisting of optionally substituted C3-C18alkyl, optionally substituted C3-C18alkenyl and a peptide.

[0009] In some embodiments, R6is C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle.

[0010] In one aspect, provided herein is a cationic polymer comprising n unit(s) of a first repeating unit of Formula (I) and m unit(s) of a second repeating unit of Formula (II): 3ny-2728093Attorney Ref.28767-20004.40wherein L1, L2, L3, L4, L5, L6, L7 and L8 are each independently -O-, -NH-, optionally substituted C1-C12alkylene, optionally substituted C2-C12alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or optionally substituted C1-C12 alkyl; R6is C3-C18alkyl or C3-C18alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end-capped by at least one capping groups selected from the group consisting of C3-C18 alkyl, C3-C18alkenyl and a peptide.

[0011] In some embodiments, L1-L8 are each independently C1-C12 alkylene, C2-C12 alkenylene, C2-C12alkynylene, C3-C6cycloalkylene, 3 to 8 membered heterocyclylene, C6- C12 arylene, or 5 to 10 membered heteroarylene, each of which are independently and optionally substituted by C1-C6alkyl, halo, OH, or NH2. In some embodiments, L1-L8are each independently C1-C12 alkylene. In some embodiments, L1-L8 are ethylene. In some embodiments, L9is a bond. In some embodiments, L9is -C(O)O-, -O-, -S-, -NH-, -C(O)NH-, 4ny-2728093Attorney Ref.28767-20004.40 -NHC(O)-, -S(O)2-, -S(O)NH-, -NHC(O)NH-, C1-C18 alkylene optionally interrupted by one or more -O-, 3 to 12 membered heterocyclylene, or a peptide, wherein the C1-C18alkylene and 3 to 12 membered heterocyclylene are optionally substituted by one or more C1-C6 alkyl, halo, OH, or NH2. In some embodiments, L9is C1-C6alkylene, C2-C6PEGylated linker, or a peptide linker. In some embodiments, L9 is propylene. In some embodiments, R5is H, -ORa, - COORa, or NRaRb, wherein Raand Rbare each independently H or C1-C12alkyl optionally substituted by one or more halo, OH, or NH2. In some embodiments, R5is NRaRb. In some embodiments, Raand Rbare H. In some embodiments, R5is H. In some embodiments, one, two, or three of R1, R2, R3, and R4are each independently C1-C12 alkyl, C2-C12 alkenyl, or C2- C12alkynyl, each of which are independently and optionally substituted by one or more halo, OH, or NH2. In some embodiments, R1, R2, R3, and R4are H. In some embodiments, R6is C9- C18alkyl or C9-C18alkenyl (e.g., C12-C18alkyl or C12-C18alkenyl). In some embodiments, R6is C9-C18 alkyl (e.g., C12-C18 alkyl). In some embodiments, R6is dodecyl. In some embodiments, n is an integer from 1 to 100. In some embodiments, m is an integer from 1 to 100. In some embodiments, the ratio of n to m is in a range of 10:1 to 1:10. In some embodiments, m is 0 or n is 0, and the cationic polymer is a homopolymer; or m is an integer from 1 to 50 (e.g., 1 to 20), n is an integer from 1 to 50 (e.g., 1 to 20), and the cationic polymer is a block copolymer, or a random copolymer.

[0012] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18 alkyl, C3-C18 alkenyl or a peptide;5ny-2728093Attorney Ref.28767-20004.40are each independently H, optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide; provided that,optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; and when EG1is SRC, thenleast one of RCand RFis optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide.

[0013] In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3- C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O-(C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH- (C1-C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle.

[0014] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18 alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or 6ny-2728093Attorney Ref.28767-20004.40and RD, RE, and RFare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl.

[0015] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18 alkyl, C3-C18 alkenyl or a peptide;H, C3-C18 alkyl, C3-C18 alkenyl or a peptide; provided that, 7ny-2728093Attorney Ref.28767-20004.40alkyl, C3-C18alkenyl, or a peptide; and when EG1is SRC, thenleast one of RCand RFis C3-C18 alkyl, C3-C18 alkenyl, or a peptide.

[0016] In some embodiments, the cationic polymer comprises a structural unit of Formula (A)(A), wherein n is an integer from 1 to 500; m is an integer from 1 to 500; and wherein each of the n unit(s) of the first repeating unit and each of the m unit(s) of the second repeating unit are connected in a random sequence; and wherein the first repeating unit and the second repeating unit are as defined in claim 1.

[0017] In some embodiments, the cationic polymer is a polymer of Formula (A-1)(A-1) wherein RAis H or C12H25; RBis C12H25; RDis H or C12H25; and REis C12H25. In some embodiments, RAis H; RBis C12H25; RDis H; and REis C12H25. In some embodiments, the first repeating unit is of Formula (I-1) and the second repeating unit is of Formula (II-1),8ny-2728093Attorney Ref.28767-20004.40wherein L9, R5, and R6are as defined in claim 1. In some embodiments, the first repeating unit is of Formula (I-2) and the second repeating unit is of Formula (II-2),

[0018] In some embodiments, the ratio of n to m is about 1:10 to about 3:1. In some embodiments, the cationic polymer has a molecular weight of about 1 kDa to about 500 kDa.

[0019] In some embodiments, n is 0 and wherein the cationic polymer comprises a Formula (B)wherein m is an integer from 1 to 500; and wherein L5, R3, L6, L7, R4, L8, and R6are as defined in claim 1.

[0020] In some embodiments, the cationic polymer has Formula (B-1)wherein m is an integer from 1 to 100.

[0021] In some embodiments, the cationic polymer is of Formula (B-2) 9ny-2728093Attorney Ref.28767-20004.40(B-2), wherein m is an integer from 1 to 100. In some embodiments, m is about 10 to 100. In some embodiments, m is 0, and the cationic polymer is of Formula (C)wherein EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18 alkyl, C3-C18 alkenyl or a peptide, provided that RAand RBare not both H; wherein EG2isindependently H, C3-C18alkyl, C3-C18alkenyl or a peptide, provided that RDand REare not both H; n is an integer from 1 to 500; and wherein L1, R1, L2, L3, R2, and L4 are as defined in Formula (I) and (II).

[0022] In some embodiments, the cationic polymer is a polymer of Formula (C-1)(C-1), wherein RCand RFare each independently selected peptide. In some embodiments, RCand RFis each independently selected peptide comprising Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof. In some embodiments, n is an integer from 1 to 10ny-2728093Attorney Ref.28767-20004.40

[0023] In some embodiments, the cationic polymer is a polymer of Formula (C-2)(C-2), wherein RA, RB, RD, and REare each independently H, C3-C18 alkyl, or C3-C18 alkenyl, provided that RAand RBare not both H, and RDand REare not both H. In some embodiments, RAand RDare H, and RBand REare C12-C18 alkenyl. In some embodiments, RA, RB, RCand RDare each independently selected C3-C18 alkyl. In some embodiments, the C3-C18alkyl is C4H9, C6H13, C8H17, C9H19, C12H25, or C18H37. In some embodiments, the C3- C18 alkyl is C12H25. In some embodiments, n is an integer from 1 to 100.

[0024] In some embodiments, the cationic polymer is selected from the group consisting of polymer No.5, No.6, No.7, No.8, No.9, No.10, No.11, No.12, No.13, No.14, No.16, No.17, No.18, No.19, No.20, No.21, No.22, No.23, No.24, No.25, No.26, No.27, No. 28, No.29, No.30, No.31, No.32, No.33, No.34, No.35, No.36, No.37, No.38, No.39, No.40, No.41, No.42, No.43, No.44, No.45, No.70, No.71, No.72, No.73, No.74, No. 75, No.76, No.77, No.78, No.79, No.80, No.81, No.82, No.83, No.90, No.91, No.92, No.93, No.94, No.95, No.96, No.97, No.98, No.99, No.100, No.101, No.146, No.147, No.148, No.149, No.150, No.151, No.152, No.153, No.154, No 155, No.156, No.157, No.158, No.159, No.160, No.161, No.162, No.163, No.164, No.165, No.172, and No.173 in Table 1.

[0025] In some embodiments, the cationic polymer further comprises an anion. In some embodiments, the anion is acetate, trifluoroacetate, triflate, chloride, bromide, sulfate, phosphate, succinate, or citrate. In some embodiments, the anion is trifluoroacetate or chloride.

[0026] In one aspect, provided herein is a complex comprising the cationic polymer of any of the foregoing, and a nucleic acid non-covalently bound to the cationic polymer.

[0027] In some embodiments, nucleic acid is selected from the group consisting of messenger RNA (mRNA), small interference RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), self-amplifying mRNA (saRNA), transactivating RNA (tracrRNA), guide RNA (gRNA), single guide RNA (sgRNA), gene editing including CRISPR RNA (crRNA), RNA component in CRISPR, DNA component in CRISPR, plasmid DNA (pDNA), minicircle DNA, circular DNA (cDNA), single-stranded DNA (ssDNA), single-stranded circular DNA (circDNA), and genomic DNA (gDNA). In some embodiments, the nucleic 11ny-2728093Attorney Ref.28767-20004.40 acid is mRNA. In some embodiments, the nucleic acid is CRISPR RNA. In some embodiments, the complex has an N / P ratio of about 1:1 to about 100:1, such as about any of 1:1 to 90:1, 1:1 to 80:1, 1:1 to 70:1, 1:1 to 60:1, 1:1 to 50:1, 1:1 to 40:1, 1:1 to 30:1, 2:1 to 35:1, 3:1 to 35:1, 3:1 to 30:1, or 5:1 to 25:1. In some embodiments, the N / P ratio is about 3:1 to about 25:1. In some embodiments, the N / P ratio is about 5:1. In some embodiments, the N / P ratio is about 10:1. In some embodiments, the N / P ratio is about 25:1. In some embodiments, the N / P ratio is about 3:1 to about 15:1.

[0028] In another aspect, provided herein is a nanoparticle composition comprising a plurality of the complexes provided herein. In some embodiments, the average particle size of the nanoparticles is about 50 nm to about 500 nm.

[0029] In another aspect, provided herein is a pharmaceutical composition comprising a plurality of the complexes provided herein, and a pharmaceutical excipient.

[0030] In another aspect, provided herein is a method of introducing a nucleic acid into a cell, wherein the method comprises contacting the cell with a plurality of the complexes provided herein.

[0031] In another aspect, provided herein is a method of delivering a nucleic acid into a target organ and / or tissue of a subject in need thereof, wherein the method comprises administering an effective amount of the pharmaceutical composition provided herein. In some embodiments, the target organ is selected from the group consisting of brain, heart, lungs, liver, spleen, stomach, intestines, kidneys, and skeletal muscle. In some embodiments, the target tissue is in the eye. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] The drawings illustrate certain embodiments of the features and advantages of this disclosure. These embodiments are not intended to limit the scope of the appended claims in any manner.

[0033] FIG.1 shows microscopic images with fluorescence of HEK 293T cells treated with various complexes comprising various polymer transporters and EGFP mRNA, and treated with positive control (PC) and negative control (NC). The images were collected at 24 hours.

[0034] FIG.2A and FIG.2B show comparison of whole-body total luminescence of mice administered i.v. with various polymer / Fluc mRNA complexes and the negative control in abdominal view and side view, respectively.

[0035] FIG.3 compares organ luminescence from mice treated with various polymer / mRNA complexes. 12ny-2728093Attorney Ref.28767-20004.40

[0036] FIG.4 shows luminescence images of mice treated with Polymer No.45 / Fluc mRNA. FIG.4A shows whole-body luminescence images of treated mice. FIG.4B shows the quantification results of whole-body total luminescence of mice. FIG.4C shows the organ luminescence quantification results in spleen, lung, and liver, in comparison to negative control.

[0037] FIG.5 shows luminescence images of mice treated with Polymer No.43 / Fluc mRNA by i.v. injection. FIG.5A shows whole-body luminescence images of a treated mice. FIG. 5B shows the quantification results of whole-body total luminescence of mice. FIG.5C shows the organ luminescence quantification results in spleen, lung, and liver, in comparison to negative control.

[0038] FIG.6 shows luminescence images of mice treated with Polymer No.13 / Fluc mRNA by i.v. injection. FIG.6A shows whole-body luminescence images of a treated mice. FIG. 6B shows the quantification results of whole-body total luminescence of mice. FIG.6C shows the organ luminescence quantification results in spleen and lung in comparison to negative control.

[0039] FIG.7 shows luminescence images of mice treated with Polymer No.7 / Fluc mRNA by i.v. injection. FIG.7A shows whole-body luminescence images of a treated mice. FIG. 7B shows the quantification results of whole-body total luminescence of mice. FIG.7C shows the organ luminescence quantification results in spleen and lung in comparison to negative control.

[0040] FIG.8 shows luminescence images of mice treated with Fluc mRNA (negative control) by i.v. injection. FIG.8A shows the whole-body luminescence images and FIG.8B shows the quantification results.

[0041] FIG.9 shows quantification results for whole-body total luminescence and various organs / tissues luminescence of the mice treated with Polymer No.45 / Fluc mRNA by i.v. injection.

[0042] FIG.10 shows quantification results for whole-body total luminescence and various organs / tissues luminescence of the mice treated with Polymer No.43 / Fluc mRNA by i.v. injection.

[0043] FIG.11 shows quantification results for whole-body total luminescence and various organs / tissues luminescence of the mice treated with Polymer No.13 / Fluc mRNA by i.v. injection. 13ny-2728093Attorney Ref.28767-20004.40

[0044] FIG.12A and FIG.12B shows quantification results for whole-body total luminescence and various organs / tissues luminescence of the mice treated with Polymer No. 7 / Fluc mRNA and Polymer No.8 / Fluc mRNA, respectively, by i.v. injection.

[0045] FIG.13 shows the whole-body luminescence imaging results of mice treated with Polymer No.17 / Fluc mRNA.

[0046] FIG.14 shows the whole-body luminescence imaging results of mice treated with Polymer No.19 / Fluc mRNA.

[0047] FIG.15 shows the whole-body luminescence imaging results of mice treated with Polymer No.21 / Fluc mRNA.

[0048] FIG.16 shows the whole-body luminescence imaging results of mice treated with Polymer No.31 / Fluc mRNA.

[0049] FIG.17 shows the whole-body luminescence imaging results of mice treated with Polymer No.33 / Fluc mRNA.

[0050] FIG.18 shows the whole-body luminescence imaging results of mice treated with Polymer No.39 / Fluc mRNA.

[0051] FIG.19A shows microscopic images with fluorescence of cells treated with various complexes comprising polymer transporters and EGFP mRNA.

[0052] FIG.19B and FIG.19C show flow cytometry results of selected polymers.

[0053] FIG.20A, FIG.20B, and FIG.20C show the size, PDI, and zeta potential change of polymer No.43 / EGFP mRNA nanoparticles over 24 h storage in water and PBS at pH 5 and 8, respectively, under room temperature.

[0054] FIG.21 shows the buffer compatibility of Polymer No.45 / Fluc mRNA complex at N / P ratio of 10. The nanoparticles were formulated in water, 10 mM HEPES (pH 7.8), 10 mM Acetate (pH 5.0), and 1X PBS (pH 7.4).

[0055] FIG.22 shows the counteranion effect (TFA vs. Cl) on Polymer No.43 for delivering Fluc mRNA at N / P ratio of 25.

[0056] FIG.23 shows microscopic images with fluorescence of HEK 293T cells treated with various complexes comprising various polymer transporters and EGFP mRNA, and treated with positive control (PC) and negative control (NC). The images were collected at 24 hours.

[0057] FIG.24A shows the Fluc mRNA delivery to HEK 293T cells using various polymer transporters at N / P ratio of 25. FIG.24B shows the Fluc mRNA delivery to HEK 293T cells using various polymer transporters at N / P ratio of 25 (signals were normalized to Lipo2000).

[0058] FIG.25A shows gene editing efficiency for various Cas9 mRNA : sgRNA w / w ratio (10 ng in total per 96-well) in Huh7 cells at N / P ratio of 25. FIG.25B shows a dose response 14ny-2728093Attorney Ref.28767-20004.40 of gene editing efficiency for the mRNA : sgRNA w / w ratio of either 9:1 (left) or 4:1 (right) in Huh7 cells at N / P ratio of 25.

[0059] FIG.26A shows the changes in particle size over time at room temperature for Polymer No.43 and No.45 samples with addition of 0%, 1% and 3% PEG. FIG.26B shows the changes in particle PDI over time at room temperature for Polymer No.43 and No.45 samples with addition of 0%, 1% and 3% PEG.

[0060] FIG.27 shows changes of serum cytokines in mice treated with Polymer No. 43 / / 45(Cas9 / sgRNA) (N = 2, Mean ± SD).

[0061] FIG.28A shows in vivo bioluminescence of ICR mice dosed with Polymer / Fluc mRNA nanocomplexes. FIG.28B shows the bioluminescence of spleen in ICR mice dosed with Polymer / Fluc mRNA nanocomplexes. FIG.28C shows the bioluminescence of liver in ICR mice dosed with Polymer / Fluc mRNA nanocomplexes. FIG.28D shows the bioluminescence of lung in ICR mice dosed with Polymer / Fluc mRNA nanocomplexes.

[0062] FIG.29A shows the images of fundus autofluorescence in eyes of Group 1 mice on Day 7.

[0063] FIG.29B shows the images of fundus autofluorescence in eyes of Group 1 mice on Day 11.

[0064] FIG.29C shows the images of fundus autofluorescence in eyes of Group 2 mice on Day 7. DETAILED DESCRIPTION

[0065] The following description sets forth exemplary methods, parameters and the like. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments. I. Definition

[0066] As used herein, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of cells. In other examples, reference to "a nucleic acid" or "nucleic acid" includes a plurality of nucleic acid molecules, i.e. nucleic acids.

[0067] The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated 15ny-2728093Attorney Ref.28767-20004.40 value ± 10%, ± 5%, or ± 1%. In certain embodiments, the term “about” indicates the designated value ± one standard deviation of that value.

[0068] Also as used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").

[0069] As used herein the terms "oligomer" and "polymer" refer to a compound that has a plurality of repeating sub-units, (e.g., monomeric unit or repeating unit). The term "co- polymer" typically refers to an oligomer or polymer that includes two or more different monomeric units or repeating units. As used herein, “a polymer comprises a repeating unit” typically means that at least one monomeric unit or repeating unit in the polymer is the specified repeating unit, and is linked with other monomeric units by covalent bond and in any order. For example, a polymer comprising a repeating unit A refers to a polymer wherein at least one monomeric unit or repeating unit is A, such as AAAAAAAA, AABAAAA, BBBBBABB, or ABABABABAB, wherein A and B are linked by a covalent bond. For another example, a polymer comprising a first repeating unit A and a second repeating unit B refers to a polymer wherein at least one monomeric unit is A and at least one monomeric unit is B, and these units can be linked by covalent bond in any order, such as ABABABAB, ABBBBBBBBA, BBBBBAAAAA, ABCABCABC, or CABBABBBABBABBAC, wherein C is a repeating unit other than A and B.

[0070] As used herein, the term "homopolymer" refers to a polymer that is derived essentially from a single type of monomeric unit or repeating unit. In some embodiments, a homopolymer may comprise end groups different from the monomeric unit or repeating unit.

[0071] The term "block copolymer" is used in accordance with its ordinary meaning and typically refers to two or more portions (e.g., blocks) of polymerized monomeric units or repeating units linked by a covalent bond, a portion or block being defined as a polymer molecule in which the monomeric units or repeating units have at least one constitutional or configurational feature absent from the adjacent portions. In embodiments, the block copolymer includes two or more monomeric units or repeating units in a periodic (e.g., repeating pattern) sequence. For example, a di-block copolymer may have the formula: -(A)n- (B)m- (e.g., AAAAAAAAABBBBBBBBBB) where A is a first repeating unit and B is a second repeating unit covalently bound together. A triblock copolymer is a copolymer with three distinct blocks, two of which may be the same (e.g., -(B)m-(A)n-(B)p-) or all three are different (e.g., -(A)n-(B)m-(C)p-), wherein A is a first repeating unit, B is a second repeating unit, and C is a third repeating unit, covalently bound together. 16ny-2728093Attorney Ref.28767-20004.40

[0072] The terms “random polymer” or “random copolymer” are used in accordance with its ordinary meaning and typically refers to a polymer wherein the monomeric units or repeating units are located randomly in the polymer molecule and linked with each other via covalent bonds. In some embodiments, the terms "random polymer" and "random copolymer" are polymers in which the monomeric units or repeating units are incorporated into the chain wherein there can exist various combinations of ordering including block copolymer units where, for example, either the first repeating unit or second repeating unit (or third repeating unit, fourth repeating unit etc., as provided herein) or both repeating units may be repeated and are adjacent to one another. For example, a random copolymer may have the formula: - A-B-B-B-A-B-A-B-A-A-, where A is a first repeating unit and B is a second repeating unit covalently bound together. In some embodiments, a random copolymer has the formula: - (A)n-(B)m-, wherein n refers to a total number of unit(s) of the first repeating unit A and m refers to the total number of unit(s) of the second repeating unit B, and wherein each of the n unit(s) of the first repeating unit and each of the m unit(s) of the second repeating unit can be connected in any random sequence. For example, a random copolymer with the formula: - (A)n-(B)m- can be AAAAAAAAAAAB, ABABABABABAB, AABBBBBABBBABABBBBA, AABBAABBAABB, or ABAAABBAABABBAA, provided the total number of A is n and the total of B is m.

[0073] In some embodiments, “alternating polymer” refers to the copolymers wherein the first repeating unit and the second repeating unit occur in repeating alternate sequences on the polymer chain in atactic structures (such as isotactic or syndiotactic).

[0074] As used herein, the term "cationic polymer" refers to a polymer that contains cationic groups and / or groups that can be ionized into cationic groups. Cationic polymers may be hydrophilic or amphiphilic. In certain embodiments, the cationic polymer may comprise primary, secondary, tertiary amine and / or quaternary amine groups. The amine group may be part of the main polymer chain, or may dangle from the polymer chain, or may attach to the polymer chain end, or may join to the side chain or chain end group via one or more linkers or side groups by covalent bonding.

[0075] “Alkyl” as used herein refers to and includes, unless otherwise stated, a saturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having the number of carbon atoms designated (i.e., C1-C10means one to ten carbon atoms). Particular alkyl groups are those having 1 to 20 carbon atoms (a “C1-C20 alkyl”), having 1 to 10 carbon atoms (a “C1-C10 alkyl”), having 6 to 10 carbon atoms (a “C6-C10 alkyl”), having 1 to 6 carbon atoms (a “C1-C6 alkyl”), having 2 to 6 carbon atoms (a “C2-C6 alkyl”), or having 17ny-2728093Attorney Ref.28767-20004.40 1 to 4 carbon atoms (a “C1-C4 alkyl”). Examples of alkyl groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n- pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.

[0076] “Alkylene” as used herein refers to the same residues as alkyl, but having bivalency. Particular alkylene groups are those having 1 to 20 carbon atoms (a “C1-C20 alkylene”), having 1 to 10 carbon atoms (a “C1-C10alkylene”), having 6 to 10 carbon atoms (a “C6-C10alkylene”), having 1 to 6 carbon atoms (a “C1-C6 alkylene”), 1 to 5 carbon atoms (a “C1-C5 alkylene”), 1 to 4 carbon atoms (a “C1-C4alkylene”) or 1 to 3 carbon atoms (a “C1-C3alkylene”). Examples of alkylene include, but are not limited to, groups such as methylene (CH2), ethylene (CH2CH2), propylene (CH2CH2CH2), isopropylene (CH2CH(CH3)-), butylene (CH2(CH2)2CH2), isobutylene (CH2CH(CH3)CH2), pentylene (CH2(CH2)3CH2), hexylene (CH2(CH2)4CH2), heptylene (CH2(CH2)5CH2), octylene (CH2(CH2)6CH2), and the like.

[0077] “Alkenyl” as used herein refers to and includes, unless otherwise stated, an unsaturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination thereof, having at least one site of olefinic unsaturation (i.e., having at least one moiety of the formula C=C) and having the number of carbon atoms designated (i.e., C2-C10 means two to ten carbon atoms). An alkenyl group may have “cis” or “trans” configurations, or alternatively have “E” or “Z” configurations. Particular alkenyl groups are those having 2 to 30 carbon atoms (a “C3-C30alkenyl”), having 3 to 30 carbon atoms (a “C3-C30alkenyl”), having 3 to 20 carbon atoms (a “C3-C20 alkenyl”), having 3 to 15 carbon atoms (a “C3-C15 alkenyl”), or having 12 carbon atoms (a “C12alkenyl”). Alkenyl groups also include dienes, including cumulated dienes (i.e., two C=C share a common carbon), conjugated dienes (i.e., two conjugated C=C separated by a single bond), and unconjugated dienes (i.e., two C=C separated by two or more single bonds). Examples of alkenyl groups include, but are notas used herein refers to the same residues as alkenyl, but having bivalency. In some embodiments, the bivalency can be at any two positions on the alkenyl.

[0078] “Alkynyl” as used herein refers to and includes, unless otherwise stated, an unsaturated linear (i.e., unbranched) or branched univalent hydrocarbon chain or combination 18ny-2728093Attorney Ref.28767-20004.40 thereof, having at least one site of acetylenic unsaturation (i.e., having at least one moiety of the formula CŁC) and having the number of carbon atoms designated (i.e., C2-C10means two to ten carbon atoms). Particular alkynyl groups are those having 2 to 20 carbon atoms (a “C2- C20alkynyl”), having 6 to 10 carbon atoms (a “C6-C10alkynyl”), having 2 to 8 carbon atoms (a “C2-C8 alkynyl”), having 2 to 6 carbon atoms (a “C2-C6 alkynyl”), or having 2 to 4 carbon atoms (a “C2-C4alkynyl”). Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2- ynyl, but-3-ynyl, and the like. “Alkynylene” as used herein refers to the same residues as alkynyl, but having bivalency. In some embodiments, the bivalency can be at any two positions on the alkynyl.

[0079] “Cycloalkyl” as used herein refers to and includes, unless otherwise stated, saturated cyclic univalent hydrocarbon structures, having the number of carbon atoms designated (i.e., C3-C10 means three to ten carbon atoms). Cycloalkyl can consist of one ring, such as cyclohexyl, or multiple rings, such as adamantyl. A cycloalkyl comprising more than one ring may be fused, spiro, or bridged, or combinations thereof. Particular cycloalkyl groups are those having from 3 to 20 annular carbon atoms, from 3 to 13 annular carbon atoms, or from 3 to 6 annular carbon atoms. A particular cycloalkyl is a cyclic hydrocarbon having from 3 to 20 annular carbon atoms (a "C3-C20 cycloalkyl"), 3 to 13 annular carbon atoms (a "C3-C13 cycloalkyl"), having 3 to 6 annular carbon atoms (a “C3-C6cycloalkyl”), or having from 3 to 4 annular carbon atoms (a "C3-C4 cycloalkyl"). Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and the like. “cycloalkylene” as used herein refers to the same residues as cycloalkyl, but having bivalency. In some embodiments, the bivalency can be at any two positions on the cycloalkyl.

[0080] In some embodiments, “greasy lipid”, as used herein, refers to hydrophobic groups with at least 5 (e.g., at least any of 6, 7, 8, 9, 10, 11, or 12) carbons and without hydrophilic components such as heteroatom, amine, -OH, or heterocycle. In some embodiments, greasy lipid may refer to branched or unbranched C6-C20 alkyl, branched or unbranched C6-C20 alkenyl, or branched or unbranched C6-C20alkynyl, each of which may be optionally substituted with hydrophobic groups such as aryl. In some embodiments, greasy lipid may refer to branched or unbranched C9-C18alkyl, branched or unbranched C9-C18alkenyl, or branched or unbranched C9-C18 alkynyl, each of which is unsubstituted. In some embodiments, greasy lipid may refer to branched or unbranched C9-C18 alkyl, such as C12 alkyl, or branched or unbranched C9-C18 alkenyl, such as C18 alkenyl. In some embodiments, 19ny-2728093Attorney Ref.28767-20004.40 greasy lipid does not comprise amine. In some embodiments, greasy lipid does not comprise heterocycle, such as piperazine. In some embodiments, greasy lipid does not comprise -OH.

[0081] “Aryl” or “Ar” as used herein refers to an unsaturated aromatic carbocyclic group having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic. Particular aryl groups are those having from 6 to 14 annular carbon atoms (a “C6-C14aryl”). “arylene” as used herein refers to the same residues as aryle, but having bivalency. In some embodiments, the bivalency can be at any two positions on the aryl.

[0082] “Heteroaryl” as used herein refers to an aromatic cyclic group having from 1 to 14 annular carbon atoms and at least one annular heteroatom, including but not limited to heteroatoms such as nitrogen, oxygen and sulfur. A heteroaryl group may have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl), provided the entire group is aromatic. Particular heteroaryl groups are 5 to 14-membered rings having 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 5 to 10-membered rings having 1 to 8 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 5, 6 or 7-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, particular heteroaryl groups are monocyclic aromatic 5-, 6- or 7-membered rings having from 1 to 6 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, particular heteroaryl groups are polycyclic aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. “heteroarylene” as used herein refers to the same residues as heteroaryl, but having bivalency. In some embodiments, the bivalency can be at any two positions on the heteroaryl.

[0083] “Heterocycle”, “heterocyclic”, or “heterocyclyl” as used herein refers to a saturated or a partially unsaturated non-aromatic cyclic group having a single ring or multiple condensed rings, and having from 1 to 14 annular carbon atoms and from 1 to 6 annular heteroatoms, such as nitrogen, sulfur or oxygen, and the like. A heterocycle comprising more than one ring may be fused, bridged, or spiro, or any combination thereof, but excludes heteroaryl groups. A heterocyclyl group may comprise multiple rings, wherein at least one of the condensed rings is not aromatic, and the remaining ring(s) can be aromatic or non-aromatic. A heterocyclyl group having more than one ring where at least one ring is non-aromatic may be connected to the parent structure at either an aromatic ring position or at a non-aromatic ring 20ny-2728093Attorney Ref.28767-20004.40 position. In one variation, a heterocyclyl group having more than one ring wherein at least one ring is non-aromatic is connected to the parent structure at an aromatic ring position. A heterocyclyl group may be connected to the parent structure via either a heteroatom or a carbon atom. Particular heterocyclyl groups are 3 to 14-membered rings having 1 to 13 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 12-membered rings having 1 to 11 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 10- membered rings having 1 to 9 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, 3 to 8-membered rings having 1 to 7 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur, or 3 to 6-membered rings having 1 to 5 annular carbon atoms and 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In one variation, heterocyclyl includes monocyclic 3-, 4-, 5-, 6- or 7-membered rings having from 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 annular carbon atoms and 1 to 2, 1 to 3, or 1 to 4 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. In another variation, heterocyclyl includes polycyclic non-aromatic rings having from 1 to 12 annular carbon atoms and 1 to 6 annular heteroatoms independently selected from nitrogen, oxygen and sulfur. “Heterocyclene” as used herein refers to the same residues as heterocyclyl,but having bivalency. In some embodiments, the bivalency can be at any two positions on the heterocyclyl.

[0084] “Halo” or “halogen” refers to elements of the Group 17 series having atomic number 9 to 85. Preferred halo groups include the radicals of fluorine, chlorine, bromine and iodine.

[0085] “Oxo” refers to the moiety =O.

[0086] “Optionally substituted” unless otherwise specified means that a group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents listed for that group in which the substituents may be the same of different. In one embodiment, an optionally substituted group has one substituent. In another embodiment, an optionally substituted group has two substituents. In another embodiment, an optionally substituted group has three substituents. In some embodiments, an optionally substituted group has more than one substituents, wherein each substituent is independently selected. In another embodiment, an optionally substituted group has four substituents. In some embodiments, an optionally substituted group has 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, or 2 to 5 substituents. In one embodiment, an optionally substituted group is unsubstituted. 21ny-2728093Attorney Ref.28767-20004.40

[0087] In some embodiments, “optionally substituted” means the group may be unsubstituted or substituted by one or more (e.g., 1, 2, 3, 4 or 5) of the substituents described herein. In some embodiments, the substituents include, but are not limited to oxo, halo, R’, OH, OR’,- 2, group - H, -C1-C20alkyl, -C3-C20cycloalkyl, -C6-C20aryl, 3- to 20-membered heterocycle, or C1-C20alkyl substituted with one or more -OH. In some embodiments, the substituent may be oxo, halo, R’, OH, OR’, SR’, -NHR’, N(R’)2, N(R’)3, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl (e.g., C1-C10 alkyl, or C3-C10alkyl), -C3-C20cycloalkyl (e.g., -C5-C14cycloalkyl), -C6-C20aryl (e.g., phenyl), 3- to 20-membered heterocycle (e.g., 3- to 10-membered heterocycle or 5- to 6-membered heterocycle), or C1-C20alkyl substituted with one or more (e.g., 1, 2, 3, or 4) -OH.

[0088] It is understood that an optionally substituted moiety can be substituted with more than five substituents, if permitted by the number of valences available for substitution on the moiety. For example, a propyl group can be substituted with seven halogen atoms to provide a perhalopropyl group. The substituents may be the same or different. Where there are multiple substituents within a moiety or compound, it is to be understood that each substituent may be selected independently of each other substituent.

[0089] “Protecting group” as used here means a moiety that prevents or reduces the ability of the atom or functional group to which it is linked from participating in unwanted reactions. Typical protecting groups for atoms or functional groups are given in Greene (1999), “PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, 3RDED.”, Wiley Interscience. Protecting groups for heteroatoms such as oxygen, sulfur and nitrogen are used in some instances to minimize or avoid unwanted their reactions with electrophilic compounds. In other instances, the protecting group is used to reduce or eliminate the nucleophilicity and / or basicity of the unprotected heteroatom. Non-limiting examples of protected oxygen are given by -ORPR, wherein RPRis a protecting group for hydroxyl, wherein hydroxyl is typically protected as an ester (e.g. acetate, propionate or benzoate). Other protecting groups for hydroxyl avoid interfering with the nucleophilicity of organometallic reagents or other highly basic reagents, where hydroxyl is typically protected as an ether, including alkyl or heterocycloalkyl ethers, (e.g., methyl or tetrahydropyranyl ethers), alkoxymethyl ethers (e.g., methoxymethyl or ethoxymethyl ethers), optionally substituted aryl ethers ,and silyl ethers (e.g., trimethylsilyl 22ny-2728093Attorney Ref.28767-20004.40 (TMS), triethylsilyl (TES), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBS / TBDMS), triisopropylsilyl (TIPS) and [2-(trimethylsilyl)ethoxy]-methylsilyl (SEM)). Nitrogen protecting groups include those for primary or secondary amines as in -NHRPRor - N(RPR)2-, wherein least one of RPRis a nitrogen atom protecting group or both RPRtogether comprise a protecting group. In some embodiments, the protecting group is a nitrogen atom protecting group having the formula -C(O)-O-(C1-C6alkyl), such as tert-butyloxycarbonyl.

[0090] Unless the context indicates otherwise, it is specifically intended that the various features of the disclosure described herein can be used in any combination. Moreover, the disclosure also contemplates that in some embodiments any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B, or C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.

[0091] In the descriptions herein (e.g., Formula (I), (II), (A), (A-1), (I-1), (II-1), (I-2), (II-2), (B), (B-1), (B-2), (C), (C-1), or (C-2)) it is understood that every description, variation, embodiment or aspect of a moiety may be combined with every description, variation, embodiment or aspect of other moieties the same as if each and every combination of descriptions is specifically and individually listed. For example, every description, variation, embodiment or aspect provided herein with respect to R5of Formula (I) may be combined with every description, variation, embodiment or aspect of L9 of Formula (I) or R6of Formula (II) the same as if each and every combination were specifically and individually listed.

[0092] As used herein, by “pharmaceutically acceptable” or “pharmacologically acceptable” is meant a material that is not biologically or otherwise undesirable, e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients have in some embodiments met the required standards of toxicological and manufacturing testing and / or are included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug administration.

[0093] “Pharmaceutically acceptable salts” are those salts which retain at least some of the biological activity of the free (non-salt) compound and which can be administered as drugs or pharmaceuticals to an individual. Such salts, for example, include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric 23ny-2728093Attorney Ref.28767-20004.40 acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, oxalic acid, propionic acid, succinic acid, maleic acid, tartaric acid and the like; (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. Pharmaceutically acceptable salts can be prepared in situ in the manufacturing process, or by separately reacting a purified compound in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and isolating the salt thus formed during subsequent purification.

[0094] The disclosure intends to include all salts of compounds referred to herein, such as pharmaceutically acceptable salts. The disclosure also includes any or all of the stereochemical forms, including any enantiomeric or diastereomeric forms, and any tautomers or other forms of the compounds described. Unless stereochemistry is explicitly indicated in a chemical structure or name, the structure or name is intended to embrace all possible stereoisomers of a compound depicted. In addition, where a specific stereochemical form is depicted, it is understood that other stereochemical forms are also described and embraced by the disclosure. It is also understood that prodrugs, solvates and metabolites of the compounds are embraced by this disclosure. Compositions comprising a compound described herein are also intended, such as a composition of substantially pure compound, including a specific stereochemical form thereof. Compositions comprising a mixture of compounds described herein in any ratio are also embraced by the disclosure, including mixtures of two or more stereochemical forms of a compound in any ratio, such that racemic, non-racemic, enantioenriched and scalemic mixtures of a compound are embraced.

[0095] The disclosure also includes isotopically-labeled and / or isotopically-enriched forms of compounds described herein. The compounds herein may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. In some embodiments, the compound is isotopically-labeled, such as an isotopically-labeled compound of Formula (I), (II), (A), (A-1), (I-1), (II-1), (I-2), (II-2), (B), (B-1), (B-2), (C), (C- 1), or (C-2), or variations thereof described herein, where one or more atoms are replaced by an isotope of the same element. Exemplary isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, such as2H,3H,11C,13C,14C,13N,15N,15O,17O,34S,35S,18F,36Cl,37Cl, or32P. Incorporation of heavier isotopes such as deuterium (2H or D) can afford certain therapeutic 24ny-2728093Attorney Ref.28767-20004.40 advantages resulting from greater metabolic stability, for example, increased in vivo half-life, or reduced dosage requirements, and hence may be preferred in some instances. As used herein, each instance of enrichment, substitution, or replacement of an atom with corresponding isotope of that atom encompasses isotopic enrichment levels of one of about: 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99,6%, 99.7%, 99.8%, 99.9%, or 100%, or a range between any two of the preceding percentages.

[0096] Isotopically-labeled compounds of the present disclosure can generally be prepared by standard methods and techniques known to those skilled in the art or by procedures similar to those described in the accompanying Examples substituting appropriate isotopically-labeled reagents in place of the corresponding non-labeled reagent.

[0097] Unless otherwise stated, "substantially pure" intends a composition that contains no more than 10% impurity, such as a composition comprising less than 9%, 7%, 5%, 3%, 1%, 0.5% impurity.

[0098] “Contacting” is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g. chemical compounds including biomolecules or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated, however, that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture. In some embodiments, contacting encompasses the process of treating, recognizing, and / or targeting. For example, contacting a cell with a complex may encompass the process of treating the cell with the complex, recognizing a cell to which the complex is to be introduced, and / or targeting a cell for introduction of a complex.

[0099] A "vector" is a nucleic acid that carries the information for synthesis of another nucleic acid inside a cell. A vector is capable of directing the expression of a protein or proteins encoded by one or more genes carried by the vector when it is present in the appropriate environment.

[0100] Unless clearly indicated otherwise, “an individual” or “a subject” as used herein intends a mammal, including but not limited to a primate, human, bovine, horse, feline, canine, or rodent. In one variation, the individual is a human.

[0101] As used herein, “treatment” or “treating” is an approach for obtaining beneficial or desired results including clinical and diagnostic results. In some embodiments, “treatment” or “treating” encompasses methods to obtain diagnostic results, such as detecting a biomarker or molecule, determining level and biodistribution of gene expression, measuring cell viability, 25ny-2728093Attorney Ref.28767-20004.40 imaging a tissue or cell, or diagnosing a disease or disorder. In some embodiments, “treatment” or “treating” encompasses methods to obtain therapeutically beneficial results, such as ameliorating the symptoms of a disease or disorder. Beneficial or desired clinical and diagnostic results include, but are not limited to, one or more of the following: detecting and diagnosing a disease or a disorder or underlying cause thereof, monitoring the development of a disease or a disorder, decreasing one more symptoms resulting from the disease, diminishing the extent of the disease, stabilizing the disease (e.g., preventing or delaying the worsening of the disease), preventing or delaying the spread of the disease, delaying the occurrence or recurrence of the disease, delay or slowing the progression of the disease, ameliorating the disease state, providing a remission (whether partial or total) of the disease, decreasing the dose of one or more other medications required to treat the disease, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival. The methods provided herein contemplate any one or more of these aspects of treatment.

[0102] In certain instances, the terms "prevention", "prophylaxis" and "preclusion" are used synonymously and refer to the avoidance or reduction of the risk of contracting, experiencing, suffering from or having a disease, a condition, a disorder (e.g., a proliferative disorder), a symptom or a health problem, or a development or advancement of such states and / or the symptoms of such states. In some embodiments, prevention encompasses gene- level diagnosis and prevention. In some embodiments, the prevention can be achieved by gene therapy and / or gene editing. In certain instances, prevention means delaying the development of a disease or any symptom thereof. For example, prevention of a disorder means to delay, defer, hinder, slow, retard, stabilize, and / or postpone development of the disorder or any symptom thereof, optionally via gene editing. This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant prevention or delay can, in effect, result in the individual does not develop the disease. A method that prevents development of a disorder or a disease is a method that reduces probability of disease development in a given time frame and / or reduces the extent of the disorder in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a statistically significant number of subjects. Development may also refer to disease progression that may be initially undetectable and includes occurrence, recurrence, and onset. The treatment or prevention of a disease, a condition, a disorder, an injury or a health problem may be partial or complete. 26ny-2728093Attorney Ref.28767-20004.40

[0103] The term “effective amount” as used herein, refers to a sufficient amount of at least one agent being administered in vitro or in vivo to achieve a desired result, e.g., to introduce or transfect a nucleic acid into a target cell, or to deliver a nucleic acid to a target organ or tissue. In certain instances, the method is in vitro, and the desired result may comprise certain desired alteration of cells or biological processes. In certain instances, the method is in vivo, and the result may comprise a delivery or transfection of a nucleic acid into a target organ or tissue, a reduction and / or alleviation of the signs, symptoms, or causes of a disease. As is understood in the art, an effective amount may be in one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents (e.g., a compound, or pharmaceutically acceptable salt thereof), and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved. Suitable doses of any of the co- administered compounds may optionally be lowered due to the combined action (e.g., additive or synergistic effects) of the compounds.

[0104] In certain instances, an “effective amount” is considered in the context of therapeutical and / or diagnostic uses and may be optionally referred to as “therapeutically or pharmaceutically effective amount”. A “therapeutically effective amount” refers to an amount of the compound or the composition comprising a compound or salt thereof as set forth herein sufficient to produce a desired alteration of a target organ or tissue, or a desired therapeutic outcome and / or required to provide a clinically significant decrease in a disease. An appropriate “effective” or “therapeutically effective” amount in any individual case is determined using any suitable technique, such as a dose escalation study. In various embodiments, an effective amount or a therapeutically effective amount of the compound may (i) introduce or transfect a nucleic acid into a target cell or target cells (e.g., lung cells, spleen cells, liver cells, skeletal muscle cells, brain cells, or any combination thereof); (ii) deliver or transfect a nucleic acid into a target organ or target organs (e.g., lung, liver, spleen, brain, or any combination thereof); (iii) deliver or transfect a nucleic acid into a target tissue or target tissues (e.g., lung tissue, spleen tissue, liver tissue, skeletal muscle tissue, brain tissue, or any combination thereof); or (iv) alter the biological process in a cell or cells (e.g., lung cells, spleen cells, liver cells, skeletal muscle cells, brain cells, or any combination thereof) after introduction or transfection of the nucleic acid.

[0105] It is understood that embodiments of the invention described herein include “consisting of” and / or “consisting essentially of” embodiments. 27ny-2728093Attorney Ref.28767-20004.40 II. Polymer

[0106] In one aspect, provided herein is a cationic polymer comprising n unit(s) of a first repeating unit of Formula (Ia) and m unit(s) of a second repeating unit of Formula (IIa):or a salt thereof, wherein L1, L2, L3, L4, L5, L6, L7and L8are each independently -O-, -NH-, optionally substituted C1-C12 alkylene, optionally substituted C2-C12 alkenylene, optionally substituted C2-C12alkynylene, optionally substituted C3-C6cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12 arylene, or optionally substituted 5 to 10 membered heteroarylene; L9 is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12 alkyl, optionally substituted C2-C12alkenyl, or optionally substituted C2-C12alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H, optionally substituted C1-C12alkyl, or a protecting group; R6is optionally substituted C3-C20 alkyl or optionally substituted C3-C20 alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end-capped by at least one capping group selected from the group consisting of C3-C18 alkyl, C3-C18 alkenyl and a peptide.

[0107] In some embodiments, R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H, C1-C12 alkyl, or -C(O)O-(C1-C6 alkyl). 28ny-2728093Attorney Ref.28767-20004.40

[0108] In some embodiments, R6is C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected R’, OR’, -NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20alkyl, -C3-C20cycloalkyl, -C6-C20aryl, 3- to 10-membered heterocycle, or C1- C20 alkyl substituted with one or more -OH. In some embodiments, R6is C1-C20 alkyl or C3- C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O-(C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1- C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle. In some embodiments, R6is C3-C18 alkyl or C3-C18 alkenyl.

[0109] In one aspect, provided herein is a cationic polymer comprising n unit(s) of a first repeating unit of Formula (I) and m unit(s) of a second repeating unit of Formula (II):wherein: L1, L2, L3, L4, L5, L6, L7 and L8 are each independently -O-, -NH-, optionally substituted C1-C12alkylene, optionally substituted C2-C12alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or optionally substituted C1-C12 alkyl; R6is C3-C18alkyl or C3-C18alkenyl; n is an integer from 0 to 500; 29ny-2728093Attorney Ref.28767-20004.40 m is an integer from 0 to 500; and at least one of m and n is not 0.

[0110] In some embodiments, the capping group that “end-caps” the polymer refers to the one added at the end(s) of the polymer by reacting the polymer with an end-capping reagent. In some embodiments, for example, when the repeating unit at one end of the cationic polymer is a first repeating unit of Formula (I), and an end group (EG) at the end of the cationic polymer is a -NHREG, -N(REG)2 or a –SREGdirectly connected to L1, then REGis a capping group for the polymer and the cationic polymer is end-capped by REG. In some embodiments, for another example, when the repeating unit at another end of the cationic polymer is a first repeating unit of Formula (I), and a REGgroup directly connected to –N- (L9-R5) and forms –N(REG)-(L9-R5), then REGis a capping group for the polymer and the cationic polymer is end-capped by REG.

[0111] In some embodiments of the cationic polymer, when m or n is 0, the cationic polymer is end-capped by one or more capping groups selected from the group consisting of C3-C18alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), and -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18alkenyl. In some embodiments of the cationic polymer, when m or n is 0, the cationic polymer is end-capped by one or more (e.g., one to four) capping groups selected from the group consisting of C3-C18alkyl, C3-C18alkenyl and a peptide. In some embodiments, when m or n is 0, the cationic polymer is end-capped by one to four C3-C18 alkyl. In some embodiments, when m or n is 0, the cationic polymer is end-capped by one to four C9-C18alkyl (e.g., C12 alkyl). In some embodiments, when m or n is 0, the cationic polymer is end- capped by one to four C3-C18alkenyl. In some embodiments, when m or n is 0, the cationic polymer is end-capped by one to four C12-C18 alkenyl (e.g., C18 alkenyl). In some embodiments, when m or n is 0, the cationic polymer is end-capped by one or two peptides.

[0112] In some embodiments, the peptide is a polymer of amino acids. In some embodiments, the amino acids are all naturally occurring amino acids. In some embodiments, at least one amino acid is an artificial chemical mimetic of a corresponding naturally occurring amino acid. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof. 30ny-2728093Attorney Ref.28767-20004.40

[0113] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18alkyl, C3-C18alkenyl or a peptide;H, optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide; provided that,optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; and 31ny-2728093Attorney Ref.28767-20004.40 when EG1is SRC, thenleast one of RCand RFis optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide.

[0114] In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3- C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected R’, OR’, -NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl, -C3-C20 cycloalkyl, -C6-C20 aryl, or - 3- to 10- membered heterocycle, or C1-C20 alkyl substituted with one or more -OH. In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O- (C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), - NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle.

[0115] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARB, wherein RA, RB, and RCare each independently H, C3-C18 alkyl, C3-C18alkenyl or a peptide;each independently H, optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; provided that, at least one of RA, RB, RD, and REis optionally substituted C1-C18 alkyl, optionally substituted C3-C18alkenyl, or a peptide.

[0116] In some embodiments, RDand REare each independently H, C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently 32ny-2728093Attorney Ref.28767-20004.40 selected R’, OR’, -NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20alkyl, -C3-C20cycloalkyl, -C6-C20aryl, or - 3- to 10- membered heterocycle, or C1-C20 alkyl substituted with one or more -OH. In some embodiments, RD, RE, and RFare each independently H, C1-C20alkyl or C3-C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O- (C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), - NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle. In some embodiments, RDis H, C1- C20alkyl or C3-C20alkenyl, and REis C1-C20alkyl or C3-C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O-(C1-C20 alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle.

[0117] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is SRC, wherein RCis H, C3-C18alkyl, C3-C18alkenyl or a peptide;H, optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; at least one of RCand RFis optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide.

[0118] In some embodiments, RFis H, C1-C20alkyl or C3-C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected R’, OR’, -NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl, -C3-C20 cycloalkyl, -C6-C20 aryl, or - 3- to 10-membered heterocycle, or C1-C20alkyl substituted with one or more -OH. In some embodiments, RFis H, C1-C20alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O-(C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle. In some embodiments, RFis C1-C20 alkyl or C3-C20 alkenyl. In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: 33ny-2728093Attorney Ref.28767-20004.40 end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18 alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18alkenyl; andand RD, RE, and RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl. In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18 alkyl, C3-C18alkenyl or a peptide; andand RD, RE, and RFare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide. In some embodiments, RCand RFare each an independently selected peptide. In some embodiments, the peptide is a polymer of amino acids. In some embodiments, the amino acids are all naturally occurring amino acids. In some embodiments, at least one amino acid is an artificial chemical mimetic of a corresponding naturally occurring amino acid. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of one amino acid 34ny-2728093Attorney Ref.28767-20004.40 in the peptide. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of a cysteine in the end-capping peptide.

[0119] In some embodiments, when EG1is NRARB, then EG2isand the cationic polymer is end-capped by RA, RB, RD, and RE, wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, and at least one of RA, RB, RD, and REis C3-C18 alkyl, C3-C18 alkenyl, or a peptide. In some embodiments, RA, RB, RD, and REare each independently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20- membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl, and at least one of RA, RB, RD, and REis not H. In some embodiments, when EG1is SRC, then EG2isthe cationic polymer is end-capped by RCand RF, wherein RCand RFare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide and at least one of RCand RFis C3-C18 alkyl, C3-C18 alkenyl, or a peptide. In some embodiments, RCand RFare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl, and at least one of RCand RFis not H.

[0120] In some embodiments of Formula (I) and Formula (II), L1, L2, L3, L4, L5, L6, L7and L8 are each independently optionally substituted C1-C12 alkylene, wherein one or more of the C-C bonds in the alkylene are optionally replaced by a C=C or CŁC, and wherein the C1-C12alkylene is optionally interrupted by one or more groups independently selected from the group consisting of -O-, -NH-, optionally substituted 3 to 12 membered heterocycloalkylene, optionally substituted C3-C6cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12 arylene, and optionally substituted 5 to 10 membered heteroarylene, as valency permits. In some embodiments, L1, L2, L3, L4, L5, L6, L7and L8 are each independently C1-C12 alkylene, C2-C12 alkenylene, C2-C12 alkynylene, C3-C6 cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12arylene, or 5 to 10 membered 35ny-2728093Attorney Ref.28767-20004.40 heteroarylene, each of which is independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. In some embodiments, L1, L2, L3, L4, L5, L6, L7and L8are each independently C1-C12 alkylene optionally interrupted by one or more -O- or -NH-. In some embodiments, L1-L8are each independently uninterrupted C1-C12alkylene, wherein the C1-C12alkylene can be branched or unbranched. In some embodiments, L1, L2, L3, L4, L5, L6, L7 and L8 are each independently uninterrupted C2-C10alkylene, such as any of C2alkylene, C4alkylene, C6alkylene, C8 alkylene, or C10 alkylene. In some embodiments, L1, L4, L5, and L8 are all ethylene or butadienylene, and L2, L3, L6, and L7are each independently C1-C12alkylene, C2- C12 alkenylene, C2-C12 alkynylene, C1-C12 alkenylene, C3-C6 cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12arylene, or 5 to 10 membered heteroarylene, each of which are independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. In some embodiments, L1, L2, L3, L4, L5, L6, L7and L8are all ethylene. In some embodiments, L1, L2, L3, L4, L5, L6, L7 and L8 are each independently C2 -C12 alkylene interrupted by one to six -O- or -NH-. In some embodiments, L1, L2, L3, L4, L5, L6, L7and L8are each independently C2- C12 polyethylene glycol.

[0121] In some embodiments of Formula (I), L1, L2, L3, and L4 are each independently optionally substituted C1-C12alkylene, wherein one or more of the C-C bonds in the alkylene are optionally replaced by a C=C or CŁC, and wherein the C1-C12 alkylene is optionally interrupted by one or more groups independently selected from the group consisting of -O-, - NH-, optionally substituted 3 to 12 membered heterocycloalkylene, optionally substituted C3- C6cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12 arylene, and optionally substituted 5 to 10 membered heteroarylene, as valency permits. In some embodiments, L1, L2, L3, and L4are each independently C1-C12alkylene, C2-C12 alkenylene, C2-C12 alkynylene, C3-C6 cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12arylene, or 5 to 10 membered heteroarylene, each of which is independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. In some embodiments, L1, L2, L3, and L4are each independently C1-C12alkylene optionally interrupted by one or more -O- or -NH-. In some embodiments, L1, L2, L3, and L4 are each independently uninterrupted C1-C12alkylene, wherein the C1-C12alkylene can be branched or unbranched. In some embodiments, L1, L2, L3, and L4 are each independently uninterrupted C2-C10alkylene, such as any of C2alkylene, C4alkylene, C6alkylene, C8alkylene, or C10alkylene. In some embodiments, L1, and L4, are both ethylene or butadienylene, and L2, and L3, are each independently C1-C12 alkylene, C2-C12 alkenylene, C2-C12 alkynylene, C1-C12 alkenylene, C3-C6 cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12 arylene, or 5 to 10 36ny-2728093Attorney Ref.28767-20004.40 membered heteroarylene, each of which are independently and optionally substituted by C1- C6alkyl, halo, OH, or NH2. In some embodiments, L1, L2, L3, and L4are all ethylene. In some embodiments, L1, L2, L3, and L4 are each independently C2 -C12 alkylene interrupted by one to six -O- or -NH-. In some embodiments, L1, L2, L3, and L4are each independently C2- C12 polyethylene glycol.

[0122] In some embodiments of Formula (II), L5, L6, L7and L8are each independently optionally substituted C1-C12 alkylene, wherein one or more of the C-C bonds in the alkylene are optionally replaced by a C=C or CŁC, and wherein the C1-C12alkylene is optionally interrupted by one or more groups independently selected from the group consisting of -O-, - NH-, optionally substituted 3 to 12 membered heterocycloalkylene, optionally substituted C3- C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, and optionally substituted 5 to 10 membered heteroarylene, as valency permits. In some embodiments, L5, L6, L7 and L8 are each independently C1-C12 alkylene, C2-C12alkenylene, C2-C12alkynylene, C3-C6cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12 arylene, or 5 to 10 membered heteroarylene, each of which is independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. In some embodiments, L5, L6, L7and L8are each independently C1-C12alkylene optionally interrupted by one or more -O- or -NH-. In some embodiments, L1-L8 are each independently uninterrupted C1-C12alkylene, wherein the C1-C12alkylene can be branched or unbranched. In some embodiments, L5, L6, L7 and L8 are each independently uninterrupted C2 -C10 alkylene, such as any of C2alkylene, C4alkylene, C6alkylene, C8alkylene, or C10alkylene. In some embodiments, L5, and L8 are all ethylene or butadienylene, and L6, and L7 are each independently C1-C12alkylene, C2-C12alkenylene, C2-C12alkynylene, C1-C12alkenylene, C3- C6 cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12 arylene, or 5 to 10 membered heteroarylene, each of which are independently and optionally substituted by C1-C6alkyl, halo, OH, or NH2. In some embodiments, L5, L6, L7 and L8 are all ethylene. In some embodiments, L5, L6, L7and L8are each independently C2-C12alkylene interrupted by one to six -O- or -NH-. In some embodiments, L5, L6, L7 and L8 are each independently C2 -C12 polyethylene glycol.

[0123] In some embodiments of Formula (I), L9 is a bond. In some embodiments, L9 is a bifunctional linker capable of forming a chemical bond with the nitrogen and R5. In some embodiments, L9 is selected from the group consisting of -C(O)O-, -O-, -S-, -NH-, -C(O)NH- , -NHC(O)-, -S(O)2-, -S(O)NH-, -NHC(O)NH-, 3- to 12-membered heterocyclylene, a peptide, and C1-C18 alkylene optionally interrupted by one or more -O-, wherein the C1-C18 37ny-2728093Attorney Ref.28767-20004.40 alkylene and the 3- to 12-membered heterocyclylene are optionally substituted by one or more C1-C6alkyl, halo, OH, or NH2. In some embodiments, L9comprises a C1-C6alkylene, a C2-C6 PEGylated linker, a peptide linker (e.g., a dipeptide, tripeptide, or tetrapeptide linker), or any combination thereof. In some embodiments, L9is a linking group comprising C1-C6alkylene and peptide. In some embodiments, L9 is a C1-C6 alkylene, a C2-C6 PEGylated linker, or a peptide linker (e.g., a dipeptide, tripeptide, or tetrapeptide linker). In some embodiments, L9 is a C1-C6 alkylene or a C2-C6 PEGylated linker. In some embodiments, L9 is C1-C6alkylene, C3-C6alkylene, ethylene, propylene, butylene, or pentylene. In some embodiments, the peptide is a polymer of amino acids. In some embodiments, the amino acids are all naturally occurring amino acids. In some embodiments, at least one amino acid is an artificial chemical mimetic of a corresponding naturally occurring amino acid. In some embodiments, L9is propylene.

[0124] In some embodiments of Formula (I), R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or C1-C12alkyl optionally substituted by one or more halo, - OH, or -NH2. In some embodiments, R5is H. In some embodiments, R5is -ORa, wherein Rais H or C1-C3 alkyl. In some embodiments, R5is -COORa, wherein Rais H or C1-C3 alkyl. In some embodiments, R5is NRaRb, wherein Raand Rbare each independently H or C1-C3alkyl. In some embodiments, R5is -NH2. In some embodiments, R5is NRaRb, wherein the NRaRbis protonated. In some embodiments, R5is NH(Ra)(Rb)+. In some embodiments, R5is NH3+. In some embodiments, the N to which L9-R5is attached is protonated. In some embodiments, the N to which L9-R5is attached is not protonated.

[0125] In some embodiments of Formula (I), L9-R5is -CH2CH2NH2, - CH2CH2NHCOOC(CH3)3, –CH2CH2CH2NH2, -CH2CH2CH2NHCOOC(CH3)3, – CH2CH2CH2CH2NH2, -CH2CH2CH2CH2NHCOOC(CH3)3, –CH2CH2CH2CH2CH2NH2, - CH2CH2CH2CH2CH2NHCOOC(CH3)3, –(CH2)6NH2, or –(CH2)6COOC(CH3)3. In some embodiments, L9-R5is –CH2CH2CH2NH2 or -CH2CH2CH2NHCOOC(CH3)3.

[0126] In some embodiments of Formula (I) and Formula (II), R1, R2, R3, and R4are each independently H, optionally substituted C1-C12 alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12alkynyl. In some embodiments, R1, R2, R3, and R4are H. In some embodiments, one, two, three, or four of R1, R2, R3, and R4are each independently C1- C12alkyl, C2-C12alkenyl, or C2-C12alkynyl, each of which are independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. In some embodiments, one, two, three, or four of R1, R2, R3, and R4are each independently C1-C3 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl, each of which are independently and optionally substituted by one or more halo, OH, or NH2. 38ny-2728093Attorney Ref.28767-20004.40 In some embodiments, one, two, three, or four of R1, R2, R3, and R4are methyl. In some embodiments, any of the N to which R1, R2, R3, and R4are attached can be protonated. In some embodiments, the N to which R1is attached is protonated. In some embodiments, the N to which R2is attached is protonated. In some embodiments, the N to which R3is attached is protonated. In some embodiments, the N to which R4is attached is protonated. In some embodiments, the N to which R1is attached is not protonated. In some embodiments, the N to which R2is attached is not protonated. In some embodiments, the N to which R3is attached is not protonated. In some embodiments, the N to which R4is attached is not protonated.

[0127] In some embodiments of Formula (I), R1and R2are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12alkenyl, or optionally substituted C2- C12 alkynyl. In some embodiments, R1and R2are H. In some embodiments, one of R1and R2is C1-C12alkyl, C2-C12alkenyl, or C2-C12alkynyl, each of which are independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. In some embodiments, one of R1and R2is C1-C3alkyl, C2-C4alkenyl, or C2-C4alkynyl, each of which are independently and optionally substituted by one or more halo, OH, or NH2. In some embodiments, one of R1and R2is methyl. In some embodiments, any of the N to which R1or R2is attached to can be protonated. In some embodiments, the N to which R1is attached is protonated. In some embodiments, the N to which R2is attached is protonated. In some embodiments, the N to which R1is attached is not protonated. In some embodiments, the N to which R2is attached is not protonated.

[0128] In some embodiments of Formula (I), R3and R4are each independently H, optionally substituted C1-C12 alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2- C12alkynyl. In some embodiments, R3and R4are H. In some embodiments, one of R3and R4is C1-C12 alkyl, C2-C12 alkenyl, or C2-C12 alkynyl, each of which are independently and optionally substituted by C1-C6alkyl, halo, OH, or NH2. In some embodiments, one of R3and R4is C1-C3 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl, each of which are independently and optionally substituted by one or more halo, OH, or NH2. In some embodiments, one of R3and R4is methyl. In some embodiments, any of the N to which R3and R4is attached to can be protonated. In some embodiments, the N to which R3is attached is protonated. In some embodiments, the N to which R4is attached is protonated. In some embodiments, the N to which R3is attached is not protonated. In some embodiments, the N to which R4is attached is not protonated.

[0129] In some embodiments, R6is optionally substituted C3-C20 alkyl or optionally substituted C3-C20 alkenyl. In some embodiments, R6is C1-C20 alkyl or C3-C20 alkenyl, each 39ny-2728093Attorney Ref.28767-20004.40 of which is unsubstituted, or substituted with one or more independently selected R’, OR’, - NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl, -C3-C20 cycloalkyl, -C6-C20 aryl, 3- to 10-membered heterocycle, or C1-C20alkyl substituted with one or more -OH. In some embodiments, R6is C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O-(C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle. In some embodiments of Formula (II), R6is C3-C18alkyl or C3-C18alkenyl. In some embodiments, R6is C9-C18 alkyl or C9-C18 alkenyl (e.g., C12-C18 alkyl or C12-C18 alkenyl). In some embodiments, R6is C9-C18alkyl (e.g., C12-C18alkyl or C12alkyl). In some embodiments, R6is C9, C10, C12, C14, C16, or C18 alkyl. In some embodiments, R6is C9-C18 alkenyl (e.g., C9-C18alkenyl). In some embodiments, R6is C9, C10, C12, C14, C16, or C18alkenyl. In some embodiments, the N to which R6is attached is protonated. In some embodiments, the N to which R6is attached is not protonated.

[0130] In some embodiments, m is 0, and the cationic polymer is a homopolymer made of the repeating unit of Formula (I), end-capped by one or more capping groups, wherein at least one capping group is C3-C18alkyl, C3-C18alkenyl or a peptide. In some embodiments, n is 0, and the cationic polymer is a homopolymer made of the repeating unit of Formula (II), end- capped by one or more capping groups, wherein at least one capping group is C3-C18alkyl, C3-C18 alkenyl or a peptide.

[0131] In some embodiments, m is an integer from 1 to 500, n is an integer from 1 to 500, and the cationic polymer is a block copolymer. In some embodiments, m is an integer from 1 to 500, n is an integer from 1 to 500, and the cationic polymer is a random copolymer.

[0132] In some embodiments, n is an integer from 0 to 500, for example, any of 0 to 400, 0 to 350, 0 to 300, 0 to 250, 0 to 200, 0 to 150, 0 to 130, 0 to 100, 0 to 90, 0 to 80, 0 to 70, 0 to 60, 0 to 50, 0 to 40, 0 to 30, 0 to 20, or 0 to 10.

[0133] In some embodiments, m is an integer from 0 to 500, for example, any of 0 to 400, 0 to 350, 0 to 300, 0 to 250, 0 to 200, 0 to 150, 0 to 130, 0 to 100, 0 to 90, 0 to 80, 0 to 70, 0 to 60, 0 to 50, 0 to 40, 0 to 30, 0 to 20, or 0 to 10.

[0134] In some embodiments, the ratio of n to m is at least about 1:20, such as at least about any of 1:18, 1:16, 1:14, 1:12, 1:10, 1:8, 1:6, 1:4, 1:2, or 1:1. In some embodiments, the ratio of n to m is no more than about 20:1, such as at least about any of 18:1, 16:1, 14:1, 12:1, 10:1, 8:1, 6:1, 4:1, 2:1, or 1:1. In some embodiments, the ratio of n to m is about 1:20 to 20:1, such as about any of 1:15 to 15:1, 1:10 to 10:1, 1:10 to 3:1, or 1:10 to 2:1. In some 40ny-2728093Attorney Ref.28767-20004.40 embodiments, the ratio of n to m is in a range of about 0.1 to about 1.2, about 0.2 to about 1.0, or about 0.3 to about 0.8.

[0135] In some embodiments, the cationic polymer has a molecular weight of about 1 to 150 kDa, such as about any of 1 to 130 kDa, 1 to 100 kDa, 1 to 75 kDa, 1 to 50 kDa, 1 to 25 kDa, 1 to 20 kDa, 2 to 20 kDa, 2 to 15 kDa, 2 to 10 kDa, 1 to 10 kDa, 1 to 8 kDa, 2 to 8 kDa, 1 to 6 kDa, 2 to 6 kDa, 1 to 4 kDa, 2 to 4 kDa, 1 to 3 kDa, or 2 to 3 kDa. Copolymer

[0136] In some embodiments, the cationic polymer comprises a structural unit of Formula (A)(A), wherein n is an integer from 1 to 500; m is an integer from 1 to 500; and wherein the n unit(s) of the first repeating unit and the m unit(s) of the second repeating unit can be connected in any sequence; and wherein the first repeating unit and the second repeating unit are as defined for any of the Formulae described herein (e.g., Formula (Ia) or Formula (I)).

[0137] In some embodiments, the n unit(s) of the first repeating unit and the m unit(s) of the second repeating unit are connected to form a block copolymer. In some embodiments, the structural unit of Formula (A) comprises blocks of the first repeating unit and blocks of the second repeating unit. In some embodiments, the n unit(s) of the first repeating unit and the m unit(s) of the second repeating unit are connected in a random sequence and form a random copolymer.

[0138] In some embodiments, the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18 alkyl, C3-C18 alkenyl or a peptide; 41ny-2728093Attorney Ref.28767-20004.40H, optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide; provided that,optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; and when EG1is SRC, thenleast one of RCand RFis optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide. 42ny-2728093Attorney Ref.28767-20004.40

[0139] In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3- C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected R’, OR’, -NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20alkyl, -C3-C20cycloalkyl, -C6-C20aryl, or - 3- to 10- membered heterocycle, or C1-C20 alkyl substituted with one or more -OH. In some embodiments, RD, RE, and RFare each independently H, C1-C20alkyl or C3-C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O- (C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), - NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle.

[0140] In some embodiments of Formula (A), the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, orand RD, RE, and RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl. In some embodiments of Formula (A), the cationic polymer further comprises two end groups EG1and EG2. In some embodiments, end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide; and43ny-2728093Attorney Ref.28767-20004.40 and RD, RE, and RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide. In some embodiments, the peptide is a polymer of amino acids. In some embodiments, the amino acids are all naturally occurring amino acids. In some embodiments, at least one amino acid is an artificial chemical mimetic of a corresponding naturally occurring amino acid. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof.

[0141] In some embodiments, when EG1is SRC, then EG2isthe cationic polymer is end-capped by RCand RF, wherein RCand RFare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, and at least one of RCand RFis C3-C18 alkyl, C3-C18 alkenyl, or a peptide. In some embodiments, RCand RFare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl, and at least one of RCand RFis not H. In some embodiments, RCand RFare each independently selected C3-C18 alkyl. In some embodiments, RCand RFare each independently selected C9-C18alkyl. In some embodiments, RCand RFare both C12 alkyl. In some embodiments, RCand RFare each independently selected peptide. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of one amino acid in the peptide. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of a cysteine in the end-capping peptide. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof.

[0142] In some embodiments, when EG1is NRARB, then EG2is44ny-2728093Attorney Ref.28767-20004.40the cationic polymer is end-capped by RA, RB, RD, and RE, wherein RA, RB, RD, and REare each independently H, optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide, and at least one of RA, RB, RD, and REis optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide. In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3- C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected R’, OR’, -NHR’, N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl, -C3-C20 cycloalkyl, -C6-C20 aryl, or - 3- to 10- membered heterocycle, or C1-C20alkyl substituted with one or more -OH. In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, O- (C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), - NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle.

[0143] In some embodiments, when EG1is NRARB, then EG2isand the cationic polymer is end-capped by RA, RB, RD, and RE, wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, and at least one of RA, RB, RD, and REis C3-C18 alkyl, C3-C18 alkenyl, or a peptide. In some embodiments, RA, RB, RD, and REare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20- membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl, and at least one of RA, RB, RD, and REis not H. In some embodiments, at least one of RA, RB, RD, and REis C3-C18 alkyl or C3-C18 alkenyl. In some embodiments, at least one of RAand RBis C3-C18 alkyl or C3-C18 alkenyl and at least one of RD, and REis C3-C18alkyl or C3-C18alkenyl. In some embodiments, at least one of RAand RBis C9-C18 alkyl or C9-C18 alkenyl and at least one of RD, and REis C9-C18alkyl or C9-C18alkenyl. In some embodiments, at least one of RAand RBis C9-C18 alkyl and at least one of RD, and REis C9-C18 alkyl. 45ny-2728093Attorney Ref.28767-20004.40

[0144] In some embodiments, the cationic polymer comprises a structural unit of Formula (Aa)wherein RAis H or C12H25; RBis C12H25; RDis H, C12H25; and REis C12H25, C12-C18 alkenyl, or C1-C8alkyl substituted with one or more independently selected phenyl, -O-(C1- C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle.

[0145] In some embodiments of the foregoing, the cationic polymer is a polymer of Formula (A-1):(A-1) wherein RAis H or C12H25; RBis C12H25; RDis H or C12H25; and REis C12H25, wherein n is an integer from 1 to 500, m is an integer from 1 to 500, and the n unit(s) of the first repeating unit and the m unit(s) of the second repeating unit are connected to form a block copolymer or a random copolymer; and wherein the first repeating unit is as defined in Formula (I) and second repeating unit is as defined in Formula (II). In some embodiments, the first repeating unit of Formula (A-1) can be any of the embodiments of the first repeating unit as defined in Formula (I). In some embodiments, the second repeating unit of Formula (A-1) can be any of the embodiments of the second repeating unit as defined in Formula (II). In some embodiments of Formula (A-1), the cationic polymer is a block copolymer. In some embodiments of Formula (A-1), the cationic polymer is a random copolymer, wherein the first repeating unit(s) and the second repeating unit(s) are connected in any random sequence. In some embodiments of Formula (A-1), wherein RAis H; RBis C12H25; RDis H; and REis C12H25. 46ny-2728093Attorney Ref.28767-20004.40

[0146] In some embodiments of Formula (A-1), the first repeating unit is of Formula (I-1):wherein L9and R5are as defined in any of the formulae described herein (e.g., Formula (I)). In some embodiments of the foregoing, L9-R5is –CH2CH2NH2, -CH2CH2NHCOOC(CH3)3, –CH2CH2CH2NH2, - CH2CH2CH2NHCOOC(CH3)3, –CH2CH2CH2CH2NH2, -CH2CH2CH2CH2NHCOOC(CH3)3, – CH2CH2CH2CH2CH2NH2, -CH2CH2CH2CH2CH2NHCOOC(CH3)3, –(CH2)6NH2, or – (CH2)6COOC(CH3)3. In some embodiments, L9-R5is –CH2CH2CH2NH2 or - CH2CH2CH2NHCOOC(CH3)3. In some embodiments of Formula (A-1), the first repeating unit is of Formulasome embodiments of Formula (A-1), the second repeating unit is of Formula (II-1)wherein R6is as defined in any of the formulae described herein (e.g., Formula (II)). In some embodiments, R6is C1-C18alkyl, C12 alkyl, C14 alkyl, C16 alkyl, C18 alkyl, isoamyl, C2-C18 alkenyl, nonenyl, or oleyl. In some embodiments, R6is C9alkyl, C10alkyl, C12alkyl, C14alkyl, C16alkyl, C18alkyl. In some embodiments of Formula (A-1), the second repeating unit is of Formula (II-2)

[0147] In some embodiments, the cationic polymer is a polymer of Formula (A-3):(A-3), wherein L9and R5are as defined in any of the formulae described herein (e.g., Formula (I)), R6is as defined in any of the formulae described herein (e.g., Formula (II)). In some embodiments, RD, RE, and RFare each independently H, C1-C20alkyl or C3-C20alkenyl, 47ny-2728093Attorney Ref.28767-20004.40 each of which is unsubstituted, or substituted with one or more independently selected -R’, -OR’, -NHR’, -N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl, -C3-C20 cycloalkyl, -C6-C20 aryl, or - 3- to 10-membered heterocycle, or C1-C20alkyl substituted with one or more -OH. In some embodiments, RD, RE, and RFare each independently H, C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O- (C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), - NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle. In some embodiments, RA, RB, RD, and REare each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide, and at least one of RA, RB, RD, and REis C3-C18alkyl, C3-C18alkenyl, or a peptide; and the n unit(s) of the first repeating unit and the m unit(s) of the second repeating unit are connected to form a block copolymer or a random copolymer. In some embodiments of Formula (A-3), RA, RB, RD, and REare each independently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl, and at least one of RA, RB, RD, and REis not H. In some embodiments of Formula (A-3), RAis H or C12H25; RBis C12H25; RDis H or C12H25; and REis C12H25. In some embodiments, L9-R5is –CH2CH2NH2, - CH2CH2NHCOOC(CH3)3, –CH2CH2CH2NH2, -CH2CH2CH2NHCOOC(CH3)3, – CH2CH2CH2CH2NH2, -CH2CH2CH2CH2NHCOOC(CH3)3, –CH2CH2CH2CH2CH2NH2, - CH2CH2CH2CH2CH2NHCOOC(CH3)3, –(CH2)6NH2, or –(CH2)6COOC(CH3)3. In some embodiments, L9-R5is –CH2CH2CH2NH2or -CH2CH2CH2NHCOOC(CH3)3. In some embodiments, R6is C1-C18 alkyl, C12 alkyl, C14 alkyl, C16 alkyl, C18 alkyl, isoamyl, C2-C18 alkenyl, nonenyl, or oleyl. In some embodiments, R6is C9alkyl, C10alkyl, C12alkyl, C14alkyl, C16 alkyl, C18 alkyl. In some embodiments, R6is C12H25.

[0148] In some embodiments, the cationic polymer is a copolymer (e.g., a block copolymer or a random copolymer), wherein n is an integer from 1 to 500, for example, any of 1 to 400, 1 to 350, 1 to 300, 1 to 250, 1 to 200, 1 to 150, 1 to 130, 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to 20, or 1 to 10. In some embodiments, the cationic polymer is a copolymer (e.g., a block copolymer or a random copolymer), wherein m is an integer from 1 to 500, for example, any of 1 to 400, 1 to 350, 1 to 300, 1 to 250, 1 to 200, 1 to 150, 1 to 130, 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 5 to 50, 5 to 40, 5 to 30, or 5 to 20. In some embodiments, the cationic polymer is a copolymer (e.g., a block copolymer or a random copolymer), wherein the ratio of n to m is 48ny-2728093Attorney Ref.28767-20004.40 about 1:20 to 20:1, such as about any of 1:15 to 15:1, 1:10 to 10:1, 1:10 to 5:1, 1:10 to 3:1, or 1:10 to 2:1.

[0149] In some embodiments, the cationic polymer is a copolymer (e.g., a block copolymer or a random copolymer) with a molecular weight of about 1 to 150 kDa, such as about any of 1 to 130 kDa, 1 to 100 kDa, 1 to 75 kDa, 1 to 50 kDa, 1 to 25 kDa, 1 to 20 kDa, 2 to 20 kDa, 2 to 15 kDa, 2 to 10 kDa, 1 to 10 kDa, 1 to 8 kDa, 2 to 8 kDa, 1 to 6 kDa, 2 to 6 kDa, 1 to 4 kDa, 2 to 4 kDa, 1 to 3 kDa, or 2 to 3 kDa. Homopolymer

[0150] In some embodiments, n is 0 and wherein the cationic polymer is a homopolymer comprising m repeating unit(s) of Formula (II). In some embodiments, the cationic polymer is a homopolymer comprising a structural unit of Formula (B):wherein m is an integer from 1 to 500; and wherein L5, R3, L6, L7, R4, L8, and R6are as defined in Formula (II). In some embodiments, L5, R3, L6, L7, R4, L8, and R6can be any of the embodiments defined for Formula (II).

[0151] In some embodiments, the cationic polymer is a homopolymer comprising a structuralinteger from 1 to 500.

[0152] In some embodiments of Formula (B) or Formula (B-1), the cationic polymer further comprises two end groups EG1and EG2, wherein: end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18 alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl; and end group49ny-2728093Attorney Ref.28767-20004.40and RD, RE, and RFare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl. In some embodiments, the cationic polymer further comprises two end groups EG1and EG2. In some embodiments, end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl or a peptide. In some embodiments, end group EG2isand RD, RE, and RFare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide. In some embodiments, the peptide is a polymer of amino acids. In some embodiments, the amino acids are all naturally occurring amino acids. In some embodiments, at least one amino acid is an artificial chemical mimetic of a corresponding naturally occurring amino acid. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof.

[0153] In some embodiments, when EG1is NRARB, then EG2isand the cationic polymer is end-capped by RA, RB, RD, and RE, wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, and at least one of RA, RB, RD, and REis C3-C18 alkyl, C3-C18 alkenyl, or a peptide. In some embodiments, RA, RB, RD, and REare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20- membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl, and at least one of RA, RB, RD, and REis not H. In some embodiments, at least one of RA, RB, RD, and REis C3-C18 alkyl or C3-C18alkenyl. In some embodiments, at least one of RAand RBis C3-C18alkyl or C3-C1850ny-2728093Attorney Ref.28767-20004.40 alkenyl and at least one of RD, and REis C3-C18 alkyl or C3-C18 alkenyl. In some embodiments, at least one of RAand RBis C9-C18alkyl or C9-C18alkenyl and at least one of RD, and REis C9-C18 alkyl or C9-C18 alkenyl. In some embodiments, at least one of RAand RBis C9-C18alkyl and at least one of RD, and REis C9-C18alkyl.

[0154] In some embodiments, the cationic polymer is a polymer of Formula (B-2):(B-2), wherein RAand RDare each independently H or C12H25 and wherein m is an integer from 1 to 500.

[0155] In some embodiments, when EG1is SRC, then EG2isthe cationic polymer is end-capped by RCand RF, wherein RCand RFare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, and at least one of RCand RFis C3-C18 alkyl, C3-C18 alkenyl, or a peptide. In some embodiments, RCand RFare each independently H, C3-C18alkyl, C3-C18alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18alkyl, or C3-C18alkenyl, and at least one of RCand RFis not H. In some embodiments, RCand RFare each independently selected C3-C18 alkyl. In some embodiments, RCand RFare each independently selected C9-C18alkyl. In some embodiments, RCand RFare both C12 alkyl. In some embodiments, RCand RFare each independently selected peptide. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of one amino acid in the peptide. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of a cysteine in the end-capping peptide. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof.

[0156] In some embodiments of Formula (B), (B-1), or (B-2), m is an integer from 1 to 500. In some embodiments of the foregoing, m is an integer from 1 to 500, for example, any of 1 to 400, 1 to 350, 1 to 300, 1 to 250, 1 to 200, 1 to 150, 1 to 130, 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 5 to 50, 5 to 40, 5 to 30, or 5 to 20. 51ny-2728093Attorney Ref.28767-20004.40 Homopolymer with End Modification

[0157] In some embodiments, m is 0, and the cationic polymer comprises n repeating unit(s) of Formula (I). In some embodiments, the cationic polymer is of Formula (C-0)wherein EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6- membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl, provided that RAand RBare not both H; wherein EG2isindependently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl, provided that RDand REare not both H; wherein n is an integer from 1 to 500; and wherein L1, R1, L2, L3, R2, and L4are as defined in Formula (I). In some embodiments, L1, R1, L2, L3, R2, and L4 can be any of the embodiments defined for Formula (I).

[0158] In some embodiments, m is 0, and the cationic polymer comprises n repeating unit(s) of Formula (I). In some embodiments, the cationic polymer is of Formula (C) 52ny-2728093Attorney Ref.28767-20004.40wherein EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3- C18alkyl, C3-C18alkenyl or a peptide, provided that RAand RBare not both H; wherein EG2isindependently H, C3-C18alkyl, C3-C18alkenyl or a peptide, provided that RDand REare not both H; wherein n is an integer from 1 to 500; and wherein L1, R1, L2, L3, R2, and L4 are as defined in Formula (I). In some embodiments, L1, R1, L2, L3, R2, and L4can be any of the embodiments defined for Formula (I).

[0159] In some embodiments, the cationic polymer is of Formula (C-1)(C-1), wherein RCand RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide, and at least one of RCand RFis C3-C18alkyl, C3-C18alkenyl, or a peptide, and wherein L9, R5, and n are as defined for Formula (I). In some embodiments, RCand RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6- membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl, and at least one of RCand RFis not H. In some embodiments, RCand RFare each independently selected C3-C18alkyl. In some embodiments, RCand RFare 53ny-2728093Attorney Ref.28767-20004.40 each independently selected C9-C18 alkyl. In some embodiments, RCand RFare both C12 alkyl. In some embodiments, RCand RFare each independently selected peptide. In some embodiments, the peptide is a polymer of amino acids. In some embodiments, the amino acids are all naturally occurring amino acids. In some embodiments, at least one amino acid is an artificial chemical mimetic of a corresponding naturally occurring amino acid. In some embodiments, the peptide is a dipeptide, tripeptide, tetrapeptide, or an oligopeptide, or a polypeptide. In some embodiments, the peptide is a polypeptide comprising at least two (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or between 1 to 10) amino acids. In some embodiments, the peptide comprises Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of one amino acid in the peptide. In some embodiments, the sulfur in the SRCand SRFis part of the side chain of a cysteine in the end-capping peptide.

[0160] In some embodiments, the cationic polymer is of Formula (C-2)(C-2), wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, or C3-C18alkenyl, provided that RAand RBare not both H, and RDand REare not both H, and wherein L9, R5, and n are as defined for Formula (I). In some embodiments, RA, RB, RD, and REare each independently H, C3-C18 alkyl, C3-C18 alkenyl, a peptide, 3- to 20-membered heterocycle (e.g., 5- to 6-membered heterocycle or piperazine), or -NRN2, wherein RNis each independently H, C3-C18 alkyl, or C3-C18 alkenyl, and at least one of RA, RB, RD, and REis not H. In some embodiments, at least one of RA, RB, RD, and REis C3-C18 alkyl or C3-C18 alkenyl. In some embodiments, at least one of RAand RBis C3-C18alkyl or C3-C18alkenyl and at least one of RD, and REis C3-C18 alkyl or C3-C18 alkenyl. In some embodiments, at least one of RAand RBis C9-C18alkyl or C9-C18alkenyl and at least one of RD, and REis C9-C18alkyl or C9- C18 alkenyl. In some embodiments, at least one of RAand RBis C9-C18 alkyl and at least one of RD, and REis C9-C18alkyl. In some embodiments, at least one of RAand RBis C9-C18alkenyl and at least one of RD, and REis C9-C18 alkenyl. In some embodiments, RAand RDare H, and RBand REare C12-C18alkenyl. In some embodiments, RA, RB, RCand RDare each independently selected C3-C18 alkyl. In some embodiments, the C3-C18 alkyl is C4H9, C6H13, C8H17, C9H19, C12H25, or C18H37. In some embodiments, the C3-C18alkyl is C12H25. 54ny-2728093Attorney Ref.28767-20004.40

[0161] In some embodiments of Formula (C), (C-1), or (C-2), L9-R5is –CH2CH2NH2, - CH2CH2NHCOOC(CH3)3, –CH2CH2CH2NH2, -CH2CH2CH2NHCOOC(CH3)3, – CH2CH2CH2CH2NH2, -CH2CH2CH2CH2NHCOOC(CH3)3, –CH2CH2CH2CH2CH2NH2, - CH2CH2CH2CH2CH2NHCOOC(CH3)3, –(CH2)6NH2, or –(CH2)6COOC(CH3)3. In some embodiments, L9-R5is –CH2CH2CH2NH2 or -CH2CH2CH2NHCOOC(CH3)3. In some embodiments of Formula (C), (C-1), or (C-2), n is an integer from 1 to 500. In some embodiments of the foregoing, n is an integer from 1 to 500, for example, any of 1 to 400, 1 to 350, 1 to 300, 1 to 250, 1 to 200, 1 to 150, 1 to 130, 1 to 100, 1 to 90, 1 to 80, 1 to 70, 1 to 60, 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 5 to 50, 5 to 40, 5 to 30, or 5 to 20.

[0162] In some embodiments, any of the cationic polymer described herein can be optionally protonated. In some embodiments, any of the nitrogen, oxygen, and sulfur in the cationic polymer described herein can be optionally protonated. In some embodiments, any of the protonated cationic polymer provided herein can be deprotonated. In some embodiments, despite that the formula or structure of the cationic polymer provided herein may show the cationic polymer as a deprotonated form, a partially protonated form, or a fully protonated form, it is to be understood that the formula or structure encompasses all of the deprotonated forms, possible partially protonated forms, and fully protonated forms of the cationic polymer.

[0163] In some embodiments, the cationic polymer is a polymer selected from polymers in Table 1. In some embodiments, the cationic polymer is a polymer selected from the group consisting of polymer No.5, No.6, No.7, No.8, No.9, No.10, No.11, No.12, No.13, No. 14, No.16, No.17, No.18, No.19, No.20, No.21, No.22, No.23, No.24, No.25, No.26, No.27, No.28, No.29, No.30, No.31, No.32, No.33, No.34, No.35, No.36, No.37, No. 38, No.39, No.40, No.41, No.42, No.43, No.44, No.45, No.70, No.71, No.72, No.73, No.74, No.75, No.76, No.77, No.78, No.79, No.80, No.81, No.82, No.83, No.90, No. 91, No.92, No.93, No.94, No.95, No.96, No.97, No.98, No.99, No.100, No.101, No. 146, No.147, No.148, No.149, No.150, No.151, No.152, No.153, No.154, No 155, No. 156, No.157, No.158, No.159, No.160, No.161, No.162, No.163, No.164, No.165, No. 172, and No.173. In some embodiments, the cationic polymer is a polymer selected from the group consisting of polymer No.5, No.6, No.7, No.8, No.9, No.10, No.11, No.12, No. 13, No.14, No.16, No.17, No.18, No.19, No.20, No.21, No.22, No.23, No.24, No.25, No.26, No.27, No.28, No.29, No.30, No.31, No.32, No.33, No.34, No.35, No.36, No. 37, No.38, No.39, No.40, No.41, No.42, No.43, No.44, No.45, No.70, No.71, No.72, No.73, No.74, No.75, No.76, No.77, No.78, No.79, No.80, No.81, No.82, and No.83. 55ny-2728093Attorney Ref.28767-20004.40 In some embodiments, the cationic polymer is a polymer selected from the group consisting of polymer No.90, No.91, No.92, No.93, No.94, No.95, No.96, No.97, No.98, No.99, No.100, No.101, No.146, No.147, No.148, No.149, No.150, No.151, No.152, No.153, No.154, No 155, No.156, No.157, No.158, No.159, No.160, No.161, No.162, No.163, No.164, No.165, No.172, and No.173. In some embodiments, the cationic polymer is Polymer No.43 in Table 1. In some embodiments, the cationic polymer is Polymer No.45 in Table 1. 56ny-272809304.4e0di= = =0 t02-76782.feRyenrottA 1elbaTre390m8yl. 27oo2-PN3 4 5 6 7yn04.4e0di0 t0 pe2- p / t7dn6iet7p n8i o2L C.feRtlmry aSoe FnrottA puorG dnEre390m8yl. 27oo0 1 2-PN8 9 1 12131yn04.4e0di0 t0 pe2- p / t7dn6iet7p8ino2L C.feRtlmry ae SoFnrottA puorG dnEre390m8yl2o .o 745 6 7 2-PN1 1 1 18191yn04.4e0di0 t0 pe2- p / t7dne6i t7p n8i2LoC.feRtlmary oe S FnrottA puorG dnEre390m8yl27o.o2-PN02122232yn04.4e0di0 t0 pe2- p / tn7d6iet7p8ino2L C.feRtlmry aSoe FnrottA puorG dnEre390m8yl27o.o4 5 6 7 8 2-PN2 2 2 2 29203yn04.4e0di0 t0 pe2- p / t7dn6iet7p8ino2L C.feRtlmry ae SoFnrottA puorG dnEre390m8yl2o .o 712 3 4 2-PN3 3 3 35363yn04.4e0di0 t0 pe2- p / t7dn6iet7p8ino2L C.feRtlmry ae SoFnrottA puorG dnEre390m8yl2o .o 778 9 0 2-PN3 3 3 41424yn04.4e0di0 t0 pe2- p / t7dn6iet7p n8i o2L C.feRtlmry aSoe FnrottA puorG dnEre390m8yl. 27oo3 4 2-PN4 4540717yn04.4e0di0 t0 pe2- p / t7dn6iet7p n8i o2L C.feRtlmry aSoe FnrottA puorG dnEre390m8yl. 27oo2 3 2-PN7 7475767yn04.4e0di0 t0 pe2- p / t7dn6iet7p n8i o2L C.feRtlmry aSoe FnrottA puorG dnEre390m8yl. 27oo7 8 2-PN7 7970818yn04.4e0di0 t0 pe2- p / t7dne6i t7p n8i2LoC.feRtlmary oe S FnrottA puorG dnE76re390m8ylo . 272-P oN283809yn04. edi40 i0 t al0 pety2- p / nel7d e6i7ptn o:c8i2LoCo.feRtlmary oe S FnrottA puorG dnEre390m8ylo . 2o712 3 2-PN9 9 9yn04.4e0dil0 ty0 pe2- p / tna7d eosi6i7ptn:8i oco2L C.feRtlmry ae SoFnrottA puorG dnE96re390m8ylo . 2o745 6 2-PN9 9 9yn04.4e0di0 t0 p aley2- p / t7dneel6i t o:27p8ino2L C.feRtlmry a oe S FnrottA puorG dnEn N n N N2N O H2O H N H N H S S S S H N H N O O re390m8yl27o.o7 8 2-PN9 999yn04.4ely0di0 t0 pe2- p / tna7d eosi6i t:27p8ino2L C.feRtlmarySoe FnrottA puorG dnEre390m8ylo . 2Po 0 1 6 7 72- N01014141yneditpep / tdn -ieptin 6:LocCotlmarSoFpuorG dnEre390m8ylo . 2o8 74940 12-PN1 15151yn04.4e0di0 t0 pe -2- p / t7dne 16i t7p8in:c2LoCo.feRtlmy aroe S FnrottA puorG dnE37re390m8ylo .o 253542752-PN1 1 1yn04.4e0di0 t0 p-e22- p / t(n(7d e -36ipt:ino2782L C.feRtlmry aSoe FnrottA puorG dnEre390m8ylo .o 556572752-PN1 1 1yn04.4e0di0 t0 pe2- p / t7dne6i t -37p8in:c2LoCo.feRtlmarySoe FnrottA puorG dnEre390m8ylo .o 859502762-PN1 1 1yn04.4e0di-0 t0 pe2t2(- p / n-7d e6iptn :278i2LoC.feRtlmarye SoFnrottA puorG dnEHn n N N N N2O HcO H N HoB N H S S S S H N H N O O re390m8ylo .o 1626364652762-PN1 1 1 1 1yn04.4e0di0 t0 pe 22- p / t7dn1e6iptn :278i2LoC.feRtlmry a o le S FnrottAH H p Na Nee emab o:diu5o2N52ot,elwdr H2tis ylor2 seHnG1H2)1copmebgn pn myN.i2dC CBanHxe oiitni il sH E NaS o puN -rroarrt-SpooFano enirg neeH2 .t l cno 2ht S-ew enmHoeN tSnite- s eh mabN-,.ophtpu tlyoitg.m e(ost nneeor ot x ags ehrrtcn e eswt d p-lale derebn uoy onit po eo peer itdrng htm de- epp 21arane 2 htmorCco) :2raslni dadn n sat7n7ecliyHohnn N.mca sesnni saeroiteaklr ehdia hpec aeti a8s s h c r41my tni ceed Rfo Cl-4onpesespdis :2uis nH oitCcard irnp o nii2N oerrg sH.sretit r5pNpualut acoH2uo nooitsesn21rgergmbhtoiCe ewleuhsty ntia-cni eits lhzeyeab loa la)2 5f2 itnndfr ooepit ehtwoiotHoh p21moiitp areradnas osrC(dnaerrht lif oso N- amnitlnyd nilet kl naooh moi e aththcna a coc8earoeH2ht htrt sdiC1Nioalresed-i 4 -wtrtso fenip Cnred ee rememr 2feehenH.sep 3 / etuwtyelo rt oiNpmnu90mdyiti ltb poS- t Ssraleoyerg 827o.Po 2 3pisboi N7171Ltm:2*usarohC1 efexwt d2-rehebneynAttorney Ref.28767-20004.40 III. Salt

[0164] In some embodiments, provided herein is a salt form of the cationic polymer described herein. In some embodiments, the salt is a pharmaceutically acceptable salt.

[0165] In some embodiments, the salt (e.g., pharmaceutically acceptable salt) may be derived from a variety of organic and inorganic counter-ions well known in the art. Such salt includes, but is not limited to: (1) acid addition salt formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, adepic, aspartic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-oct-2-ene-i-carboxylic, glucoheptonic, 3- phenylpropionic, trimethylacetic, tert-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid and the like acids; or (2) base addition salt formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion or an aluminium ion, or alkali metal or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminium, lithium, zinc, and barium hydroxide, ammonia or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like.

[0166] In some embodiments, the salt (e.g., pharmaceutically acceptable salt) may include, but are not limited to, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrohalides, e.g. hydrochloride, hydrobromide and hydroiodide, carbonate or bicarbonate, sulfate or bisulfate, borate, phosphate, hydrogen phosphate, dihydrogen phosphate, pyroglutamate, saccharate, stearate, sulfamate, nitrate, orotate, oxalate, 78ny-2728093Attorney Ref.28767-20004.40 palmitate, pamoate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, tannate, tartrate, tosylate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, camsylate, citrate, cyclamate, benzoate, isethionate, esylate, formate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), methylsulphate, naphthylate, 2-napsylate, nicotinate, ethanesulfonate, 1,2-ethane-disulfonate, 2- hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2- naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4- methylbicyclo[2.2.2]-oct-2-ene-i-carboxylate, glucoheptonate, 3-phenylpropionate, trimethylacetate, tert-butylacetate, lauryl sulfate, gluceptate, gluconate, glucoronate, hexafluorophosphate, hibenzate, benzoate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate, xinofoate and the like. Hemisalts of acids and bases may also be formed, for example, hemisulphate salts. In one embodiment, the cationic polymer is in the form of a hydrochloric salt. In one embodiment, the cationic polymer is in the form of a trifluoroacetate salt. IV. Polymer / Nucleic Acid Complex and Nanoparticle Composition

[0167] In some embodiments, provided herein is a complex comprising the cationic polymer described herein, or a salt thereof, or a pharmaceutically acceptable salt thereof, and a nucleic acid. In some embodiments, the nucleic acid binds to the cationic polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, via non-covalent interaction. In some embodiments, the nucleic acid binds to the cationic polymer via electro-static interaction.

[0168] In some embodiments, the nucleic acid can be any polyanion that includes multiple negatively charged groups that can be complexed with the cationic polymer described herein. In some embodiments, the nucleic acid can be any deoxyribonucleotides or ribonucleotides and polymers thereof in either single-, double- or multiple-stranded form, or complements thereof. In some embodiments, the nucleic acid can be a polynucleotide or an oligonucleotide, wherein the polynucleotide and oligonucleotide are used in the usual and customary sense and refer to a linear sequence of nucleotides with various lengths. In some embodiments, the nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof. In some embodiments, examples of polynucleotides contemplated herein include, but are not limited to, single and 79ny-2728093Attorney Ref.28767-20004.40 double stranded DNA, single and double stranded RNA, and hybrid molecules having mixtures of single and double stranded DNA and RNA. In some embodiments, examples of polynucleotides contemplated herein include, but are not limited to, any types of RNA, such as messenger RNA (mRNA), small interference RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), self-amplifying mRNA (saRNA), transactivating RNA (tracrRNA), guide RNA (gRNA), gene editing including CRISPR RNA (crRNA), RNA component in CRISPR (e.g. Cas protein encoding mRNA, guide RNA, etc.), DNA component in CRISPR (e.g. Cas protein encoding plasmid, single-guide RNA encoding plasmid, etc.), plasmid DNA (pDNA), minicircle DNA, circular DNA (cDNA), single-stranded DNA (ssDNA), single-stranded circular DNA (circDNA), genomic DNA (gDNA), or any fragments thereof, or any combination thereof. In some embodiments, the nucleic acid can be linear or branched. For example, nucleic acids can be a linear chain of nucleotides or the nucleic acids can be branched, e.g., such that the nucleic acids have one or more arms or branches of nucleotides. Optionally, the branched nucleic acids are repetitively branched to form higher ordered structures such as dendrimers and the like.

[0169] In some embodiments, the nucleic acid, including for example a nucleic acid with a phosphothioate backbone, can include one or more reactive moieties. In some embodiments, the reactive moiety may include any group capable of reacting with another molecule, for example, a nucleic acid or polypeptide through covalent, non-covalent or other interactions. In some embodiments, for example, the nucleic acid can include an amino acid reactive moiety that reacts with an amino acid on a protein or polypeptide through a covalent, non-covalent or other interaction.

[0170] In some embodiments, the nucleic acid comprises a nucleotide analog or modified backbone residues or linkages, which can be naturally occurring or non-naturally occurring, and have similar binding properties as the reference nucleic acid, and are metabolized in a manner similar to the reference nucleotides. In some embodiments, examples of such analogs include, but are not limited to, phosphodiester derivatives, such as phosphoramidate, phosphorodiamidate, phosphorothioate (also known as phosphothioate having double bonded sulfur replacing oxygen in the phosphate), phosphorodithioate, phosphonocar- boxylic acids, phosphonocarboxylates, phosphonoacetic acid, phosphonoformic acid, methyl phosphonate, boron phosphonate, or O-methylphosphoroamidite linkages, as well as modifications to the nucleotide bases such as in 5-methyl cytidine or pseudouridine; and peptide nucleic acid 80ny-2728093Attorney Ref.28767-20004.40 backbones and linkages. In some embodiments, other analog nucleic acids include, but are not limited to those with positive backbones; non-ionic backbones, modified sugars, and non-ribose backbones (e.g. phosphorodiamidate morpholino oligos or locked nucleic acids (LNA) as known in the art). In some embodiments, the nucleic acid comprises one or more carbocyclic sugars. In some embodiments, the nucleic acid is an aptamer.

[0171] In some embodiments, the nucleic acid can comprise nonspecific sequences. “Nonspecific sequence” typically refers to a nucleic acid sequence that contains a series of residues that are not designed to be complementary to or are only partially complementary to any other nucleic acid sequence. In some embodiments, the nonspecific nucleic acid sequence is a sequence of nucleic acid residues that does not function as an inhibitory nucleic acid when contacted with a cell or organism. “Inhibitory nucleic acid” typically refers to a nucleic acid (e.g. DNA, RNA, oligonucleotide, polymer or oligomer of nucleotide analogs) that is capable of binding to a target nucleic acid (e.g. an mRNA translatable into a protein) and reducing transcription of the target nucleic acid or a fragment of nucleic acid (e.g. mRNA from DNA) or reducing the translation of the target nucleic acid (e.g. mRNA) or altering transcript splicing (e.g. single stranded morpholino oligo). In some embodiments, the nucleic acid is an inhibitory nucleic acid.

[0172] In some embodiments, the complex comprises more than one nucleic acid, wherein each nucleic acid is independently selected from any of the nucleic acids described herein, provided that the more than one nucleic acids are chemically and biologically compatible. In some embodiments, the complex comprises only one type of nucleic acid independently selected from any of the nucleic acids described herein. In some embodiments, the nucleic acid may comprise messenger RNA (mRNA), small interference RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), self-amplifying mRNA (saRNA), transactivating RNA (tracrRNA), guide RNA (gRNA), gene editing including CRISPR RNA (crRNA), a RNA component in CRISPR (e.g. Cas protein encoding mRNA, guide RNA, etc.), a DNA component in CRISPR (e.g. Cas protein encoding plasmid, single-guide RNA encoding plasmid, etc.), plasmid DNA (pDNA), minicircle DNA, circular DNA (cDNA), single-stranded DNA (ssDNA), single-stranded circular DNA (circDNA), genomic DNA (gDNA), or any combination thereof. In embodiments, the nucleic acid is RNA (e.g. mRNA). In some embodiments, the nucleic acid is a RNA component in CRISPR (e.g. Cas protein encoding mRNA, guide RNA, etc.). In some embodiments, the nucleic 81ny-2728093Attorney Ref.28767-20004.40 acid is a DNA component in CRISPR (e.g. Cas protein encoding plasmid, single-guide RNA encoding plasmid, etc.). In some embodiments the nucleic acid is 10 to 100,000 bases in length. In some embodiments the nucleic acid is about 10 and 10,000 bases in length. In some embodiments the nucleic acid is about 10 and 50 bases in length. In some embodiments the nucleic acid is about 50 and 5,000 bases in length. In embodiments the nucleic acid is about 50 and 1,000 bases in length.

[0173] In some embodiments, the molar ratio of the cationic polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, to the nucleic acid in the complex (N / P ratio) ranges from about 1:200 to 200:1, for example, about any of 1:150 to 200:1, 1:100 to 200:1, 1:50 to 200:1, 1:1 to 200:1, 1:1 to 175:1, 1:1 to 150:1, 1:1 to 125:1, 1:1 to 100:1, 5:1 to 100:1, 10:1 to 100:1, 10:1 to 75:1, 10:1 to 50:1, 10:1, 20:1, 25:1, 30:1, 40:1, or 50:1.

[0174] In some embodiments, the length, composition and stoichiometry of the cationic polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, in the complex may be selected to provide for a desired amount of electrostatic interactions with the nucleic acid of interest.

[0175] In some embodiments, the complex described herein may be chemically modified to include a label, e.g., a fluorescent label. In some embodiments, the label is attached onto the cationic polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, the label is attached onto the nucleic acid. In some embodiments, the label enables the imaging of the distribution and activity of the complex, the cationic polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, and / or the nucleic acid in vitro and / or in vivo. In some embodiments, the complex comprises a labeled mRNA, such as an mRNA labeled with a fluorescent group. In some embodiments, the complex comprises an mRNA encoded with fluorescent reporter protein genes (e.g., GFP), or an mRNA encoding an enzymatic protein (e.g. luciferase) that could produce luminescence signal in presence of reporter molecules (e.g. luciferin), which allows for the measurement of level of protein expression.

[0176] In some embodiments, provided herein is a nanoparticle composition comprising a plurality of the complex described herein. In some embodiments, the nanoparticles are stable on the timescales necessary for intracellular gene delivery, and then they release the oligonucleotide cargo once inside the cell. In some embodiments, the average particle size of the nanoparticles is about 50 nm to about 1 μm, for example, about any of 50 nm to 900 nm, 50 nm to 500 nm, 70 nm to 250 nm, or 500 nm to 900 nm. In some embodiments, the average particle in a 82ny-2728093Attorney Ref.28767-20004.40 nanoparticle composition comprising a plurality of freshly prepared complex is about 30 nm to about 600 nm, for example, about any of 30 nm to 500 nm, 30 nm to 400 nm, 40 nm to 400 nm, 50 nm to 300 nm, 70 nm to 250 nm, 70 nm to 200 nm, 70 nm to 170 nm, 70 nm to 150 nm, or 100 nm to 150 nm. In some embodiments, the average particle size may increase after storing for a period of time. In some embodiments, the polydispersity index of nanoparticles in the nanoparticle composition is about 0.01 to about 0.6, for example, about any of 0.01 to 0.5, 0.02 to 0.5, or 0.05 to 0.5. In some embodiments, the average particle size and polydispersity index (PDI) of the nanoparticle composition can be tuned by the pH or media used for the preparation of the complex. In some embodiments, the nanoparticles in the nanoparticle composition have a PDI of about 0 to about 0.5, such as about any of about 0.05 to about 0.45, about 0.1 to about 0.45, about 0.1 to about 0.4, about 0.1 to about 0.35, about 0.1 to about 0.3, or about 0.1 to about 0.2.

[0177] In some embodiments, the nanoparticle composition further comprises PEG. In some embodiments, the PEG comprises DMG-PEG2000. In some embodiments, the PEG is DMG- PEG2000. In some embodiments, the weight percentage of PEG (e.g., DMG-PEG2000) in the nanoparticle composition is about 0.01% to about 20%, such as about any of 0.01% to 18%, 0.01% to 16%, 0.01% to 14%, 0.01% to 12%, 0.01% to 10%, 0.01% to 8%, 0.01% to 5%, 0.1% to 3%, 0.1% to 1%, 0.1% to 0.9%, 0.2% to 0.9%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, or about 0.7%. Nuclease-based gene editing system comprising nuclease and gRNA

[0178] In some embodiments, the cationic polymers described herein can be used to deliver nuclease-based gene editing systems, for example gene editing systems comprising a nuclease (e.g., Cas protein) and / or a guide RNA. In some embodiments, the complex comprises a first nucleic acid encoding a nuclease and / or a guide RNA (or a second nucleic acid encoding a guide RNA). In some embodiments, the first nucleic acid is mRNA encoding the nuclease. In some embodiments, the first nucleic acid is DNA encoding the nuclease.

[0179] For example, in some embodiments, the complex comprises a first vector comprising a nucleic acid encoding a nuclease and a second vector comprising a nucleic acid encoding a guide RNA. In some embodiments, the complex comprises an mRNA encoding the nuclease and a guide RNA. In some embodiments, the complex comprises a first vector comprising a nucleic acid encoding a nuclease and a guide RNA. 83ny-2728093Attorney Ref.28767-20004.40

[0180] In some embodiments, gene editing system does not comprise a nucleic acid component, e.g., the gene editing system comprises a TALE or zinc finger, or a portion thereof capable of binding to double stranded DNA.

[0181] In some embodiments, the gene editing system comprises a nuclease and a guide RNA. For example, in some embodiments, the nuclease is a Cas protein. In certain embodiments, the Cas protein is selected from the group consisting of: Type I Cas, Type II Cas, Type V Cas, and Type VI Cas.

[0182] In other embodiments, the nuclease comprises a Cas protein such as Cas9, Cas12, Cas13, CasX, CasY, Cpf1, C2c1, C2c2, or C2c3, that binds DNA or RNA, or a fragment thereof. In some embodiments, the nuclease is a Cas9 protein. Cas9 recognizes a protospacer adjacent motif (PAM) of 5’-NGG-3’. Cas9 comprises a RuvC domain for cleavage of the non-target strand and a HNH domain for cleavage of the target strand. In certain embodiments, the nuclease is nicking Cas9, i.e., nCas9. nCas9 is a mutated form of Cas9 wherein an amino acid substitution disables cleavage of one strand of dsDNA. In some embodiments, this mutation is D10A in the RuvC domain, enabling cleavage of only the target strand. In some embodiments, this mutation is H840A in the HNH domain, enabling cleavage of only the non-target strand. In certain embodiments, the site-specific DNA binding domain is dead Cas9, i.e., dCas9. dCas9 is a mutated form of Cas9 with no endonuclease activity, comprising mutations of D10A in the RuvC domain and H840A in the HNH domain.

[0183] In some embodiments, the guide RNA (gRNA) described herein comprises spacer sequence capable of hybridizing to a target site and tracr RNA (scaffolding to Cas protein) as a single RNA molecule known as single guide RNA (sgRNA). sgRNA is known in the field, e.g., US Pat. No.11,015,193, which is hereby incorporated by reference herein in its entirety. In some embodiments, the gRNA comprises a spacer sequence capable of hybridizing to the target site adjacent to the methylations site and does not comprise a tracrRNA. gRNA length may be varied to refine targeting of the site-specific demethylation system described herein. A gRNA described herein may be about 10 to about 200 base pairs in length. In some embodiments, such a gRNA targets a spacer sequence that is about 10 to about 25 base pairs long. In some embodiments, the gRNA is modified.

[0184] In some embodiments, the gRNA (e.g., sgRNA) comprises a nucleotide sequence targeting TTR gene (e.g., human or mouse TTR gene), for example a sequence of any of SEQ ID 84ny-2728093Attorney Ref.28767-20004.40 NO: 1 (AAAGGCUGCUGAUGACACCU) or SEQ ID NO: 2 (ACACAAAUACCAGUCCAGCG).

[0185] Hence, in some embodiments, provided herein is a nanoparticle composition comprising: (i) a cationic polymer of Formula (A-1)(A-1) wherein the first repeating unit is of Formula (I-1) and the second repeating unit is of Formula (II-1),alkenyl, or C1-C8alkyl substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), -NH(C1-C20alkyl- OH), or 5- to 6-membered heterocycle; and wherein the n to m ratio is about 0.3 to about 0.8; and

[0186] (ii) a gene editing system comprising a nucleic acid encoding a nuclease (such as an mRNA) and / or a gRNA, optionally wherein the nuclease is Cas9; optionally wherein the molar ratio of the polymer to the total nucleic acid (nucleic acid encoding the nuclease and gRNA) (N / P ratio) is about 3:1 to about 25:1. In some embodiments, the gene editing system comprising Cas9 mRNA and gRNA at a weight ratio of about 1:1. In some embodiments, the gRNA is sgRNA. In some embodiments, the gRNA (e.g., sgRNA) comprises a nucleotide sequence targeting TTR gene (e.g., human or mouse TTR gene), such as the nucleic acid of any of SEQ ID NO: 1 (AAAGGCUGCUGAUGACACCU) or SEQ ID NO: 2 (ACACAAAUACCAGUCCAGCG). In some embodiments, the nanoparticle composition 85ny-2728093Attorney Ref.28767-20004.40 further comprises PEG (e.g., DMG-PEG2000). In some embodiments, the nanoparticle composition has a pH of about 5 to about 10, such as about 5 or about 8. In some embodiments, the nanoparticle composition can be administered via intravenous injection or subretinal injection.

[0187] In some embodiments, provided herein is a nanoparticle composition comprising: (i) a cationic polymer of Formula (A-1)(A-1) wherein the first repeating unit is of Formula (I-2) and the second repeating unit is of Formula (II-2),wherein RAis H or C12H25; RBis C12H25; RDis H, C12H25; and REis C12H25; and wherein the n to m ratio is about 0.3 to about 0.8; and (ii) a gene editing system comprising a nucleic acid encoding a nuclease (such as an mRNA) and / or a gRNA, optionally wherein the nuclease is Cas9; optionally wherein the molar ratio of the polymer to the total nucleic acid (nucleic acid encoding the nuclease and gRNA) (N / P ratio) is about 3:1 to about 25:1.

[0188] In some embodiments, the gene editing system comprising Cas9 mRNA and gRNA at a weight ratio of about 1:1. In some embodiments, the gRNA is sgRNA. In some embodiments, the gRNA (e.g., sgRNA) comprises a nucleotide sequence targeting TTR gene (e.g., human or mouse TTR gene), such as the nucleic acid of any of SEQ ID NO: 1 (AAAGGCUGCUGAUGACACCU) or SEQ ID NO: 2 (ACACAAAUACCAGUCCAGCG). In 86ny-2728093Attorney Ref.28767-20004.40 some embodiments, the nanoparticle composition further comprises PEG (e.g., DMG-PEG2000). In some embodiments, the nanoparticle composition has a pH of about 5 to about 10, such as about 5 or about 8. In some embodiments, the nanoparticle composition can be administered via intravenous injection or subretinal injection.

[0189] In some embodiments, provided herein is a nanoparticle composition comprising: (i) Polymer No.43 in Table 1; and (ii) a gene editing system comprising a nucleic acid encoding a nuclease (such as an mRNA) and / or a gRNA, optionally wherein the nuclease is Cas9; optionally wherein the molar ratio of the polymer to the total nucleic acid (nucleic acid encoding the nuclease and gRNA) (N / P ratio) is about 3:1 to about 25:1.

[0190] In some embodiments, the gene editing system comprising Cas9 mRNA and gRNA at a weight ratio of about 1:1. In some embodiments, the gRNA is sgRNA. In some embodiments, the gRNA (e.g., sgRNA) comprises a nucleotide sequence targeting TTR gene (e.g., human or mouse TTR gene), such as the nucleic acid of any of SEQ ID NO: 1 (AAAGGCUGCUGAUGACACCU) or SEQ ID NO: 2 (ACACAAAUACCAGUCCAGCG). In some embodiments, the nanoparticle composition further comprises PEG (e.g., DMG-PEG2000). In some embodiments, the nanoparticle composition has a pH of about 5 to about 10, such as about 5 or about 8. In some embodiments, the nanoparticle composition can be administered via intravenous injection or subretinal injection.

[0191] In some embodiments, provided herein is a nanoparticle composition comprising: (i) Polymer No.45 in Table 1; and (ii) a gene editing system comprising a nucleic acid encoding a nuclease (such as an mRNA) and / or a gRNA, optionally wherein the nuclease is Cas9; optionally wherein the molar ratio of the polymer to the total nucleic acid (nucleic acid encoding the nuclease and gRNA) (N / P ratio) is about 3:1 to about 25:1.

[0192] In some embodiments, the gene editing system comprising Cas9 mRNA and gRNA at a weight ratio of about 1:1. In some embodiments, the gRNA is sgRNA. In some embodiments, the gRNA (e.g., sgRNA) comprises a nucleotide sequence targeting TTR gene (e.g., human or mouse TTR gene), such as the nucleic acid of any of SEQ ID NO: 1 (AAAGGCUGCUGAUGACACCU) or SEQ ID NO: 2 (ACACAAAUACCAGUCCAGCG). In some embodiments, the nanoparticle composition further comprises PEG (e.g., DMG-PEG2000). 87ny-2728093Attorney Ref.28767-20004.40 In some embodiments, the nanoparticle composition has a pH of about 5 to about 10, such as about 5 or about 8. In some embodiments, the nanoparticle composition can be administered via intravenous injection or subretinal injection. V. Pharmaceutically Compositions

[0193] In one aspect, provided herein is a composition comprising the cationic polymer described herein, or a salt thereof, or a pharmaceutically acceptable salt thereof, the nucleic acid described herein, and an excipient. In one aspect, provided herein is a composition comprising the complex described herein and an excipient. In some embodiments, the composition is a pharmaceutically acceptable composition.

[0194] In some embodiments, the excipient is an inert or inactive substance that may be used in the production of a drug or pharmaceutical, such as a tablet containing a compound provided herein as an active ingredient. In some embodiments, exemplary excipient includes, but is not limited to, a binder, disintegrant, surfactant, coating, compression / encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending / gelling agent, or wet granulation agent. In some embodiments, exemplary binders include, but are not limited to, carbomers, povidone, xanthan gum, or any combination thereof. In some embodiments, exemplary coatings include, but are not limited to, cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, or any combination thereof. In some embodiments, exemplary compression / encapsulation includes, but is not limited to, calcium carbonate, dextrose, fructose, honey, lactose (anhydrate or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, or any combination thereof. In some embodiments, exemplary disintegrants include, but are not limited to, croscarmellose sodium, gellan gum, sodium starch glycolate, or any combination thereof. In some embodiments, exemplary creams or lotions include, but are not limited to, maltodextrin, carrageenans, or any combination thereof. In some embodiments, exemplary lubricants include, but are not limited to, magnesium stearate, stearic acid, sodium stearyl fumarate, or any combination thereof. In some embodiments, exemplary materials for chewable tablets include, but are not limited to, dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), or any combination thereof. In some embodiments, exemplary suspending / gelling agents include, but are not limited to, carrageenan, 88ny-2728093Attorney Ref.28767-20004.40 sodium starch glycolate, xanthan gum, or any combination thereof. In some embodiments, exemplary wet granulation agents include, but are not limited to, calcium carbonate, maltodextrin, microcrystalline cellulose, or any combination thereof. In some embodiments, the excipients may include water, a pharmaceutical acceptable organic solvent, collagen, polyvinyl alcohol, polyvinylpyrrolidone, a carboxyvinyl polymer, carboxymethylcellulose sodium, polyacrylic sodium, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methyl cellulose, ethyl cellulose, xanthan gum, gum Arabic, casein, gelatin, agar, diglycerin, glycerin, propylene glycol, poly- ethylene glycol, Vaseline, paraffin, stearyl alcohol, stearic acid, human serum albumin (HSA), mannitol, sorbitol, lactose, a pharmaceutically acceptable surfactant and the like. The excipients used can be chosen from, but not limited to, the above or combinations thereof, as appropriate, depending on the dosage form of the present disclosure.

[0195] In some embodiments, the composition further comprises an immunological adjuvant. In some examples, the immunological adjuvant can include, but is not limited to, agonists of Toll- like Receptors (TLRs), agonists of the STING pathway, agonistic antibodies against CD40, OX40, CTLA4, PD-1, or PDL1, Freund's adjuvant, bryostatins and ligands for CD40, OX40, CD137, PD-1, CTLA4 and any combinations thereof. In some embodiments, the adjuvant can increase immunogenicity that is induced by the complex described herein when co-administered with the complex to a subject.

[0196] In some embodiments, the excipients in the pharmaceutical compositions can vary according to the route of administration selected (e.g., solution, emulsion). Routes of administration can be, for example, intramuscular, subcutaneous, intravenous, intralymphatic, subcutaneous, intramuscular, intraocular, topical skin, oral, inhalation, intravesical (bladder), intranasal, intraanal and intravaginal.

[0197] In some embodiments, the composition can further comprise a cryoprotectant agent. Non- limiting examples of cryoprotectant agents include a glycol (e.g., ethylene glycol, propylene glycol, and glycerol), dimethyl sulfoxide (DMSO), formamide, sucrose, trehalose, dextrose, and any combinations thereof.

[0198] In some embodiments, the composition is a controlled release composition. The term “controlled release”, in some embodiments, refers to sustained release and or delayed release. Controlled release formulations are well-known in the art. These include excipients that allow for 89ny-2728093Attorney Ref.28767-20004.40 sustained, periodic, pulse, or delayed release of the complex described herein. Controlled release formulations include, without limitation, embedding of the composition into a matrix; enteric coatings; micro-encapsulation; gels and hydrogels; implants; microneedles; patches; and any other formulation that allows for controlled release of the complex described herein. VI. Method of Use Introduction of delivery of nucleic acid

[0199] In one aspect, provided herein is a method of introducing a nucleic acid into a cell. In some embodiments, the method comprises contacting a cell with the complex described herein.

[0200] In some embodiments, provided herein are methods of using a cationic polymer provided herein, or a salt thereof, or a pharmaceutically acceptable salt thereof. In some embodiments, provided herein is a method of enabling or enhancing the complexation, protection, delivery and release of a nucleic acid, such as messenger RNA (mRNA), or the gene editing system described herein into target cells, tissues, and organs both in vitro and in vivo, comprising contacting the cells, tissues, or organs with a complex comprising a cationic polymer provided herein, or a salt thereof, or a pharmaceutically acceptable salt thereof and the nucleic acid. In embodiments, the cell, tissue, or organ forms part of an organism. In embodiments, the organism is a mammal. In some embodiments, the organism is a human.

[0201] In some embodiments, the delivery and release of the nucleic acid are cell-selective, tissue-selective, and / or organ-selective. In some embodiments, the selectivity of the delivery and release of the nucleic acid can be tuned by varying the cationic polymers described herein, such as the repeating units, length, block length, couterion, side chain, linker, arrangement of the repeating units, and the end modifications in these polymers. In some embodiments, the selectivity of the delivery and release of the nucleic acid can be tuned by administration routes. In some embodiments, the delivery and release of the nucleic acid is more enhanced in spleen tissues over other tissues when the complex is administered by intravenous injection. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in spleen is at least about 2 times, for example, at least about any of 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, or 10 times of the level of introduction, delivery, or transfection of the nucleic acid in lung. In some embodiments, the level of introduction, delivery, or transfection of the 90ny-2728093Attorney Ref.28767-20004.40 nucleic acid in spleen is at least about 2 times, for example, at least about any of 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, or 100 times of the level of introduction, delivery, or transfection of the nucleic acid in liver. In some embodiments, the level of transfection of the nucleic acid in spleen is at least about 10 times, for example, at least about any of 50 times, 100 times, 500 times, 1000 times, 5000 times, or 10000 times of the level of introduction, delivery, or transfection of the nucleic acid in skeletal muscle. In some embodiments, the level of introduction or transfection of the nucleic acid in spleen is at least about 10 times, for example, at least about any of 50 times, 100 times, 500 times, 1000 times, 5000 times, or 10000 times of the level of introduction, delivery, or transfection of the nucleic acid in GI track. In some embodiments, the delivery and release of the nucleic acid is more enhanced in lung tissues over other tissues when the complex is administered by intravenous injection. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in lung is at least about 2 times, for example, at least about any of 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, or 10 times of the level of introduction, delivery, or transfection of the nucleic acid in spleen, liver, skeletal muscle, or GI track. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in lung is about the same as (e.g., about 0.8 of, about 0.9 of, about 1 of, about 1.1 of, or about 1.2 of) the level of introduction, delivery, or transfection of the nucleic acid in spleen. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in lung is at least about 1.1 times, for example, at least about any of 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, or 2 times of the level of introduction, delivery, or transfection of the nucleic acid in spleen. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in lung is at least about 2 times, for example, at least about any of 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, or 10 times of the level of introduction, delivery, or transfection of the nucleic acid in liver. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in liver is at least about 1.1 times, for example, at least about any of 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, or 10 times of the level of introduction, delivery, or transfection of the nucleic acid in spleen, lung, skeletal muscle, or GI track. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in skeletal muscle is at least about 1.1 times, for example, at least about any of 91ny-2728093Attorney Ref.28767-20004.40 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, or 10 times of the level of introduction, delivery, or transfection of the nucleic acid in spleen, liver, lung, or GI track. In some embodiments, the level of introduction, delivery, or transfection of the nucleic acid in GI track is at least about 1.1 times, for example, at least about any of 1.2 times, 1.3 times, 1.4 times, 1.5 times, 1.6 times, 1.7 times, 1.8 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, or 10 times of the level of introduction, delivery, or transfection of the nucleic acid in spleen, liver, skeletal muscle, or lung.

[0202] In some embodiments, the nucleic acid comprises the gene editing system described herein. In some embodiments, the nucleic acid is an mRNA. In some embodiments, the method further comprises allowing the mRNA to be expressed in a cell. In some embodiments, the method comprises delivering an mRNA to a cell, releasing the mRNA in the cell, and converting the mRNA cellular processes into peptides and proteins, wherein the sequence and thus activity of the peptides and proteins are determined by the mRNA sequence. In some embodiments, the mRNA is specifically designed to express a protein with certain functions.

[0203] In some embodiments, the nucleic acid is DNA, siRNA, pDNA, shRNA, or gDNA.

[0204] In some embodiments, provided herein is a method of introducing a nucleic acid into a cell and inducing gene-edition in the cell. In embodiments, the gene-edition can encompass genome-edition or genome editing. In some embodiments, the genome editing comprises inserting, deleting, or replacing a DNA in the genome of a living organism using an isolated or engineered nuclease system. In certain embodiments, the method comprises delivering a genetic tool or system that can cause gene-edition in the cells introduced with the nucleic acid. In some embodiments, some non-limiting examples of a genetic tool or system for gene-edition include a CRISPR-Cas system and transposon system.

[0205] In some embodiments, the method provided herein increases the cellular transfection efficiency over the use of the corresponding nucleic acid itself by at least 2-fold, for example, at least any of 5-fold, 10-fold, 20-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold, 300-fold, 400-fold, 500-fold, 750-fold, 1000-fold, 5000-fold, 10,000-fold, 50,000-fold, or 100,000-fold. In some embodiments, the method provided herein increases of the uptake level of mRNA and / or the expression level of the protein encoded by the mRNA over the use of the corresponding mRNA itself by at least 2-fold, for example, at least any of 5-fold, 10-fold, 20-fold, 50-fold, 75- 92ny-2728093Attorney Ref.28767-20004.40 fold, 100-fold, 150-fold, 200-fold, 300-fold, 400-fold, 500-fold, 750-fold, 1000-fold, 5000-fold, 10,000-fold, 50,000-fold, or 100,000-fold.

[0206] In some embodiments, the method further comprises allowing the cationic polymer to degrade within the cell thereby forming a degradation product. In some embodiments, the degradation product can be metabolized by the cell or the organism comprising the cell. In some embodiments, the cell is in the eye. Method of Treatment or Prevention

[0207] In one aspect, provided herein are methods for inducing an immune response in a subject. In one aspect, provided herein is a method of inducing an immune response against a disease in a subject in need thereof. In some embodiments, the method comprises administering to a subject in need thereof a therapeutically effective amount of the complex described herein or a pharmaceutical composition thereof alone. In some embodiments, the method comprises administering the complex, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof alone (e.g., in monotherapy). In some embodiments, the method comprises administering the complex, or a pharmaceutical composition thereof in combination with one or more additional components, such as pharmaceutically acceptable excipients and / or additional therapeutic agents (e.g., in combination therapy). In some embodiments, the complex described herein or a pharmaceutical composition thereof is administered intravenously. In some embodiments, the complex described herein or a pharmaceutical composition thereof is administered intraocularly.

[0208] In some embodiments, the method comprises preparing and administering a vaccine comprising the complex, or a pharmaceutical composition thereof to induce an immune response in a subject.

[0209] In some embodiments, the vaccine has a prophylactic activity such that the vaccine can prevent or reduce a likelihood of the occurrence of a disease or condition in a subject. In some embodiments, the subject can be an animal without the disease or condition, e.g. a human who has not been infected or diagnosed with the disease or condition or who does not have a noticeable symptom associated with the disease or condition. 93ny-2728093Attorney Ref.28767-20004.40

[0210] In certain embodiments, the method can treat and / or prevent a disease or condition using a complex provided herein. The method typically includes administering to a subject in need thereof a therapeutically effective amount of a complex (e.g., any of the complexes comprising polymer and nucleic acid described herein) or a pharmaceutical composition comprising a complex as described herein, alone (e.g., in monotherapy) or in combination with one or more additional components, such as pharmaceutically acceptable excipients and / or additional therapeutic agents (e.g., in combination therapy).

[0211] In some other embodiments, the vaccine has a therapeutic effect such that the vaccine can be used to treat a disease or condition. In some embodiments, the disease or condition that is targeted by the vaccine can include, but not limited to, an autoimmune, inflammatory, cancer, infectious, metabolic, developmental, cardiovascular, liver, intestinal, endocrine, neurological, or other disease. In some embodiments, the disease or condition is an eye disease. In some embodiments, the disease or condition that is targeted by the vaccine can include, but not limited to, any diseases associated with lung, spleen (including immune-related and stem cell-related), brain, and pancreas. In some embodiments, the therapeutic vaccine is a cancer vaccine that can be administered to a patient who already suffers from cancer. The cancer vaccine can exhibit one or more anti-cancer activities, e.g. reduction of cancer cell number, reduction of cancer size, killing of cancer cells, reductions and / or inhibition of metastasis and reduction of cancer cell growth and / or proliferation. In some embodiments, the cancer is associated with lung, spleen (including immune-related and stem cell-related), brain, and pancreas. In some other embodiments, cancer vaccine can also be used for a prophylactic purpose, especially in a subject who is considered predisposed of cancer but presently does not have the cancer. The prophylactic vaccine can be administered to the predisposed subject with a certain cancer and prevents or reduce a likelihood of the occurrence of the cancer in the subject.

[0212] In some embodiments, the methods for inducing an immune response in a subject comprise administering a vaccine composition in a subject in need thereof. In some embodiments, the vaccine composition comprises the complex described herein, wherein the nucleic acid is an mRNA that encodes an antigenic molecule (e.g. peptide). In some embodiments, the nucleic acid can be expressed into the antigenic molecule in the target cell, tissue, or organ, and allow the subject to acquire immunity against the antigenic molecule. In some embodiments, the method comprises treating or preventing an infectious disease, and the 94ny-2728093Attorney Ref.28767-20004.40 vaccine composition comprises and can provide an mRNA encoding an antigenic molecule that is associated with a certain pathogen, e.g. one or more peptides that are known to be expressed in the pathogen (e.g. pathogenic bacterium or virus. In some embodiments, the method comprises treating or preventing a cancer, and the vaccine composition comprises and can provide an mRNA encoding certain peptides that are associated with cancer, e.g. peptides that are substantially exclusively or highly expressed in cancer cells as compared to normal cells. In some embodiments, when the nucleic acid encoding antigenic or immunogenic peptide(s) is administered to a subject and delivered (e.g., introduced or transfected) into certain cells of the subject, the introduced or transfected nucleic acid can be eventually translated and expressed into the antigenic peptide(s). In some embodiments, the subject, after vaccination with the cancer vaccine composition, develop immunity against the peptides that are associated with cancer, which can kill the cancer cells with specificity. In some embodiments, the subject can have an acquired immune response via this vaccination in which adaptive immunity can elicit immunological memory after an initial response to the immunogenic peptides that is targeted by the immune response, and leads to an enhanced response to that target on subsequent encounters, exhibiting a prophylactic effect.

[0213] In some embodiments, the method comprises administering two separate types (or sequences) of nucleic acids in a single vaccine composition, thereby providing dual activities of therapeutic and prophylactic effects. In some embodiments, the two separate nucleic acids can encode two different immunogenic peptides. In some embodiments, the vaccine composition can introduce, delivery, or transfect (1) a first nucleic acid encoding a first immunogenic peptide that can induce more immediate treatment effect to an existing disease or condition and (2) a second nucleic acid encoding a different, second immunogenic peptide that is aimed to induce adaptive immunity in the subject for future occurrence of a different disease or condition. In some embodiments, the vaccine can deliver two or more different nucleic acids to a subject and each nucleic acid independently exhibits a therapeutic or prophylactic effect.

[0214] In embodiments, the vaccine composition can have two or more different types (or different formulas) of cationic polymers provided herein. In some embodiments, the vaccine composition can have only a single type (or single formula) of cationic polymer. In some embodiments, a single type of cationic polymer can be non-covalently bound to one type (sequence) of nucleic acid. In some embodiments, a single type of cationic polymer can be non- 95ny-2728093Attorney Ref.28767-20004.40 covalently bound to two or more types (sequences) of nucleic acids. In some examples, the complex comprises a mixture of different types of cationic polymers, each of which is bound to a different sequence of nucleic acid, and the method comprises administering the mixture to a subject in order to deliver two or more sequences (or types) of nucleic acids. In some embodiments, the method comprises administering a single type (or formula) of cationic polymer that is bound to multiple types (or sequences) of nucleic acid and delivering two or more sequences (or types) of nucleic acid. In some embodiments, the method comprises administering a single type (or formula) of cationic polymer that is bound to a single sequence (or type) of nucleic acid.

[0215] In some embodiments, the method further comprises administering one or more additional therapeutic agents in an effective amount to the subject. In some embodiments, the additional therapeutic agents can contain an anti-cancer agent and optionally a pharmaceutically acceptable carrier. The additional anti-cancer agents can be, for example, antibodies, small molecules, and large molecules or combinations thereof. Examples of anti-cancer activity include, but are not limited to, reduction of cancer cell number, reduction of cancer size, killing of cancer cells, reductions and / or inhibition of metastasis and reduction of cancer cell growth and / or proliferation. In some examples, the administration of the complex described herein and the additional therapeutic agents can exhibit a synergistic effect that is more than a sum of individual administration. VII. Administration and dose Administration Route

[0216] In some aspects provided are methods for delivering a composition comprising a polymer or complex described herein to cells or a subject so as to provide a desired activity into the cells or subject. In some embodiments, the complex comprises a cationic polymer and a nucleic acid described herein and, when introduced or transfected into the cells or administered to the subject, can provide a variety of intended effects, depending on the nature of the nucleic acid sequence. Some non-limiting examples of intended effects include modulation on gene expression, modulation of cellular pathways, genome edition and induction of an immune response. In some 96ny-2728093Attorney Ref.28767-20004.40 embodiments, the complex can be administered to a subject in an effective amount that is sufficient to achieve at least part of the intended effects in the subject.

[0217] "Administration," "administering" and the like, when used in connection with a cationic polymer, a nucleic acid, or a complex may refer to administration to cells in vitro, administration to cells in vivo, administration to a subject by a medical professional or by self-administration by the subject. Typically, an effective amount is administered, which amount can be determined by one of skill in the art. Any method of administration may be used. In some embodiments, administration to cells comprises contacting the cells with the composition comprising the polymer, nucleic acid, or the complex. In some embodiments, the contacting comprises addition of the composition comprising a polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, a nucleic acid, or a complex to the cell culture media. In some embodiments, the contacting comprises injection of the composition comprising the polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, nucleic acid, or complex in vivo. Administration to a subject can be achieved by, for example, intravascular injection, direct intratumoral delivery, intraperitoneal injection, subcutaneous injection, intradermal injection, intranasal administration, inhalation, and the like.

[0218] Administering may be achieved by oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, intraocular, subretinal administration, or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, but are not limited to, intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. In some embodiments, administering is achieved intraocularly. In some embodiments, administering is achieved by subretinal injection. In some embodiments, the composition comprising a polymer, or a salt thereof, or a pharmaceutically acceptable salt thereof, a nucleic acid, or a complex described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy. 97ny-2728093Attorney Ref.28767-20004.40 Dose

[0219] The dosage and frequency (single or multiple doses) administered to a subject can vary depending upon a variety of factors, for example, whether the subject suffers from another disease, its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health-related problems. Other therapeutic regimens or agents can be used in conjunction with the methods and compositions described herein including embodiments thereof. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.

[0220] In some embodiments, the subject is a mammal, for example a human, a non-human primate, a murine (i.e., mouse and rat), a canine, a feline, or an equine. In one embodiment, the subject is a human.

[0221] In some embodiments, a composition can be administered in a dose (or an amount) of more than about 1 ng / kg to about 100mg / kg of subject body weight. In some embodiments, a composition can be administered in a dose (or an amount) of about 0.5 μg to about 5g.

[0222] In some embodiments, the administration can be repeated over a desired period, for example, repeated over a period of about 1 day to about several months. The weight herein can be a weight of a nucleic acid, a weight of complex, or a weight of a composition thereof. In some embodiments, a composition can be administered systemically or locally (e.g. intratumoral injection, intravenous injection, or subretinal injection) at intervals to elicit the desired benefit or otherwise provide a therapeutic effect. ENUMERATED EMBODIMENTS Embodiment 1A. A cationic polymer comprising n unit(s) of a first repeating unit of Formula (I) and m unit(s) of a second repeating unit of Formula (II): 98ny-2728093Attorney Ref.28767-20004.40wherein L1, L2, L3, L4, L5, L6, L7and L8are each independently -O-, -NH-, optionally substituted C1-C12 alkylene, optionally substituted C2-C12 alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9 is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or optionally substituted C1-C12alkyl; R6is C3-C18 alkyl or C3-C18 alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end- capped by at least one capping group selected from the group consisting of optionally substituted C3-C18alkyl, optionally substituted C3-C18alkenyl and a peptide. Embodiment 2A. The cationic polymer of embodiment 1A, wherein L1-L8 are each independently C1-C12 alkylene, C2-C12 alkenylene, C2-C12 alkynylene, C3-C6 cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12arylene, or 5 to 10 membered heteroarylene, each of which are independently and optionally substituted by C1-C6alkyl, halo, OH, or NH2. 99ny-2728093Attorney Ref.28767-20004.40 Embodiment 3A. The cationic polymer of embodiment 1A or 2A, wherein L1-L8 are each independently C1-C12 alkylene. Embodiment 4A. The cationic polymer of embodiment 3A, wherein L1-L8are ethylene. Embodiment 5A. The cationic polymer of any one of embodiments 1A-4A, wherein L9 is a bond. Embodiment 6A. The cationic polymer of any one of embodiments 1A-4A, wherein L9is - C(O)O-, -O-, -S-, -NH-, -C(O)NH-, -NHC(O)-, -S(O)2-, -S(O)NH-, -NHC(O)NH-, C1-C18alkylene optionally interrupted by one or more -O-, 3 to 12 membered heterocyclylene , or a peptide, wherein the C1-C18alkylene and 3 to 12 membered heterocyclylene are optionally substituted by one or more C1-C6alkyl, halo, OH, or NH2. Embodiment 7A. The cationic polymer of any one of embodiments 1A-4A and 6A, wherein L9 is C1-C6 alkylene, C2-C6 PEGylated linker, or a peptide linker. Embodiment 8A. The cationic polymer of embodiment 7A, wherein L9is propylene. Embodiment 9A. The cationic polymer of any one of embodiments 1A-8A, wherein R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or C1-C12 alkyl optionally substituted by one or more halo, OH, or NH2. Embodiment 10A. The cationic polymer of any one of embodiments 1A-9A, wherein R5is NRaRb. Embodiment 11A. The cationic polymer of embodiment 10A, wherein Raand Rbare H. Embodiment 12A. The cationic polymer of embodiment any one of embodiments 1A-9A, wherein R5is H. Embodiment 13A. The cationic polymer of any one of embodiments 1A-8A, wherein one, two, or three of R1, R2, R3, and R4are each independently C1-C12alkyl, C2-C12alkenyl, or C2-C12 alkynyl, each of which are independently and optionally substituted by one or more halo, OH, or NH2. Embodiment 14A. The cationic polymer of any one of embodiments 1A-8A, wherein R1, R2, R3, and R4are H. Embodiment 15A. The cationic polymer of any one of embodiments 1A-14A, wherein R6is C12-C18alkyl or C12-C18alkenyl. Embodiment 16A. The cationic polymer of embodiment 15A, wherein R6is C12-C18alkyl. Embodiment 17A. The cationic polymer of embodiment 16A, wherein R6is dodecyl. 100ny-2728093Attorney Ref.28767-20004.40 Embodiment 18A. The cationic polymer of any one of embodiments 1A-17A, wherein n is an integer from 1 to 10 Embodiment 19A. The cationic polymer of any one of embodiments 1A-18A, wherein m is an integer from 1 to 100. Embodiment 20A. The cationic polymer of any one of embodiments 1A-17A, wherein the ratio of n to m is in a range of 10:1 to 1:10. Embodiment 21A. The cationic polymer of embodiment 1A, wherein m is 0 or n is 0, and the cationic polymer is a homopolymer; or m is an integer from 1 to 20, n is an integer from 1 to 20, and the cationic polymer is a block copolymer, or a random copolymer. Embodiment 22A. The cationic polymer of any one of embodiments 1A-21A, wherein the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl or a peptide;C3-C18 alkyl, C3-C18 alkenyl or a peptide; provided that, 101ny-2728093Attorney Ref.28767-20004.40alkyl, C3-C18 alkenyl, or a peptide; and when EG1is SRC, thenleast one of RCand RFis C3-C18alkyl, C3-C18alkenyl, or a peptide. Embodiment 23A. The cationic polymer of embodiment 1A, comprising a structural unit of Formula (A)(A), wherein n is an integer from 1 to 500; m is an integer from 1 to 500; and wherein each of the n unit(s) of the first repeating unit and each of the m unit(s) of the second repeating unit are connected in a random sequence; and wherein the first repeating unit and the second repeating unit are as defined in embodiment 1A. Embodiment 24A. The cationic polymer of embodiment 23A, being a polymer of Formula(A-1) 102ny-2728093Attorney Ref.28767-20004.40 wherein RAis H or C12H25; RBis C12H25; RDis H or C12H25; and REis C12H25. Embodiment 25A. The cationic polymer of embodiment 24A, wherein RAis H; RBis C12H25; RDis H; and REis C12H25. Embodiment 26A. The cationic polymer of any one of embodiments 23A-25A, wherein the first repeating unit is of Formula (I-1) and the second repeating unit is of Formula (II-1),wherein L9, R5, and R6are as defined in embodiment 1A. Embodiment 27A. The cationic polymer of any one of embodiments 23A-26A, wherein the first repeating unit is of Formula (I-2) and the second repeating unit is of Formula (II-2),Embodiment 28A. The cationic polymer of any one of embodiments 23A-27A, wherein the ratio of n to m is about 1:10 to about 3:1. Embodiment 29A. The cationic polymer of any one of embodiments 23A-28A, having a molecular weight of about 1 kDa to about 500 kDa. Embodiment 30A. The cationic polymer of embodiment 1A, n is 0 and wherein the cationic polymer comprises a Formula (B) 103ny-2728093Attorney Ref.28767-20004.40wherein m is an integer from 1 to 500; and wherein L5, R3, L6, L7, R4, L8, and R6are as defined in embodiment 1A. Embodiment 31A. The cationic polymer of embodiment 30A, wherein the cationic polymerEmbodiment 32A. The cationic polymer of embodiment 30A or 31A, wherein the cationic polymer is of Formula (B-2)(B-2), wherein m is an integer from 1 to 100. Embodiment 33A. The cationic polymer of any one of embodiments 30A-32A, wherein m is about 10 to 100. Embodiment 34A. The cationic polymer of embodiment 1A, wherein m is 0, and the cationic polymer is of Formula (C)wherein EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide, provided that RAand RBare not both H; wherein EG2is 104ny-2728093Attorney Ref.28767-20004.40wherein RD, RE, and RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide, provided that RDand REare not both H; n is an integer from 1 to 500; and wherein L1, R1, L2, L3, R2, and L4 are as defined in embodiment 1A. Embodiment 35A. The cationic polymer of embodiment 34A, being a polymer of Formula (C-1)(C-1), wherein RCand RFare each independently selected peptide. Embodiment 36A. The cationic polymer of embodiment 35A, wherein RCand RFis each independently selected peptide comprising Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof. Embodiment 37A. The cationic polymer of embodiment 35A or 36A, wherein n is an integer from 1 to 100. Embodiment 38A. The cationic polymer of embodiment 34A, being a polymer of Formula (C-2)(C-2), wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, or C3-C18alkenyl, provided that RAand RBare not both H, and RDand REare not both H. 105ny-2728093Attorney Ref.28767-20004.40 Embodiment 39A. The cationic polymer of embodiment 38A, wherein RAand RDare H, and RBand REare C12-C18 alkenyl. Embodiment 40A. The cationic polymer of embodiment 38A, wherein RA, RB, RCand RDare each independently selected C3-C18 alkyl. Embodiment 41A. The cationic polymer of embodiment 40A, wherein the C3-C18 alkyl is C4H9, C6H13, C8H17, C9H19, C12H25, or C18H37. Embodiment 42A. The cationic polymer of embodiments 40A or 42A, wherein the C3-C18alkyl is C12H25. Embodiment 43A. The cationic polymer of any one of embodiments 38A-42A, wherein n is an integer from 1 to 100. Embodiment 44A. The cationic polymer of embodiment 1A, selected from the group consisting of polymer No.5, No.6, No.7, No.8, No.9, No.10, No.11, No.12, No.13, No. 14, No.16, No.17, No.18, No.19, No.20, No.21, No.22, No.23, No.24, No.25, No.26, No.27, No.28, No.29, No.30, No.31, No.32, No.33, No.34, No.35, No.36, No.37, No. 38, No.39, No.40, No.41, No.42, No.43, No.44, No.45, No.70, No.71, No.72, No.73, No.74, No.75, No.76, No.77, No.78, No.79, No.80, No.81, No.82, No.83, No.90, No. 91, No.92, No.93, No.94, No.95, No.96, No.97, No.98, No.99, No.100, No.101, No. 146, No.147, No.148, No.149, No.150, No.151, No.152, No.153, No.154, No 155, No. 156, No.157, No.158, No.159, No.160, No.161, No.162, No.163, No.164, No.165, No. 172, and No.173 in Table 1. Embodiment 45A. The cationic polymer of any one of embodiments 1A-44A, further comprising an anion. Embodiment 46A. The cationic polymer of embodiment 45A, wherein the anion is acetate, trifluoroacetate, triflate, chloride, bromide, sulfate, phosphate, succinate, or citrate. Embodiment 47A. The cationic polymer of embodiment 46A, wherein the anion is trifluoroacetate or chloride. Embodiment 48A. A complex comprising the cationic polymer of any of embodiments 1A- 47A, and a nucleic acid non-covalently bound to the cationic polymer. Embodiment 49A. The complex of embodiment 48A, wherein the nucleic acid is selected from the group consisting of messenger RNA (mRNA), small interference RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), self-amplifying mRNA (saRNA), 106ny-2728093Attorney Ref.28767-20004.40 transactivating RNA (tracrRNA), guide RNA (gRNA), gene editing including CRISPR RNA (crRNA), RNA component in CRISPR, plasmid DNA (pDNA), minicircle DNA, circular DNA (cDNA), single-stranded DNA (ssDNA), single-stranded circular DNA (circDNA), and genomic DNA (gDNA). Embodiment 50A. The complex of embodiment 49A, wherein the nucleic acid is mRNA. Embodiment 51A. The complex of embodiment 49A, wherein the nucleic acid is CRISPR RNA. Embodiment 52A. The complex of any one of embodiments 48A-51A, with an N / P ratio of about 100:1 to about 1:1. Embodiment 53A. The complex of embodiment 52A, wherein the N / P ratio is about 25:1. Embodiment 54A. The complex of embodiment 52A, wherein the N / P ratio is about 10:1 to about 15:1. Embodiment 55A. A nanoparticle composition comprising a plurality of the complexes of any of embodiments 48A-51A. Embodiment 56A. The nanoparticle of embodiment 55A, wherein the average particle size of the nanoparticles is about 50 nm to about 1 μm. Embodiment 57A. A pharmaceutical composition comprising a plurality of the complexes of any of embodiments 50A-54A, and a pharmaceutical excipient. Embodiment 58A. A method of introducing a nucleic acid into a cell, wherein the method comprises contacting the cell with a plurality of the complexes of any of embodiments 50A- 54A. Embodiment 59A. A method of delivering a nucleic acid into a target organ and / or tissue of a subject in need thereof, wherein the method comprises administering an effective amount of the pharmaceutical composition of embodiment 57A. Embodiment 60A. The method of embodiment 59A, wherein the target organ is selected from the group consisting of brain, heart, lungs, liver, spleen, stomach, intestines, kidneys and skeletal muscles. ENUMERATED EMBODIMENTS Embodiment 1. A cationic polymer comprising n unit(s) of a first repeating unit of Formula (Ia) and m unit(s) of a second repeating unit of Formula (IIa): 107ny-2728093Attorney Ref.28767-20004.40or a salt thereof, wherein L1, L2, L3, L4, L5, L6, L7and L8are each independently -O-, -NH-, optionally substituted C1-C12 alkylene, optionally substituted C2-C12 alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9 is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H, optionally substituted C1-C12alkyl, or a protecting group; R6is optionally substituted C3-C20 alkyl or optionally substituted C3-C20 alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end- capped by at least one capping group selected from the group consisting of C3-C18 alkyl, C3-C18 alkenyl and a peptide. Embodiment 2. The cationic polymer of embodiment 1, or a salt thereof, wherein R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H, C1-C12 alkyl, or - C(O)O-(C1-C6alkyl). Embodiment 3. The cationic polymer of embodiment 1 or 2, or a salt thereof, wherein R6is C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or 108ny-2728093Attorney Ref.28767-20004.40 more independently selected -R’, -OR’, -NHR’, -N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20 alkyl, -C3-C20 cycloalkyl, - C6-C20aryl, 3- to 10-membered heterocycle, or C1-C20alkyl substituted with one or more - OH. Embodiment 4. The cationic polymer of embodiment 3, or a salt thereof, wherein R6is C1- C20alkyl or C3-C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle. Embodiment 5. The cationic polymer of any one of embodiments 1-4, comprising n unit(s) of a first repeating unit of Formula (I) and m unit(s) of a second repeating unit of Formula (II):wherein L1, L2, L3, L4, L5, L6, L7 and L8 are each independently -O-, -NH-, optionally substituted C1-C12alkylene, optionally substituted C2-C12alkenylene, optionally substituted C2-C12alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12 arylene, or optionally substituted 5 to 10 membered heteroarylene; L9 is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12alkenyl, or optionally substituted C2-C12alkynyl; 109ny-2728093Attorney Ref.28767-20004.40 R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or optionally substituted C1-C12 alkyl; R6is C3-C18alkyl or C3-C18alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end- capped by at least one capping group selected from the group consisting of C3-C18alkyl, C3-C18alkenyl and a peptide. Embodiment 6. The cationic polymer of any one of embodiments 1-5, wherein L1-L8are each independently C1-C12alkylene, C2-C12alkenylene, C2-C12alkynylene, C3-C6cycloalkylene, 3 to 8 membered heterocyclylene, C6-C12 arylene, or 5 to 10 membered heteroarylene, each of which are independently and optionally substituted by C1-C6 alkyl, halo, OH, or NH2. Embodiment 7. The cationic polymer of any one of embodiments 1-6, wherein L1-L8 are each independently C1-C12 alkylene. Embodiment 8. The cationic polymer of any one of embodiments 1-7, wherein L1-L8are ethylene. Embodiment 9. The cationic polymer of any one of embodiments 1-8, wherein L9 is a bond. Embodiment 10. The cationic polymer of any one of embodiments 1-9, wherein L9is - C(O)O-, -O-, -S-, -NH-, -C(O)NH-, -NHC(O)-, -S(O)2-, -S(O)NH-, -NHC(O)NH-, C1-C18 alkylene optionally interrupted by one or more -O-, 3 to 8 membered heterocyclylene , or a peptide, wherein the C1-C18alkylene and 3 to 8 membered heterocyclylene are optionally substituted by one or more C1-C6 alkyl, halo, OH, or NH2. Embodiment 11. The cationic polymer of any one of embodiments 1-8 or 10, wherein L9is C1-C6 alkylene, C2-C6 PEGylated linker, or a peptide linker. Embodiment 12. The cationic polymer of embodiment 11, wherein L9is propylene. 110ny-2728093Attorney Ref.28767-20004.40 Embodiment 13. The cationic polymer of any one of embodiments 1-12, wherein R5is H, - ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or C1-C12 alkyl optionally substituted by one or more halo, OH, or NH2. Embodiment 14. The cationic polymer of any one of embodiments 1-13, wherein R5is NRaRb. Embodiment 15. The cationic polymer of embodiment 14, wherein Raand Rbare H. Embodiment 16. The cationic polymer of any one of embodiments 1-13, wherein R5is H. Embodiment 17. The cationic polymer of any one of embodiments 1-12, wherein one, two, or three of R1, R2, R3, and R4are each independently C1-C12alkyl, C2-C12alkenyl, or C2-C12alkynyl, each of which are independently and optionally substituted by one or more halo, OH, or NH2. Embodiment 18. The cationic polymer of any one of embodiments 1-12, wherein R1, R2, R3, and R4are H. Embodiment 19. The cationic polymer of any one of embodiments 1-18, wherein R6is C9- C18 alkyl or C9-C18 alkenyl. Embodiment 20. The cationic polymer of any one of embodiments 1-18, or a salt thereof, wherein R6is unsubstituted C12-C18alkyl, unsubstituted C12-C18alkenyl, or C1-C6alkyl substituted with one or more independently selected phenyl, -O-(C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6- membered heterocycle. Embodiment 21. The cationic polymer of embodiment 19 or 20, wherein R6is C12-C18 alkyl. Embodiment 22. The cationic polymer of embodiment 21, wherein R6is dodecyl. Embodiment 23. The cationic polymer of any one of embodiments 1-22, wherein n is an integer from 1 to 100. Embodiment 24. The cationic polymer of any one of embodiments 1-23, wherein m is an integer from 1 to 100. Embodiment 25. The cationic polymer of any one of embodiments 1-24, wherein the ratio of n to m is in a range of 10:1 to 1:10. Embodiment 26. The cationic polymer of embodiment 25, wherein the ratio of n to m is in a range of about 0.3 to about 0.8. 111ny-2728093Attorney Ref.28767-20004.40 Embodiment 27. The cationic polymer of any one of embodiments 1-26, wherein m is 0 or n is 0, and the cationic polymer is a homopolymer; or m is an integer from 1 to 20, n is an integer from 1 to 20, and the cationic polymer is a block copolymer, or a random copolymer. Embodiment 28. The cationic polymer of any one of embodiments 1-17, wherein the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl or a peptide;optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; provided that, when EG1is NRARB, thenleast one of RA, RB, RD, and REis optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; and 112ny-2728093Attorney Ref.28767-20004.40 when EG1is SRC, thenleast one of RCand RFis optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide. Embodiment 29. The cationic polymer of embodiment 28, or a salt thereof, wherein RD, RE, and RFare each independently H, C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected -R’, -OR’, -NHR’, -N(R’)2, or C(=O)N(R’)2, wherein each R’is independently selected from the group consisting of -H, -C1-C20alkyl, -C3-C20 cycloalkyl, -C6-C20 aryl, or - 3- to 10-membered heterocycle, or C1-C20 alkyl substituted with one or more -OH. Embodiment 30. The cationic polymer of embodiment 28 or embodiment 29, or a salt thereof, wherein RD, RE, and RFare each independently H, C1-C20alkyl or C3-C20alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O-(C1- C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle. Embodiment 31. The cationic polymer of any one of embodiments 1-30, wherein the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl or a peptide;113ny-2728093Attorney Ref.28767-20004.40are each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide; provided that,alkyl, C3-C18 alkenyl, or a peptide; and when EG1is SRC, thenleast one of RCand RFis C3-C18alkyl, C3-C18alkenyl, or a peptide. Embodiment 32. The cationic polymer of embodiment 1, comprising a structural unit of Formula (A)(A), wherein n is an integer from 1 to 500; m is an integer from 1 to 500; and wherein each of the n unit(s) of the first repeating unit and each of the m unit(s) of the second repeating unit are connected in a random sequence; and wherein the first repeating unit and the second repeating unit are as defined in any of the preceding embodiments. 114ny-2728093Attorney Ref.28767-20004.40 Embodiment 33. The cationic polymer of embodiment 32, being a polymer of Formula (Aa)wherein RAis H or C12H25; RBis C12H25; RDis H, C12H25; and REis C12H25, C12-C18 alkenyl, or C1-C8alkyl substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), - NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle. Embodiment 34. The cationic polymer of embodiment 32 or embodiment 33, being a polymer of Formula (A-1)(A-1) wherein RAis H or C12H25; RBis C12H25; RDis H or C12H25; and REis C12H25. Embodiment 35. The cationic polymer of embodiment 33, wherein RAis H; RBis C12H25; RDis H; and REis C12H25, C12-C18alkenyl, or C1-C8alkyl substituted with one or more independently selected phenyl, -O-(C1-C20 alkyl), -NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle. Embodiment 36. The cationic polymer of any one of embodiments 32-35, wherein RAis H; RBis C12H25; RDis H; and REis C12H25. Embodiment 37. The cationic polymer of any one of embodiments 32-36, wherein the first repeating unit is of Formula (I-1) and the second repeating unit is of Formula (II-1),115ny-2728093Attorney Ref.28767-20004.40wherein L9, R5, and R6are as defined in any of the preceding embodiments. Embodiment 38. The cationic polymer of any one of embodiments 32-37, wherein the first repeating unit is of Formula (I-2) and the second repeating unit is of Formula (II-2),Embodiment 39. The cationic polymer of any one of embodiments 32-38, wherein the ratio of n to m is about 0.1 to about 1. Embodiment 40. The cationic polymer of any one of embodiments 32-39, wherein the ratio of n to m is about 1:10 to about 3:1. Embodiment 41. The cationic polymer of any one of embodiments 32-40, wherein the ratio of n to m is about 0.3 to about 0.8. Embodiment 42. The cationic polymer of any one of embodiments 32-41, wherein the ratio of n to m is about 0.35 to about 0.55, or about 0.7 to about 0.8. Embodiment 43. The cationic polymer of any one of embodiments 32-42, having a molecular weight of about 1 kDa to about 500 kDa. Embodiment 44. The cationic polymer of any one of embodiments 1-31, n is 0 and wherein the cationic polymer comprises a Formula (B)wherein m is an integer from 1 to 500; and 116ny-2728093Attorney Ref.28767-20004.40 wherein L5, R3, L6, L7, R4, L8, and R6are as defined in any one of embodiments 1-31. Embodiment 45. The cationic polymer of embodiment 44, wherein the cationic polymer has Formula (B-1)integer from 1 to 100. Embodiment 46. The cationic polymer of embodiment 44 or 45, wherein the cationic polymer is of Formula (B-2)(B-2), wherein m is an integer from 1 to 100. Embodiment 47. The cationic polymer of any one of embodiments 44-46, wherein m is about 10 to 100. Embodiment 48. The cationic polymer of any one of embodiments 1-31, wherein m is 0, and the cationic polymer is of Formula (C)wherein EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl or a peptide, provided that RAand RBare not both H; wherein EG2is 117ny-2728093Attorney Ref.28767-20004.40wherein RD, RE, and RFare each independently H, C3-C18 alkyl, C3-C18 alkenyl or a peptide, provided that RDand REare not both H; n is an integer from 1 to 500; and wherein L1, R1, L2, L3, R2, and L4 are as defined in embodiment 1. Embodiment 49. The cationic polymer of embodiment 48, being a polymer of Formula (C- 1)(C-1), wherein RCand RFare each independently selected peptide. Embodiment 50. The cationic polymer of embodiment 49, wherein RCand RFis each independently selected peptide comprising Gly, Ala, Trp, Phe, Met, Orn, Cys, Arg, Lys, His, or any combination thereof. Embodiment 51. The cationic polymer of embodiment 49 or 50, wherein n is an integer from 1 to 100. Embodiment 52. The cationic polymer of embodiment 48, being a polymer of Formula (C- 2)(C-2), wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, or C3-C18alkenyl, provided that RAand RBare not both H, and RDand REare not both H. 118ny-2728093Attorney Ref.28767-20004.40 Embodiment 53. The cationic polymer of embodiment 52, wherein RAand RDare H, and RBand REare C12-C18 alkenyl. Embodiment 54. The cationic polymer of embodiment 52, wherein RA, RB, RCand RDare each independently selected C3-C18 alkyl. Embodiment 55. The cationic polymer of embodiment 54, wherein the C3-C18 alkyl is C4H9, C6H13, C8H17, C9H19, C12H25, or C18H37. Embodiment 56. The cationic polymer of embodiment 55, wherein the C3-C18alkyl is C12H25. Embodiment 57. The cationic polymer of any one of embodiments 52-56, wherein n is an integer from 1 to 100. Embodiment 58. The cationic polymer of embodiment 1, or a salt thereof, selected from the group consisting of polymer in Table 1. Embodiment 59. The cationic polymer of embodiment 1, selected from the group consisting of polymer No.5, No.6, No.7, No.8, No.9, No.10, No.11, No.12, No.13, No.14, No.16, No.17, No.18, No.19, No.20, No.21, No.22, No.23, No.24, No.25, No.26, No.27, No. 28, No.29, No.30, No.31, No.32, No.33, No.34, No.35, No.36, No.37, No.38, No.39, No.40, No.41, No.42, No.43, No.44, No.45, No.70, No.71, No.72, No.73, No.74, No. 75, No.76, No.77, No.78, No.79, No.80, No.81, No.82, No.83, No.90, No.91, No.92, No.93, No.94, No.95, No.96, No.97, No.98, No.99, No.100, No.101, No.146, No.147, No.148, No.149, No.150, No.151, No.152, No.153, No.154, No 155, No.156, No.157, No.158, No.159, No.160, No.161, No.162, No.163, No.164, No.165, No.172, and No.173 in Table 1. Embodiment 60. The cationic polymer of any one of embodiments 1-5, or a salt thereof, wherein the polymer is Polymer No.43 or Polymer No.45 in Table 1. Embodiment 61. The cationic polymer of any one of embodiments 1-5, or a salt thereof, wherein the polymer is Polymer No.43 in Table 1. Embodiment 62. The cationic polymer of any one of embodiments 1-5, or a salt thereof, wherein the polymer is Polymer No.45 in Table 1. Embodiment 63. The cationic polymer of any one of embodiments 1-62, further comprising an anion. 119ny-2728093Attorney Ref.28767-20004.40 Embodiment 64. The cationic polymer of embodiment 65, wherein the anion is acetate, trifluoroacetate, triflate, chloride, bromide, sulfate, phosphate, succinate, or citrate. Embodiment 66. The cationic polymer of embodiment 64, wherein the anion is trifluoroacetate or chloride. Embodiment 67. The cationic polymer of embodiment 66, wherein the anion is trifluoroacetate. Embodiment 68. A complex comprising the cationic polymer of any of embodiments 1-67, and a nucleic acid non-covalently bound to the cationic polymer. Embodiment 69. The complex of embodiment 68, wherein the nucleic acid is selected from the group consisting of messenger RNA (mRNA), small interference RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), self-amplifying mRNA (saRNA), transactivating RNA (tracrRNA), guide RNA (gRNA), single guide RNA (sgRNA), gene editing including CRISPR RNA (crRNA), RNA component in CRISPR, DNA component in CRISPR plasmid DNA (pDNA), minicircle DNA, circular DNA (cDNA), single-stranded DNA (ssDNA), single-stranded circular DNA (circDNA), and genomic DNA (gDNA). Embodiment 70. The complex of embodiment 69, wherein the nucleic acid is mRNA. Embodiment 71. The complex of embodiment 69, wherein the nucleic acid is CRISPR RNA. Embodiment 72. The complex of embodiment 69, comprising i) a first nucleic acid encoding a nuclease, and / or ii) a guide RNA, or a second nucleic acid encoding a guide RNA. Embodiment 73. The complex of embodiment 69 or 72, comprising a single guide RNA (sgRNA) or a DNA encoding a sgRNA. Embodiment 74. The complex of embodiment 73, wherein the sgRNA targets at TTR gene, optionally wherein the sgRNA comprises a nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:2. Embodiment 75. The complex of any one of embodiments 69 or 72-74, comprising a Cas mRNA and an sgRNA. Embodiment 76. The complex of embodiment 75, wherein the weight ratio between the Cas mRNA and the sgRNA is about 0.1 to about 20, optionally about 1:1. Embodiment 77. The complex of embodiment 76, wherein the Cas is Cas9. 120ny-2728093Attorney Ref.28767-20004.40 Embodiment 78. The complex of any one of embodiments 68-77, with an N / P ratio of about 100:1 to about 1:1. Embodiment 79. The complex of embodiment 78, wherein the N / P ratio is about 3:1 to about 25:1. Embodiment 80. The complex of embodiment 78, wherein the N / P ratio is about 5:1 to about 25:1. Embodiment 81. The complex of embodiment 78, wherein the N / P ratio is about 5:1. Embodiment 82. The complex of embodiment 78, wherein the N / P ratio is about 10:1. Embodiment 83. The complex of embodiment 78, wherein the N / P ratio is about 25:1. Embodiment 84. The complex of embodiment 79, wherein the N / P ratio is about 10:1 to about 15:1. Embodiment 85. A nanoparticle composition comprising a plurality of the complexes of any of embodiments 68-84. Embodiment 86. The nanoparticle composition of embodiment 85, wherein the average particle size of the nanoparticles is about 50 nm to about 1 μm. Embodiment 87. The nanoparticle composition of embodiment 85 or 86, wherein the average particle size of the nanoparticles is about 100 nm to 150 nm. Embodiment 88. The nanoparticle composition of any one of embodiments 85-87, further comprising PEG. Embodiment 89. The nanoparticle composition of embodiment 88, wherein the PEG is DMG-PEG2000. Embodiment 90. The nanoparticle composition of any one of embodiments 85-89, further comprising a buffer, optionally an acetate buffer, a HEPES buffer, or PBS buffer. Embodiment 91. The nanoparticle composition of any one of embodiments 85-90, having a pH of about 5 to about 10. Embodiment 92. A pharmaceutical composition comprising a plurality of the complexes of any of embodiments 68-84, or the nanoparticle composition of any one of embodiments 85- 91, and a pharmaceutical excipient. Embodiment 93. A method of introducing a nucleic acid into a cell, wherein the method comprises contacting the cell with a plurality of the complexes of any of embodiments 68-84 121ny-2728093Attorney Ref.28767-20004.40 or the nanoparticle composition of any one of embodiments 85-91, or the pharmaceutical composition of embodiment 92. Embodiment 94. A method of delivering a nucleic acid into a target organ and / or tissue of a subject in need thereof, wherein the method comprises administering to the subject a plurality of the complexes of any of embodiments 68-84 or the nanoparticle composition of any one of embodiments 85-91, or the pharmaceutical composition of embodiment 92. Embodiment 95. The method of embodiment 94, wherein the target organ is selected from the group consisting of brain, heart, lungs, liver, spleen, stomach, intestines, kidneys and skeletal muscles. Embodiment 96. The method of embodiment 94, wherein the target tissue is in the eye. Embodiment 97. The method of any one of embodiments 94-96, wherein the pharmaceutical composition is administered intravenously. Embodiment 98. The method of any one of embodiments 94-96, wherein the pharmaceutical composition is administered via subretinal injection. EXAMPLE

[0223] The examples are merely intended to illustrate embodiments and are not to be construed to limit the scope herein. Example S-1: General materials and methods 1.1 Materials

[0224] All reagents and solvents were acquired from commercial sources (Sigma-Aldrich, VWR, Fisher, TCI, Oakwood Chemicals, ChemScene) and used without purification unless otherwise noted. Dialysis tubing (MWCO 1.0 kDa, Spectra / Por® 7 Dialysis Tubing) was purchased from Repligen. All consumables such as syringes, needles, syringe filters, glass vials, etc. were acquired from commercial sources (VWR, Fisher, Zoro, Chemglass). 1.2 Instruments and characterizations

[0225] NMR:1H NMR was recorded on Varian 400, 500, or 600 MHz spectrometers. Chemical shifts are reported in delta (į) units, expressed in parts per million (ppm) downfield from tetramethylsilane using protio-solvent (residual) as internal standard (CD3OD, įH = 3.31 ppm for 122ny-2728093Attorney Ref. 28767-20004.401H NMR, D2O, įH = 4.79 ppm for1H NMR). Data are reported as chemical shift (į), multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet, br = broad), and integration.

[0226] DLS and Zeta Potential: Dynamic light scattering was used to determine particle size and polydispersity on a Malvern Zetasizer Pro. Zeta potential measurements were also conducted on the same instrument. Example S-2. General synthetic procedure for homopolymerScheme 1-1 123ny-2728093Attorney Ref.28767-20004.40Scheme 1-2

[0227] General procedures for synthesizing homopolymers comprising the first repeating unit or the second repeating unit are shown in Scheme 1-1 and Scheme 1-2. The homopolymers were synthesized^following a two-step procedure. First, the polymer backbone was synthesized by Michael addition of a primary amine with a diacrylate at a 1:1 mole ratio (amine:diacrylate). The amine could comprise cationic groups, alkyl groups, alkenyl groups, other applicable groups described herein, or any combination thereof. The R5in the polymer after the first step can optionally be protected by a common protecting group. For example, when R5is -NH2, then R5(optionally protected) could be -NHBoc. Then, extra amine (used in the first step) was added to cap any free acrylate chain end. After obtaining the homopolymers, optionally the protecting groups were removed. For example, when R5is -NH2 and R5(optionally protected) is -NHBoc, then the deprotection step can be performed following Example S-5. Example S-3. General synthetic procedure of polymers with end modification 124ny-2728093Attorney Ref. 28767-20004.40Scheme 2-2

[0228] Scheme 2-1 and Scheme 2-2 show general synthetic schemes for polymers with chain- end modifications. The chain end modified polymers were synthesized following a two-step procedure. First, a acrylate-terminated polymer was synthesized by Michael addition of primary amines with diacrylates at a 1:1.2 mole ratio (amine:diacrylate). The amine could comprise cationic groups, alkyl groups, alkenyl groups, other applicable groups described herein, or any combination thereof. Then, the chain end modified polymers were obtained by addition of 125ny-2728093Attorney Ref.28767-20004.40 different kinds of amines NHREndCap1REndCap2, wherein REndCap1and REndCap2are each independently H, alkyl, alkenyl, peptide, or applicable groups described herein. REndCap1and REndCap2can be different from the amine source used in the first step, i.e., -L9-R5or R6. In Scheme 2-1, the R5in the polymer after the first step and end groups (REndCap1and REndCap2) after the second step can optionally be protected by a common protecting group. For example, when R5is -NH2, then R5(optionally protected) could be -NHBoc. After obtaining the end capped polymers, the protecting groups are removed. For example, when R5is -NH2and R5(optionally protected) is -NHBoc, then the deprotection step can be performed following Example S-5. Example S-4. General synthetic procedure of random copolymersScheme 3

[0229] Scheme 3 shows a general procedure for synthesizing random copolymers. The random copolymers were synthesized following a two-step procedure. First, the polymer backbone was synthesized by Michael addition of primary amines with diacrylates at a 1:1 mole ratio (total amines: total diacrylates), where more than one type of amines, acrylates, or both can be used. The amine source may comprise cationic groups, alkyl groups, alkenyl groups, other applicable groups described herein, or any combination thereof. Then, extra amine (used in the first step) was added to cap any free acrylate chain end. In Scheme 3, the R5in the polymer can optionally be protected by a common protecting group. For example, when R5is -NH2, then R5(optionally protected) could be -NHBoc. After obtaining the end capped polymers, the protecting groups are removed. For example, when R5is -NH2and R5(optionally protected) is -NHBoc, then the deprotection step can be performed following Example S-5. Example S-5. General procedure for Boc-deprotection 126ny-2728093Attorney Ref.28767-20004.40Scheme 4

[0230] Scheme 4 shows the general deprotection procedures for -NHBoc. Two general methods can be used. The first general method: to a solution of Boc-protected polymer dissolved in dry, degassed dichloromethane was added trifluoroacetic acid. The reaction was sealed under an inert atmosphere and stirred at room temperature for a period of time. The sample was concentrated and dried under vacuum to afford the deprotected polymer. The second general method: To a vial containing Boc-protected polymer and a stir bar was added HCl / dioxane or HCl / diethyl ether. The reaction was sealed under an inert atmosphere and stirred at room temperature for a period of time. The sample was concentrated and dried under vacuum to afford the deprotected polymer. 127ny-2728093Attorney Ref.28767-20004.40 Example S-6: Synthesis of Polymer No.5, Polymer No.7, and Polymer No.8Scheme 5

[0231] N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1.2 eq.), N-Boc-1,3- propanediamine (2, 104.5 mg, 0.60 mmol, 1 eq.), and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water mixture (4 / 1, v / v) ([M]0= 0.60 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (1 / 1, v / v) and precipitated into cold Et2O. The polymer with acrylate chain ends was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold Et2O three times, and dried under vacuum, giving a white solid (251.4 mg).

[0232] Suspended the above polymer (251.4 mg) in a MeOH / water solvent mixture (5 / 1, v / v) (0.9 mL). Then didodecylamine solution (3, 85.0 mg, 0.24 mmol, 0.4 eq.) in CH2Cl2(0.43 M) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added consecutively. The vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 24 h. Upon completion, the polymer was purified by dialysis (MWCO 1.0 kDa, Spectra / Por® 7 Dialysis Tubing) against isopropanol / DCM (2 / 1, v / v) for 16 h by changing the outside solvent in regular interval (2 times). The polymer was condensed and dried under vacuum, giving a white solid 128ny-2728093Attorney Ref.28767-20004.40 (Polymer No.5, 161.0 mg).1H NMR (600 MHz, Methanol-d4) į 3.55 – 3.47 (m, 16H), 3.09 – 3.02 (m, 7H), 2.90 – 2.69 (m, 35H), 2.55 – 2.42 (m, 11H), 2.41 – 2.31 (m, 16H), 1.69 – 1.58 (m, 8H), 1.52 – 1.40 (m, 37H), 1.37 – 1.24 (m, 36H), 0.93 – 0.87 (t, 6H). The Boc / diC12ratio (3.72:1) of the polymer was determined by comparing the signal from Boc group (1.52 – 1.40 ppm, 9H) to the signal from dodecyl group (0.93 – 0.87 ppm, 6H).

[0233] To a solution of a Boc-protected polymer (Polymer No.5, 11.5 mg) dissolved in dry, degassed dichloromethane (0.8 mL) was added trifluoroacetic acid (0.4 mL). The reaction was sealed under an inert atmosphere and stirred at room temperature for 3 h. The sample was concentrated and dried under vacuum to afford the deprotected polymer as a colorless oil (Polymer No.7, 13.4 mg).1H NMR (600 MHz, Methanol-d4) į 3.76 – 3.34 (m, 36H), 3.20 – 3.03 (m, 11 H), 3.00 – 2.64 (m, 31 H), 2.37 – 2.00 (m, 7 H), 1.91 – 1.68 (m, 4H), 1.45 – 1.23 (m, 38H), 0.93 – 0.87 (m, 6H). The NH2 / diC12 ratio determined by comparing the signal from NH2 side chain (2.37 – 2.00 ppm, 2H) to the signal from dodecyl group (0.93 – 0.87 ppm, 6H) was consistent with the Boc-protected precursor Polymer No.5.

[0234] To a vial containing Boc-protected polymer (Polymer No.5, 10.0 mg) and a stir bar was added 0.5 mL of HCl / dioxane (1.6 M). The reaction was sealed under inert atmosphere and stirred at room temperature for 4 h. The sample was concentrated and dried under vacuum to afford the deprotected polymer as a pale-yellow oil (Polymer No.8, 11.6 mg).1H NMR (500 MHz, Methanol-d4) į 3.88 – 2.54 (m, 78H), 1.96 – 1.15 (m, 40H), 0.95 – 0.84 (m, 6H). The NH2 / diC12ratio determined by comparing the signal from backbone (3.88 – 2.54 ppm, 20H from the polymer backbone and the side chain) to the signal from dodecyl group (0.95 – 0.84 ppm, 6H) was consistent with the Boc-protected precursor Polymer No.5. Example S-7: Synthesis of homopolymer Polymer No.14Scheme 6

[0235] N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq.), dodecylamine (2, 133.5 mg, 0.72 mmol, 1 eq.), and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial 129ny-2728093Attorney Ref.28767-20004.40 charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v) ([M]0 = 0.51 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra dodecylamine (2, 26.7 mg, 0.144 mmol, 0.2 eq.) in a CH2Cl2 solution (0.48 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air. The reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No.14) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white gooey solid (295.6 mg).1H NMR (500 MHz, Methanol-d4) į 3.77 – 3.41 (m, 3H), 3.20 – 2.20 (m, 12H), 1.68 – 1.42 (m, 2H), 1.42 – 1.22 (m, 18H), 0.95 – 0.87 (t, 3H). The C12 / S-S ratio (1.16:1) was determined by comparing the signal from dodecyl group (0.95 – 0.87 ppm, 3H) to the signal from backbone (3.77 – 2.20 ppm, 18H). Example S-8. Synthesis of random copolymer Polymer No.45Scheme 7-1 Polymer No.44

[0236] N,Nƍ-Bis(acryloyl)cystamine (1, 194.1 mg, 0.745 mmol, 1 eq.), N-Boc-1,3- propanediamine (2, 43.0 mg, 0.247 mmol, 0.33 eq.), dodecylamine (3, 92.9 mg, 0.501 mmol, 130ny-2728093Attorney Ref.28767-20004.40 0.66) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v^ [1]0= 0.56 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra dodecylamine (3, 16.1 mg, 0.087 mmol, 0.10 eq.) in a CH2Cl2solution (0.35 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 44) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (332.4 mg).1H NMR (600 MHz, Methanol-d4) į 3.68 – 3.39 (m, 5H), 3.18 – 2.30 (m, 18H), 1.69 – 1.58 (m, 1H), 1.55 – 1.42 (m, 5H), 1.41 – 1.23 (m, 19H), 0.96 – 0.85 (m, 3H). The Boc / C12ratio (0.38:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.42 ppm, 9H) to the signal from dodecyl group (0.96 – 0.85 ppm, 3H). Polymer No.45

[0237] To a solution of a Boc-protected polymer (Polymer No.44, 9.3 mg) dissolved in dry, degassed dichloromethane (0.6 mL) was added trifluoroacetic acid (0.3 mL). The reaction was sealed under an inert atmosphere and stirred at room temperature for 3 h. The sample was concentrated and dried under vacuum to afford the deprotected polymer as a colorless oil (Polymer No.45, 15.8 mg).1H NMR (600 MHz, Methanol-d4) į 3.79 – 3.33 (m, 8H), 3.29 – 2.61 (m, 12H), 2.29 – 2.04 (m, 1H), 1.84 – 1.57 (m, 2H), 1.48 – 1.22 (m, 18H), 0.94 – 0.86 (m, 3H). The NH2 / C12 ratio determined by comparing the signal from NH2 side chain (2.29 – 2.04 ppm, 2H) to the signal from dodecyl group (0.94 – 0.86 ppm, 3H) was consistent with the Boc- protected precursor (Polymer No.44). Polymer No.12

[0238] Polymer No.12 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 83.6 mg, 0.48 mmol, 0.67 eq.), dodecylamine (3, 44.6 mg, 0.24 mmol, 0.33), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.56 M). Additional dodecylamine (3, 13.4 131ny-2728093Attorney Ref.28767-20004.40 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.35 M) was added to cap the chain end. The polymer (Polymer No.12) was purified by precipitation from cold hexane twice, giving a white solid (188.8 mg).1H NMR (600 MHz, Methanol-d4) į 3.66 – 3.43 (m, 10H), 3.15 – 2.27 (m, 36H), 1.70 – 1.59 (m, 3H), 1.57 – 1.39 (m, 16H), 1.38 – 1.22 (m, 18H), 0.92 – 0.89 (m, 3H).The Boc / C12 ratio (1.59:1) of the product was determined by comparing the signal from Boc group (1.57 – 1.39 ppm, 9H) to the signal from dodecyl group (1.38 – 1.22 ppm, 18H). Polymer No.13

[0239] Polymer No.13 was synthesized by deprotecting 13.6 mg of Polymer No.12 using 1.4 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (22.0 mg).1H NMR (600 MHz, Methanol-d4) į 3.79 – 3.32 (m, 15H), 3.28 – 2.57 (m, 19H), 2.36 – 1.94 (m, 3H), 1.84 – 1.59 (m, 2H), 1.45 – 1.22 (m, 18H), 0.92– 0.86 (m, 3H). The NH2 / C12 ratio (1.59:1) was determined by comparing the signal from NH2side chain (2.36 – 1.94 ppm, 2H) to the signal from dodecyl group (1.45 – 1.22 ppm, 18H), which was consistent with the Boc-protected precursor (Polymer No.12). Polymer No.42

[0240] Polymer No.42 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.7 mg, 0.36 mmol, 0.5 eq.), dodecylamine (3, 66.7 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v, [1]0 = 0.55 M). Additional dodecylamine (3, 14.0 mg, 0.076 mmol, 0.10 eq.) in a CH2Cl2solution (0.35 M) was added to cap the chain end. The polymer (Polymer No.42) was purified by precipitation from cold hexane twice, giving a white solid (321.0 mg).1H NMR (600 MHz, Methanol-d4) į 3.66 – 3.43 (m, 7H), 3.22 – 2.28 (m, 24H), 1.70 – 1.57 (m, 2H), 1.55 – 1.42 (m, 9H), 1.42 – 1.23 (m, 19H), 0.95 – 0.85 (m, 3H). The Boc / C12ratio (0.75:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.42 ppm, 9H) to the signal from dodecyl group (0.95 – 0.85 ppm, 3H). Polymer No.43 Polymer No.43 was synthesized by deprotecting 15.7 mg of Polymer No.42 using 0.9 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (29.0 mg).1H NMR 132ny-2728093Attorney Ref.28767-20004.40 (600 MHz, Methanol-d4) į 3.80 – 3.33 (m, 11H), 3.29 – 2.62 (m, 16H), 2.33 – 2.02 (m, 1H), 1.85 – 1.56 (m, 2H), 1.50 – 1.21 (m, 18H), 0.93-0.86 (m, 3H).The NH2 / C12 ratio determined by comparing the signal from NH2side chain (2.33 – 2.02 ppm, 2H) to the signal from dodecyl group (0.93 – 0.86 ppm, 3H) was consistent with the Boc-protected precursor (Polymer No.42).Scheme 7-2 Polymer No.73

[0241] To the vial (7 mL) was added N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq), N-boc-1,3-propanediamine (2, 62.7 mg, 0.360 mmol, 0.5 eq), dodecylamine (3, 66.7 mg, 0.360 mmol, 0.5 eq), and triethylamine (4, 7.3 mg, 0.072 mmol, 0.1 eq.). The above reagents were suspended in a MeOH / water / CH2Cl2mixture (4 / 1 / 2, v / v / v, [1]0= 0.61 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h and then cooled down to room temperature. Additional dodecylamine (3, 13.4 mg, 0.072 mmol, 0.1 eq.) in a CH2Cl2solution (0.35 M) was added to the mixture. The vial was sealed under air and the reaction continued at 60 ^ for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer sample was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No.73) was collected by centrifugation at 3000 rpm at -10 ^ for 5 min, washed with cold hexane three times, and dried 133ny-2728093Attorney Ref.28767-20004.40 under vacuum, giving a white solid (336.2 mg).1H NMR (600 MHz, Methanol-d4) į 3.67 – 3.44 (m, 7H), 3.20 – 2.22 (m, 24H), 1.70 – 1.57 (m, 2H), 1.56 – 1.41 (m, 9H), 1.41 – 1.24 (m, 19H), 0.95 – 0.85 (t, 3H). The Boc / C12ratio (0.78:1) of the product was determined by comparing the signal from Boc group (1.56 – 1.41 ppm, 9H) to the signal from dodecyl group (0.95 – 0.85 ppm, 3H). Polymer No.80

[0242] The Boc-protected polymer Polymer No.73 (24.7 mg) was dissolved in a dry, degassed dichloromethane and trifluoroacetic acid (v / v=2 / 1, 2.5 mL) to make the concentration to be 10 mg / ml. The reaction was sealed under inert atmosphere and stirred at room temperature for 3 h. The sample was concentrated and dried under vacuum to afford the deprotected polymer as an oil (43.2 mg).1H NMR (600 MHz, Methanol-d4) į 4.00 – 3.32 (m, 14H), 3.30 – 2.63 (m, 19H), 2.26 – 2.04 (m, 2H), 1.92 – 1.67 (m, 3H), 1.44 – 1.24 (m, 21H), 0.91 – 0.88 (m, 3H). The NH2 / C12 ratio determined by comparing the signal from NH2 side chain (2.26 – 2.04 ppm, 2H) to the signal from dodecyl group (0.91 – 0.88 ppm, 3H), was consistent with the Boc-protected precursor (Polymer No.73). Polymer No.70

[0243] Polymer No.70 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq), N-boc-1,3-propanediamine (2, 114.1 mg, 0.654 mmol, 0.91 eq), dodecylamine (3, 12.1 mg, 0.066 mmol, 0.091 eq), triethylamine (4, 7.3 mg, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2, v / v / v, [M]0= 0.61 M). Additional dodecylamine (3, 13.4 mg, 0.072 mmol, 0.1 eq.) in a CH2Cl2solution (0.35 M) was added to cap the chain end. The polymer was purified by precipitation from cold hexane twice, giving a white solid (334.5 mg).1H NMR (600 MHz, Methanol-d4) į 3.63 – 3.44 (m, 22H), 3.22 – 2.28 (m, 79H), 1.84 – 1.73 (m, 2H), 1.71– 1.56 (m, 9H), 1.55 – 1.41 (m, 44H), 1.40 – 1.25 (m, 20H), 0.94 – 0.87 (t, 3H). The Boc / C12 ratio (4.69:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.41 ppm, 9H) to the signal from dodecyl group (0.94 – 0.87 ppm, 3H). Polymer No.77 134ny-2728093Attorney Ref.28767-20004.40

[0244] Polymer No.77 was synthesized by deprotecting 21.5 mg of Polymer No.70 using 2.2 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (34.2 mg).1H NMR (600 MHz, Methanol-d4) į 4.01 – 3.32 (m, 47H), 3.30 – 2.63 (m, 62H), 2.25 – 2.04 (m, 9H), 1.92 – 1.67 (m, 4H), 1.45 – 1.25 (m, 20H), 0.91 – 0.88 (m, 3H). The NH2 / C12 ratio determined by comparing the signal from NH2 side chain (2.25 – 2.04 ppm, 2H) to the signal from dodecyl group (0.91 – 0.88 ppm, 3H) was consistent with the Boc-protected precursor Polymer No.70. Polymer No.71

[0245] Polymer No.71 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq), N-boc-1,3-propanediamine (2, 104.5 mg, 0.600 mmol, 0.83 eq), dodecylamine (3, 22.2 mg, 0.12 mmol, 0.17 eq), triethylamine (4, 7.3 mg, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2, v / v / v, [M]0= 0.61 M). Additional dodecylamine (3, 13.4 mg, 0.072 mmol, 0.1 eq.) in a CH2Cl2 solution (0.35 M) was added to cap the chain end. The polymer was purified by precipitation from cold hexane twice, giving a white solid (337.7 mg).1H NMR (600 MHz, Methanol-d4) į 3.66 – 3.43 (m, 16H), 3.21 – 2.23 (m, 57H), 1.81 – 1.72 (m, 1H), 1.68 –1.57 (m, 6H), 1.55 – 1.41 (m, 29H), 1.40 – 1.24 (m, 20H), 0.94 – 0.87 (t, 3H). The Boc / C12 ratio (3.02:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.41 ppm, 9H) to the signal from dodecyl group (0.94 – 0.87 ppm, 3H). Polymer No.78

[0246] Polymer No.78 was synthesized by deprotecting 20.9 mg of Polymer No.71 using 2 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (33.9 mg).1H NMR (600 MHz, Methanol-d4) į 4.02 – 3.32 (m, 33H), 3.30 – 2.63 (m, 45H), 2.28 – 2.03 (m, 6H), 1.91 – 1.67 (m, 3H), 1.44 – 1.24 (m, 23H), 0.91 – 0.88 (m, 3H). The NH2 / C12 ratio determined by comparing the signal from NH2side chain (2.28 – 2.03 ppm, 2H) to the signal from dodecyl group (0.91 – 0.88 ppm, 3H) was consistent with the Boc-protected precursor Polymer No.71. Polymer No.72 135ny-2728093Attorney Ref.28767-20004.40

[0247] Polymer No.72 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq), N-boc-1,3-propanediamine (2, 89.6 mg, 0.514 mmol, 0.71 eq), dodecylamine (3, 38.1 mg, 0.206 mmol, 0.29 eq), triethylamine (4, 7.3 mg, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2, v / v / v, [M]0 = 0.61 M). Additional dodecylamine (3, 13.4 mg, 0.072 mmol, 0.1 eq.) in a CH2Cl2 solution (0.35 M) was added to cap the chain end. The polymer was purified by precipitation from cold hexane twice, giving a white solid (320.9 mg).1H NMR (600 MHz, Methanol-d4) į 3.68 – 3.43 (m, 11H), 3.17 – 2.30 (m, 39H), 1.81 – 1.72 (m, 1H), 1.70 – 1.56 (m, 4H), 1.55 – 1.41 (m, 18H), 1.41 – 1.23 (m, 19H), 0.95 – 0.86 (t, 3H). The Boc / C12ratio (1.82:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.41 ppm, 9H) to the signal from dodecyl group (0.95 – 0.86 ppm, 3H). Polymer No.79

[0248] Polymer No.79 was synthesized by deprotecting 21.0 mg of Polymer No.72 using 2.1 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (37.5 mg).1H NMR (600 MHz, Methanol-d4) į 4.02 – 3.32 (m, 23H), 3.30 – 2.63 (m, 31H), 2.27 – 2.02 (m, 4H), 1.92 – 1.67 (m, 3H), 1.46 – 1.23 (m, 22H), 0.91 – 0.88 (m, 3H). The NH2 / C12ratio determined by comparing the signal from NH2side chain (2.27 – 2.02 ppm, 2H) to the signal from dodecyl group (0.91 – 0.88 ppm, 3H) was consistent with the Boc-protected precursor Polymer No.72. Polymer No.74

[0249] Polymer No.74 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq), N-boc-1,3-propanediamine (2, 35.8 mg, 0.206 mmol, 0.29 eq), dodecylamine (3, 95.3 mg, 0.514 mmol, 0.71 eq), triethylamine (4, 7.3 mg, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2, v / v / v, [M]0 = 0.53 M). Additional dodecylamine (3, 13.4 mg, 0.072 mmol, 0.1 eq.) in a CH2Cl2solution (0.35 M) was added to cap the chain end. The polymer was purified by precipitation from cold hexane twice, giving a white solid (336.41 mg).1H NMR (600 MHz, Methanol-d4) į 3.69 – 3.44 (m, 5H), 3.22 – 2.24 (m, 17H), 1.72 – 1.57 (m, 1H), 1.54 – 1.43 (m, 4H), 1.42 – 1.23 (m, 19H), 0.97 – 0.85 (t, 3H). The Boc / C12ratio (0.31:1) of the product was determined by comparing the signal from Boc group (1.54 – 1.43 ppm, 9H) to the signal from dodecyl group (0.97 – 0.85 ppm, 3H). 136ny-2728093Attorney Ref.28767-20004.40 Polymer No.81

[0250] Polymer No.81 was synthesized by deprotecting 20.6 mg of Polymer No.74 using 2.1 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (37.4 mg).1H NMR (600 MHz, Methanol-d4) į 4.00 – 3.33 (m, 9H), 3.30 – 2.61 (m, 14H), 2.27 – 2.00 (m, 1H), 1.92 – 1.67 (m, 2H), 1.44 – 1.24 (m, 20H), 0.91 – 0.88 (m, 3H). The NH2 / C12ratio determined by comparing the signal from NH2side chain (2.27 – 2.00 ppm, 2H) to the signal from dodecyl group (0.91 – 0.88 ppm, 3H) was consistent with the Boc-protected precursor (Polymer No.74). Polymer No.75

[0251] Polymer No.75 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq), N-boc-1,3-propanediamine (2, 20.9 mg, 0.120 mmol, 0.17 eq), dodecylamine (3, 111.2 mg, 0.600 mmol, 0.83 eq), triethylamine (4, 7.3 mg, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2, v / v / v, [M]0 = 0.51 M). Additional dodecylamine (3, 13.4 mg, 0.072 mmol, 0.1 eq.) in a CH2Cl2solution (0.35 M) was added to cap the chain end. The polymer was purified by precipitation from cold hexane twice, giving a white solid (344.2 mg).1H NMR (600 MHz, Methanol-d4) į 3.69 – 3.44 (m, 4H), 3.25 – 2.25 (m, 15H), 1.73 – 1.59 (m, 1H), 1.57 – 1.44 (m, 2H), 1.42 – 1.23 (m, 19H), 0.97 – 0.85 (t, 3H). The Boc / C12ratio (0.14:1) of the product was determined by comparing the signal from Boc group (1.57 – 1.44 ppm, 9H) to the signal from dodecyl group (0.97 – 0.85 ppm, 3H). Polymer No.82

[0252] Polymer No.82 was synthesized by deprotecting 20.5 mg of Polymer No.75 using 2.1 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (28.5 mg).1H NMR (600 MHz, Methanol-d4) į 4.00 – 3.33 (m, 8H), 3.30 – 2.63 (m, 12H), 2.35 – 2.00(m, 1H), 1.92 – 1.66 (m, 2H), 1.44 – 1.24 (m, 20H), 0.91 – 0.88 (m, 3H). The NH2 / C12 ratio determined by comparing the signal from NH2 side chain (2.00 – 2.35 ppm, 2H) to the signal from dodecyl group (0.91 – 0.88 ppm, 3H) was consistent with the Boc-protected precursor (Polymer No.75). Polymer No.90 137ny-2728093Attorney Ref.28767-20004.40

[0253] Polymer No.90 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 41.82 mg, 0.24 mmol, 0.333 eq.), oleylamine (3, 128.4 mg, 0.48 mmol, 0.667 eq) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v^ [1]0 = 0.615 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra oleylamine (3, 19.259 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.30 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 90) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (366.6 mg).1H NMR (600 MHz, Methanol-d4) į 5.46 – 5.30 (m, 2H), 3.67 – 3.44 (m, 6H), 3.22 – 2.26 (m, 21H), 2.13 – 1.93 (m, 4H), 1.70 – 1.57 (m, 2H), 1.55 – 1.42 (m, 7H), 1.42 – 1.23 (m, 23H), 0.96 – 0.87 (m, 3H). The Boc / oleylamine ratio (0.50:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.42 ppm, 9H) to the signal from oleylamine group (5.46 – 5.30 ppm, 2H). Polymer No.91

[0254] Polymer No.91 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.8 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.73 mg, 0.36 mmol, 0.5 eq.), oleylamine (3, 96.30 mg, 0.36 mmol, 0.5 eq.) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v^ [1]0 = 0.615 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra oleylamine (3, 19.26 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.30 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 91) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (360.2mg).1H NMR (600 MHz, Methanol-d4) į 5.43 – 5.30 (m, 2H), 3.67 – 3.41 (m, 7H), 3.21 – 2.26 (m, 25H), 2.13 – 138ny-2728093Attorney Ref.28767-20004.40 1.90 (m, 4H), 1.69 – 1.58 (m, 2H), 1.55 – 1.42 (m, 10H), 1.41 – 1.23 (m, 23H), 0.95 – 0.87 (m, 3H). The Boc / oleylamine ratio (0.84:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.42 ppm, 9H) to the signal from oleylamine group (5.43 – 5.30 ppm, 2H). Polymer No.92

[0255] Polymer No.92 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.8 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 41.82 mg, 0.24 mmol, 0.333 eq.), nonylamine (3, 68.77 mg, 0.48 mmol, 0.667 eq.) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v^ [1]0= 0.615 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra nonylamine (3, 10.32 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2solution (0.35 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 92) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (315.8 mg).1H NMR (600 MHz, Methanol-d4) į 3.69 – 3.43 (m, 5H), 3.17 – 2.24 (m, 18H), 1.69 – 1.58 (m, 1H), 1.56 – 1.42 (m, 6H), 1.41 – 1.24 (m, 12H), 0.95 – 0.87 (m, 3H). The Boc / nonylamine ratio (0.39:1) of the product was determined by comparing the signal from Boc group (1.56 – 1.42 ppm, 9H) to the signal from nonylamine group (0.95 – 0.87 ppm, 3H). Polymer No.93

[0256] Polymer No.93 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.6 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.73 mg, 0.36 mmol, 0.5 eq.), nonylamine (3, 51.58 mg, 0.36 mmol, 0.5 eq.) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v^ [1]0= 0.615 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra nonylamine (3, 10.32 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2solution (0.35 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. 139ny-2728093Attorney Ref.28767-20004.40 Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 93) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (327.3 mg).1H NMR (600 MHz, Methanol-d4) į 3.69 – 3.44 (m, 7H), 3.18 – 2.28 (m, 24H), 1.68 – 1.58 (m, 2H), 1.54 – 1.41 (m, 9H), 1.40 – 1.27 (m, 12H), 0.95 – 0.86 (m, 3H). The Boc / nonylamine (0.80:1) of the product was determined by comparing the signal from Boc group (1.54 – 1.41 ppm, 9H) to the signal from nonylamine group (0.95 – 0.86 ppm, 3H). Polymer No.94

[0257] Polymer No.94 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 1880 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 41.82 mg, 0.24 mmol, 0.333 eq.), isoamylamine (3, 41.84 mg, 0.48 mmol, 0.667 eq.) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v^ [1]0 = 0.615 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra isoamylamine (3, 6.28 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.344 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 94) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (283.4 mg).1H NMR (600 MHz, Methanol-d4) į 3.69 – 3.44 (m, 6H), 3.17 – 2.24 (m, 19H), 1.78 – 1.50 (m, 2H), 1.49 – 1.41 (m, 4H), 1.41 – 1.30 (m, 2H), 0.99 – 0.89 (m, 6H). The Boc / isoamylamine ratio (0.46:1) of the product was determined by comparing the signal from Boc group (1.49 – 1.41 ppm, 9H) to the signal from isoamylamine group (0.99 – 0.89 ppm, 6H). Polymer No.95

[0258] Polymer No.95 was synthesized by using N,Nƍ-Bis(acryloyl)cystamine (1, 187.9 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.73 mg, 0.36 mmol, 0.5 eq.), isoamylamine (3, 31.38 mg, 0.36 mmol, 0.5 eq.) and triethylamine (10 ^L, 0.072 mmol, 0.1 eq.) were added into a 140ny-2728093Attorney Ref.28767-20004.40 vial charged with a stir bar. The above reagents were suspended in a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v^ [1]0= 0.615 M) and the vial was sealed with a PTFE-lined screw cap under air. The reaction was stirred at 60 °C for 48 h. Upon cooling down, extra isoamylamine (3, 6.28 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.344 M) was added into the above mixture. The vial was sealed with a PTFE-lined screw cap under air and the reaction continued at 60 °C for 24 h. Upon completion, the reaction was cooled down to room temperature. The crude polymer was diluted with CH2Cl2 / MeOH (2 / 1, v / v) and precipitated into cold hexane twice. The polymer (Polymer No. 95) was collected by centrifugation at 3000 rpm under -10 ^ for 5 min, washed with cold hexane three times, and dried under vacuum, giving a white solid (293.4mg).1H NMR (600 MHz, Methanol-d4) į 3.67 – 3.44 (m, 7H), 3.18 – 2.28 (m, 24H), 1.79 – 1.50 (m, 3H), 1.50 – 1.41 (m, 8H), 1.41 – 1.30 (m, 2H), 0.98 – 0.90 (m, 6H). The Boc / isoamylamine ratio (0.87:1) of the product was determined by comparing the signal from Boc group (1.50 – 1.41 ppm, 9H) to the signal from isoamylamine group (0.98 – 0.90 ppm, 6H). Polymer No.96

[0259] Polymer No.96 was synthesized by deprotecting 21.20 mg of Polymer No.90 using 2.1 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (35.39 mg).1H NMR (600 MHz, Methanol-d4) į 5.48 – 5.29 (m, 2H), 3.78 – 3.33 (m, 11H), 3.28 – 2.17 (m, 17H), 2.13 – 1.94 (m, 4H), 1.83 – 1.73 (m, 2H), 1.43 – 1.27 (m, 24H), 0.92 – 0.88 (m, 3H). The NH2 / oleylamine ratio (0.50:1) was determined by comparing the signal from backbone (3.78 – 2.17 ppm, 20H) to the signal from oleylamine side chain (5.48 – 5.29 ppm, 2H), which was consistent with the Boc-protected precursor (Polymer No.90). Polymer No.97

[0260] Polymer No.97 was synthesized by deprotecting 23.27 mg of Polymer No.91 using 2.3 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (42.13 mg).1H NMR (600 MHz, Methanol-d4) į 5.43 – 5.30 (m, 2H), 3.77 – 3.33 (m, 13H), 3.30 – 2.17 (m, 20H), 2.14 – 1.94 (m, 4H), 1.84 – 1.72 (m, 2H), 1.46 – 1.24 (m, 24H), 0.92 – 0.89 (m, 3H). The NH2 / oleylamine ratio (0.84:1) was determined by comparing the signal from backbone (3.77 – 2.17 ppm, 20H) to the signal from oleylamine side chain (5.43 – 5.30 ppm, 2H), which was consistent with the Boc-protected precursor (Polymer No.91). 141ny-2728093Attorney Ref.28767-20004.40 Polymer No.98

[0261] Polymer No.98 was synthesized by deprotecting 24.12 mg of Polymer No.92 using 2.4 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (45.21 mg).1H NMR (600 MHz, Methanol-d4) į 3.77 – 3.33 (m, 9H), 3.30 – 2.17 (m, 14H), 1.82 – 1.73 (m, 1H), 1.49 – 1.25 (m, 13H), 0.92– 0.89 (m, 3H). The NH2 / nonylamine ratio (0.39:1) was determined by comparing the signal from backbone (3.77 – 2.17 ppm, 20H) to the signal from nonylamine side chain (0.92– 0.89 ppm, 3H), which was consistent with the Boc-protected precursor (Polymer No. 92). Polymer No.99

[0262] Polymer No.99 was synthesized by deprotecting 24.36 mg of Polymer No.93 using 2.4 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (43.52 mg).1H NMR (600 MHz, Methanol-d4) į 3.77 – 3.32 (m, 11H), 3.30 – 1.96 (m, 18H), 1.83 – 1.65 (m, 2H), 1.50 – 1.25 (m, 14H), 0.92– 0.89 (m, 3H). The NH2 / nonylamine ratio (0.80:1) was determined by comparing the signal from backbone (3.77 – 1.96 ppm, 20H) to the signal from nonylamine (0.92– 0.89 ppm, 3H), which was consistent with the Boc-protected precursor (Polymer No.93). Polymer No.100

[0263] Polymer No.100 was synthesized by deprotecting 22.54 mg of Polymer No.94 using 2.2 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (46.04 mg).1H NMR (600 MHz, Methanol-d4) į 3.79 – 3.32 (m, 10H), 3.30 – 2.00 (m, 15H), 1.74 – 1.52 (m, 3H), 1.50 – 1.24 (m, 2H), 1.05 – 0.95 (m, 6H). The NH2 / isoamylamine ratio (0.46:1) was determined by comparing the signal from backbone (3.79 – 2.00 ppm, 20H) to the signal from isoamylamine (1.05 – 0.95 ppm, 9H), which was consistent with the Boc-protected precursor (Polymer No.94). Polymer No.101

[0264] Polymer No.101 was synthesized by deprotecting 21.35 mg of Polymer No.95 using 2.1 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (39.21 mg).1H NMR (600 MHz, Methanol-d4) į 3.77 – 3.34 (m, 12H), 3.30 – 1.99 (m, 20H), 1.73 – 1.51 (m, 3H), 1.49 – 1.24 (m, 2H), 1.04 – 0.94 (m, 6H). The NH2 / isoamylamine ratio (0.87:1) was determined by 142ny-2728093Attorney Ref.28767-20004.40 comparing the signal from backbone (3.77 – 1.99 ppm, 20H) to the signal from isoamylamine (1.04 – 0.94 ppm, 6H), which was consistent with the Boc-protected precursor (Polymer No.95). Polymer No.146

[0265] Polymer No. 146 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.9 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.92 mg, 0.36 mmol, 0.5 eq.), 3,3- Diphenylpropan-1-amine (3, 75.8 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v, [1]0 = 0.615 M). Additional 3,3- Diphenylpropan-1-amine (3, 15.21 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.36 M) was added to cap the chain end. The polymer (Polymer No.146) was purified by precipitation from cold hexane twice, giving a white solid (338.5 mg).1H NMR (600 MHz, Methanol-d4) į 7.34 – 7.09 (m, 10H), 4.18 – 3.92 (m, 1H), 3.64 – 3.42 (m, 7H), 3.16 – 2.16 (m, 26H), 1.81 – 1.55 (m, 2H), 1.52 – 1.38 (m, 8H). The Boc / 3,3-Diphenylpropan-1-amine ratio (0.83:1) of the product was determined by comparing the signal from Boc group (1.52 – 1.38 ppm, 9H) to the signal from 3,3- Diphenylpropan-1-amine (7.34 – 7.09 ppm, 10H). Polymer No.147

[0266] Polymer No. 147 was synthesized by deprotecting 25.24 mg of Polymer No. 146 using 2.5 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (53.96 mg).1H NMR (600 MHz, Methanol-d4) į 7.40 – 7.12 (m, 10H), 4.14 – 3.90 (m, 1H), 3.74 – 3.33 (m, 12H), 3.26 – 2.00 (m, 22H). The NH2 / 3,3-Diphenylpropan-1-amine ratio (0.83:1) was determined by comparing the signal from backbone (3.74 – 2.00 ppm, 20H) the to signal from 3,3- Diphenylpropan-1-amine (7.40 – 7.12 ppm, 10H), which was consistent with the Boc-protected precursor (Polymer No.146). Polymer No.148

[0267] Polymer No. 148 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 188.2 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62. 62 mg, 0.36 mmol, 0.5 eq.), 6- Aminoundecane (3, 61.57 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.615 M). Additional 6-Aminoundecane (3, 12.34 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2solution (0.36 M) was added to cap the chain end. The polymer (Polymer No. 148) was purified by precipitation from cold hexane twice, giving a 143ny-2728093Attorney Ref.28767-20004.40 white solid (108.2 mg).1H NMR (600 MHz, Methanol-d4) į 3.66 – 3.41 (m, 9H), 3.15 – 2.27 (m, 27H), 1.73 – 1.57 (m, 2H), 1.55 – 1.19 (m, 27H), 0.97 – 0.86 (m, 6H). The Boc / 6-Aminoundecane ratio (1.18:1) of the product was determined by comparing the signal from Boc group (1.55 – 1.19 ppm, 9H) to the signal from 6-Aminoundecane (0.97 – 0.86 ppm, 6H). Polymer No.149

[0268] Polymer No. 149 was synthesized by deprotecting 26.44 mg of Polymer No. 148 using 2.6 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (54.51 mg).1H NMR (600 MHz, Methanol-d4) į 3.68 – 3.32 (m, 16H), 3.30 – 2.54 (m, 22H), 2.33 – 2.06 (m, 2H), 1.75 – 1.61 (m, 4H), 1.48 – 1.31 (m, 12H), 0.96 – 0.92 (m, 6H). The NH2 / 6-Aminoundecane ratio (1.18:1) was determined by comparing the signal from backbone (3.68 – 2.54 ppm, 20H) to the signal from 6-Aminoundecane (0.96 – 0.92 ppm, 6H), which was consistent with the Boc-protected precursor (Polymer No.148). Polymer No.150

[0269] Polymer No. 150 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.7 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.91 mg, 0.36 mmol, 0.5 eq.), hexylamine (3, 36.24 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.615 M). Additional hexylamine (3, 7.29 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2solution (0.36 M) was added to cap the chain end. The polymer (Polymer No. 150) was purified by precipitation from cold hexane twice, giving a white solid (156.0 mg).1H NMR (600 MHz, Methanol-d4) į 3.65 – 3.44 (m, 7H), 3.19 – 2.30 (m, 24H), 1.70 – 1.57 (m, 2H), 1.52 – 1.28 (m, 15H), 0.97 – 0.87 (m, 3H). The Boc / hexylamine ratio (0.79:1) of the product was determined by comparing the signal from Boc group (1.52 – 1.28 ppm, 9H) to the signal from hexylamine (0.97 – 0.87 ppm, 3H). Polymer No.151

[0270] Polymer No. 151 was synthesized by deprotecting 24.28 mg of Polymer No. 150 using 2.4 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (53.59 mg).1H NMR (600 MHz, Methanol-d4) į 3.68 – 3.33 (m, 14H), 3.29 – 2.63 (m, 20H), 2.36 – 2.03 (m, 2H), 1.83 – 1.67 (m, 2H), 1.51 – 1.33 (m, 8H), 0.96– 0.91 (m, 3H). The NH2 / hexylamine ratio (0.79:1) 144ny-2728093Attorney Ref.28767-20004.40 was determined by comparing the signal from backbone (3.68 – 2.03 ppm, 20H) to the signal from hexylamine (0.96– 0.91 ppm, 3H), which was consistent with the Boc-protected precursor (Polymer No.150). Polymer No.152

[0271] Polymer No. 152 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.8 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 63.05 mg, 0.36 mmol, 0.5 eq.), N1-(Adamantan- 1-yl)ethane-1,2-diamine (3, 69.98 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v, [1]0 = 0.615 M). Additional N1- (Adamantan-1-yl)ethane-1,2-diamine (3, 13.99 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2solution (0.36 M) was added to cap the chain end. The polymer (Polymer No. 152) was purified by precipitation from cold hexane twice, giving a white solid (272.2 mg).1H NMR (600 MHz, Methanol-d4) į 3.66 – 3.43 (m, 9H), 3.14 – 2.30 (m, 30H), 2.22 – 1.58 (m, 20H), 1.50 – 1.40 (m, 9H). The Boc / N1-(Adamantan-1-yl)ethane-1,2-diamine ratio (0.86:1) of the product was determined by comparing the signal from Boc group (1.50 – 1.40 ppm, 9H) to the signal from N1- (Adamantan-1-yl)ethane-1,2-diamine (2.22 – 1.58 ppm, 15H). Polymer No.153

[0272] Polymer No. 153 was synthesized by deprotecting 25.45 mg of Polymer No. 152 using 2.5 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (54.80 mg).1H NMR (600 MHz, Methanol-d4) į 3.67 – 3.33 (m, 18H), 3.22 – 2.60 (m, 18H), 2.27 – 2.19 (m, 4H), 2.14 – 1.67 (m, 15H). The NH2 / N1-(Adamantan-1-yl)ethane-1,2-diamine ratio (0.86:1) was determined by comparing the signal from backbone (3.67 – 2.19 ppm, 20H) to the signal from N1- (Adamantan-1-yl)ethane-1,2-diamine ratio (2.14 – 1.67 ppm, 15H), which was consistent with the Boc-protected precursor (Polymer No.152). Polymer No.154

[0273] Polymer No. 154 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.8 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.42 mg, 0.36 mmol, 0.5 eq.), 3-((2- Ethylhexyl)oxy)propan-1-amine (3, 67.37 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v, [1]0 = 0.615 M). Additional 3- 145ny-2728093Attorney Ref.28767-20004.40 ((2-Ethylhexyl)oxy)propan-1-amine (3, 13.48 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.39 M) was added to cap the chain end. The polymer (Polymer No. 154) was purified by precipitation from cold hexane twice, giving a white solid (339.4 mg).1H NMR (600 MHz, Methanol-d4) į 3.66 – 3.39 (m, 9H), 3.33 – 3.28 (m, 4H), 3.17 – 2.30 (m, 24H), 1.93 – 1.23 (m, 21H), 0.98 – 0.82 (m, 6H). The Boc / 3-((2-Ethylhexyl)oxy)propan-1-amine (0.89:1) of the product was determined by comparing the signal from Boc group (1.93 – 1.23 ppm, 11H) to the signal from 3-((2-Ethylhexyl)oxy)propan-1-amine (0.98 – 0.82 ppm, 6H). Polymer No.155

[0274] Polymer No. 155 was synthesized by deprotecting 24.62 mg of Polymer No. 154 using 2.5 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (41.57 mg).1H NMR (500 MHz, Methanol-d4) į 3.81 – 2.40 (m, 34H), 2.37 – 1.82 (m, 4H), 1.64 – 1.23 (m, 9H), 0.95– 0.87 (m, 6H). The NH2 / 3-((2-Ethylhexyl)oxy)propan-1-amine ratio (0.89:1) was determined by comparing the signal from backbone (4.00 – 1.83 ppm, 20H) to the signal from 3-((2- Ethylhexyl)oxy)propan-1-amine group (0.94 – 0.87 ppm, 6H), which was consistent with the Boc- protected precursor (Polymer No.154). Polymer No.156

[0275] Polymer No. 156 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.6 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.73 mg, 0.36 mmol, 0.5 eq.), 2-Butyloctan-1- amine (3, 66.81 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.615 M). Additional 2-Butyloctan-1-amine (3, 13.48 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2solution (0.39 M) was added to cap the chain end. The polymer (Polymer No. 156) was purified by precipitation from cold hexane twice, giving a white solid (275.2 mg).1H NMR (500 MHz, Methanol-d4) į 3.76 – 3.41 (m, 8H), 3.16 – 2.11 (m, 26H), 1.68 – 1.58 (m, 2H), 1.54 – 1.14 (m, 26H), 0.99 – 0.85 (m, 6H). The Boc / 2-Butyloctan-1- amine ratio (0.95:1) of the product was determined by comparing the signal from Boc group (1.54 – 1.14 ppm, 9H) to the signal from 2-Butyloctan-1-amine (0.99 – 0.85 ppm, 6H). Polymer No.157 146ny-2728093Attorney Ref.28767-20004.40

[0276] Polymer No. 157 was synthesized by deprotecting 24.89 mg of Polymer No. 156 using 2.5 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (47.07 mg).1H NMR (500 MHz, Methanol-d4) į 3.79 – 3.32 (m, 12H), 3.30 – 2.42 (m, 18H), 2.37 – 1.66 (m, 3H), 1.52 – 1.24 (m, 16H), 0.96 – 0.89 (m, 6H). The NH2 / 2-Butyloctan-1-amine ratio (0.95:1) was determined by comparing the signal from backbone (3.79 – 2.42 ppm, 20H) to the signal from 2- Butyloctan-1-amine (0.96 – 0.89 ppm, 6H), which was consistent with the Boc-protected precursor (Polymer No.156). Polymer No.158

[0277] Polymer No. 158 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 130.5 mg, 0.5 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 44.71 mg, 0.25 mmol, 0.5 eq.), 3-amino-N-(2- ethylhexyl)propanamide (3, 50.08 mg, 0.25 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.615 M). Additional 3-amino-N- (2-ethylhexyl)propanamide (3, 10.02 mg, 0.05 mmol, 0.10 eq.) in a CH2Cl2 solution (0.32 M) was added to cap the chain end. The polymer (Polymer No.158) was purified by precipitation from cold hexane twice, giving a white solid (144.7 mg).1H NMR (600 MHz, Methanol-d4) į 3.67 – 3.43 (m, 10H), 3.23 – 2.22 (m, 37H), 1.70 – 1.58 (m, 2H), 1.52 – 1.24 (m, 21H), 0.96 – 0.87 (m, 6H). The Boc / 3-amino-N-(2-ethylhexyl)propanamide ratio (1.15:1) of the product was determined by comparing the signal from Boc group (1.70 – 1.58 ppm, 2H) to the signal from 3-amino-N-(2- ethylhexyl)propanamide (0.96 – 0.87 ppm, 6H). Polymer No.159

[0278] Polymer No.159 was synthesized by deprotecting 20.29 mg of Polymer No.158 using 2 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (36.96 mg).1H NMR (500 MHz, Methanol-d4) į 3.76 – 3.33 (m, 17H), 3.29 – 2.37 (m, 26H), 2.27 – 2.02 (m, 2H), 1.38 – 1.26 (m, 9H), 0.93– 0.87 (m, 6H). The NH2 / 3-amino-N-(2-ethylhexyl)propanamide ratio (1.15:1) was determined by comparing the signal from backbone (3.76 – 2.37 ppm, 20H) to the signal from 3-amino-N-(2-ethylhexyl)propanamide (0.93 – 0.87 ppm, 6H), which was consistent with the Boc- protected precursor (Polymer No.158). Polymer No.160 147ny-2728093Attorney Ref.28767-20004.40

[0279] Polymer No. 160 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.8 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.55 mg, 0.36 mmol, 0.5 eq.), N-(2- Hydroxyethyl)-1,3-propanediamine (3, 42.41 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2 mixture (4 / 1 / 2.1, v / v / v, [1]0 = 0.615 M). Additional N-(2-Hydroxyethyl)-1,3-propanediamine (3, 8.51 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.38 M) was added to cap the chain end. The polymer (Polymer No. 160) was purified by precipitation from cold hexane twice, giving a white solid (313.0 mg).1H NMR (500 MHz, Methanol-d4) į 3.86 – 3.42 (m, 11H), 3.23 – 2.30 (m, 35H), 1.96 – 1.56 (m, 4H), 1.51 – 1.38 (m, 9H). The Boc / N-(2-Hydroxyethyl)-1,3-propanediamine ratio (0.81:1) of the product was determined by comparing the signal from Boc group (1.51 – 1.38 ppm, 9H) to the signal from N- (2-Hydroxyethyl)-1,3-propanediamine (1.96 – 1.56 ppm, 2H). Polymer No.161

[0280] Polymer No. 161 was synthesized by deprotecting 23.84 mg of Polymer No. 160 using 2.4 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (48.68 mg).1H NMR (500 MHz, Methanol-d4) į 4.02 – 3.34 (m, 20H), 3.25 – 2.31 (m, 23H), 2.30 – 1.82 (m, 4H). The NH2 / N-(2-Hydroxyethyl)-1,3-propanediamine ratio (0.81:1) was determined by comparing the signal from backbone (4.02 – 2.31 ppm, 20H) to the signal from N-(2-Hydroxyethyl)-1,3- propanediamine (2.30 – 1.82 ppm, 2H), which was consistent with the Boc-protected precursor (Polymer No.160). Polymer No.162

[0281] Polymer No.162 as synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 187.5 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.61 mg, 0.36 mmol, 0.5 eq.), 2- Morpholinoethanamine (3, 47.11 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.615 M). Additional 2- Morpholinoethanamine (3, 9.37 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.38 M) was added to cap the chain end. The polymer (Polymer No.162) was purified by precipitation from cold hexane twice, giving a white solid (291.6 mg).1H NMR (500 MHz, Methanol-d4) į 3.82 – 3.42 (m, 14H), 3.20 – 2.29 (m, 36H), 1.83 – 1.55 (m, 2H), 1.52 – 1.39 (m, 9H). The Boc / 2- Morpholinoethanamine ratio (0.94:1) of the product was determined by comparing the signal from 148ny-2728093Attorney Ref.28767-20004.40 Boc group (1.52 – 1.39 ppm, 9H) to the signal from 2-Morpholinoethanamine unit backbone (3.82 – 2.29 ppm, 28H). Polymer No.163

[0282] Polymer No. 163 was synthesized by deprotecting 26.37 mg of Polymer No. 162 using 2.6 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (57.60 mg).1H NMR (600 MHz, Methanol-d4) į 4.03 – 3.35 (m, 25H), 3.24 – 2.16 (m, 26H), 2.16 – 1.65 (m, 2H). The NH2 / 2-Morpholinoethanamine ratio (0.94:1) was determined by comparing the signal from NH2 unit side chain (2.16 – 1.65 ppm, 2H) to the signal from 2-Morpholinoethanamine unit backbone (4.03 – 2.16, 20H), which was consistent with the Boc-protected precursor (Polymer No.162). Polymer No.164

[0283] Polymer No. 164 was synthesized by using N, Nƍ-Bis(acryloyl)cystamine (1, 188.0 mg, 0.72 mmol, 1 eq.), N-Boc-1,3-propanediamine (2, 62.73 mg, 0.36 mmol, 0.5 eq.), N-Methyl-1,3- diaminopropane (3, 31.71 mg, 0.36 mmol, 0.5 eq.), triethylamine (10 ^L, 0.072 mmol, 0.1 eq.), and a MeOH / water / CH2Cl2mixture (4 / 1 / 2.1, v / v / v, [1]0= 0.615 M). Additional N-Methyl-1,3- diaminopropane (3, 6.35 mg, 0.072 mmol, 0.10 eq.) in a CH2Cl2 solution (0.38 M) was added to cap the chain end. The polymer (Polymer No.164) was purified by precipitation from cold hexane twice, giving a white solid (284.0 mg).1H NMR (500 MHz, Methanol-d4) į 3.77 – 3.42 (m, 9H), 3.28 – 2.25 (m, 36H), 1.94 – 1.81 (m, 3H), 1.71 – 1.60 (m, 2H), 1.52 – 1.39 (m, 9H). The Boc / ^N- Methyl-1,3-diaminopropane ratio (0.91:1) of the product was determined by comparing the signal from Boc group (1.52 – 1.39 ppm, 9H) to the signal from N-Methyl-1,3-diaminopropane unit backbone (3.77 – 3.42 ppm, 23H). Polymer No.165

[0284] Polymer No. 165 was synthesized by deprotecting 21.38 mg of Polymer No. 164 using 2.1 mL dichloromethane and trifluoroacetic acid (2 / 1, v / v), giving a colorless oil (42.88 mg).1H NMR (500 MHz, Methanol-d4) į 3.77 – 3.33 (m, 15H), 3.26 – 2.28 (m, 27H), 2.27 – 1.82 (m, 4H). The NH2 / ^N-Methyl-1,3-diaminopropane ratio (0.91:1) was determined by comparing the signal from backbone (3.77 – 2.28 ppm, 20H) to the signal from N-Methyl-1,3-diaminopropane (2.27 – 1.82 ppm, 2H), which was consistent with the Boc-protected precursor (Polymer No.164). 149ny-2728093Attorney Ref.28767-20004.40 Polymer No.172

[0285] Polymer No.172 was synthesized by deprotecting of Polymer No.42. To a 7-mL vial was added 17.40 mg of Polymer No.42, added 0.1 mL DCM and 0.1 mL MeOH to fully dissolve the sample. Added 0.54 mL of HCl in Et2O solution. Observed white precipitates. Added additional 0.1 mL MeOH to fully dissolve the sample.The reaction was sealed under air and stirred at RT. Found precipitates in 10 min. Additional 0.1 mL MeOH. It turned clear but then cloudy again in a few minutes. Continued the reaction. The reaction was stopped after 3 h. The sample was concentrated by rotavap and dried under vacuum (in lyophilizer) over weekend, giving a pale-yellow oil (15.52 mg).1H NMR (500 MHz, Methanol-d4) į 3.98 – 3.37 (m, 12H), 3.28 – 2.65 (m, 17H), 2.35 – 2.08 (m, 2H), 1.94 – 1.61 (m, 2H), 1.51 – 1.20 (m, 18H), 0.98 – 0.79 (m, 3H). The NH2 / C12 ratio (0.74:1) was determined by comparing the signal from backbone (3.98 – 2.65 ppm, 20H) to the signal from dodecyl group (0.98 – 0.79 ppm, 3H), which was consistent with the Boc-protected precursor (Polymer No.42). Polymer No.173

[0286] Polymer No.173 was synthesized by deprotecting of Polymer No.44. To a 7-mL vial was added 55.48 mg of Polymer No.44, Added 0.1 mL DCM and 0.1 mL MeOH to fully dissolve the sample. Added 2.60 mL of HCl in Et2O solution. Observed white precipitates. Added an additional 0.5 mL MeOH and 0.3 mL DCM to the reaction mixture. The solution turned less cloudy. Found an oily ball at the bottom of the vial. The reaction was sealed under air and stirred at RT for 3 h 10 min. The sample was concentrated by rotavap and dried under vacuum (in lyophilizer) over weekend, giving a white solid (58.14 mg).1H NMR (600 MHz, Methanol-d4) į 3.63 – 3.34 (m, 9H), 3.29 – 2.64 (m, 14H), 2.35 – 2.08 (m, 1H), 1.94 – 1.62 (m, 2H), 1.49 – 1.23 (m, 18H), 0.95 – 0.86 (m, 3H) The NH2 / C12 ratio (0.38:1) was determined by comparing the signal from backbone (3.63 – 2.63 ppm, 20H) to the signal from dodecyl group (0.95 – 0.86 ppm, 3H), which was consistent with the Boc-protected precursor (Polymer No.44). Example S-9. Preparation and characterization of polymer / RNA complex General procedure Polymer / RNA complex preparation 150ny-2728093Attorney Ref.28767-20004.40 Method 1

[0287] A series of polymer / RNA complex solutions were prepared with molar ratios of polymer to RNA (N / P ratios) ranging from 1:1 to 100:1. To a 1.5 mL microcentrifuge tube was added indicated amount of water or buffer or other applicable media followed by RNA stock solution at room temperature. The RNA was either a single component or a premixed blend. Then various amount of polymer stock solution was added. The sample was mixed by pipetting 20 times (about 1 time / s). For experimental groups with PEG added, a solution of 25 mg / mL DMG- PEG2000 was subsequently added, mixed by pipetting 10 times. All samples were incubated at room temperature for 5 minutes and were then diluted 30 times with RNase-free water, serum- free DMEM, or PBS (1X or 10X) with a pH range from 5.0 to 9.0.

[0288] The samples were further subjected to dynamic light scattering (DLS) testing. Upon mixing thoroughly, the solution was transferred to a clear cuvette and a capillary cell to measure nanoparticle size, polydispersity, and zeta potential, respectively, using the Malvern Zetasizer Pro. For a time-course stability test, the sample was stored at room temperature for indicated time before testing by DLS. Method 2

[0289] In some studies, polymer / RNA complexes were prepared using a shaker. The polymer was diluted first in water or buffer or other applicable media, and the RNA stock solution was then added. The RNA was either a single component or a premixed blend. The solution was mixed briefly by pipetting 3 times (about 1 time / s) in each step. The sample was further mixed on a shaker (900 rpm) for 30 s at 25 ^ followed by incubating at room temperature for 5 min or another indicated time. For experimental groups with PEG additive, a solution of 25 mg / mL DMG-PEG2000 was added following the polymer sample, mixed by pipetting 3 times (about 1 time / s), before addition of RNA stock solution. Method 3

[0290] A series of polymer / mRNA complex solutions were prepared with molar ratios of polymer to mRNA (N / P ratios) ranging from 1:1 to 100:1. To a 1.5 mL microcentrifuge tube was added indicated amount of water or buffer or other applicable media followed by mRNA stock solution at room temperature. Then various amount of polymer stock solution was added. The 151ny-2728093Attorney Ref.28767-20004.40 solution was mixed for 20 s. Then 1200 ^L of RNase-free water, serum-free DMEM, or PBS with a pH range from 5.0 to 9.0 was added to dilute the sample. Upon mixing thoroughly, the solution was transferred to a clear cuvette and a capillary cell to measure nanoparticle size, polydispersity, and zeta potential, respectively, using the Malvern Zetasizer Pro. Polymer / RNA complex preparation for in vitro study

[0291] For in vitro studies performed in 96-well plates, a series of Polymer / RNA complex solutions were prepared with N / P ratios ranging from 1:1 to 100:1 (N / P ratio) as described in the general procedure shown above. The sample was then diluted with serum-free DMEM or Opti- MEM to a final dose of 10-120 ng RNA per well for cell treatment. Polymer / RNA complex preparation for in vivo study

[0292] Polymer / RNA complexes were prepared following the general procedure as detailed above. The sample was further diluted by 10X or 2X PBS (pH 7.4), giving a final 1X PBS solution. Cell culture

[0293] HEK 293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% (v / v) FBS and 1% (v / v) penicillin-streptomycin. Cells were grown at 37 °C in a 5% CO2atmosphere. Cells were seeded at a density of 10,000 cells / well in a 96-well plate for 24 hours prior to transfection.

[0294] The human hepatocellular carcinoma cell line Huh7 was cultured in DMEM media supplemented with 10% fetal bovine serum. Cells were seeded at a density of 8,000 cells / well in a 96-well plate for 24 hours prior to transfection. Lipofection

[0295] For lipofection in a 96-well plate, Huh7 cells were transfected with Lipofectamine RNAiMax (ThermoFisher) or Fugene (Sigma-aldrich) per the manufacturer's protocol. The final volume of medium plus transfection reagents is 100 ^L per well. The weight ratio between mRNA and sgRNA varied among experiments. 152ny-2728093Attorney Ref.28767-20004.40

[0296] For transfection with polymer / RNA complex in a 96-well plate, the RNA and / or DNA mixture was first diluted with indicated amount of H2O, and the polymer stock solution was then added. The sample was mixed by pipetting 20 times (about 1 time / s) and was then incubated at room temperature for 5 minutes. The sample was added to cell culture medium to a final volume of 100 ^L per well. The spacer sequence of sgRNA targeting the human or mouse TTR gene is AAAGGCUGCUGAUGACACCU or ACACAAAUACCAGUCCAGCG, respectively. The spacer sequence unequivocally determines the editing specificity in the designated species. The sgRNA were either synthesized on a 192-YiBo solid-phase synthesizer or expressed from a plasmid. The Cas9 was either in the form of mRNA from in vitro transcription or in a plasmid for mammalian cell expression. Genomic DNA extraction

[0297] The transfected cells were harvested post-transfection at 48 or 72 hours. The genomic DNA was extracted using QuickExtract DNA Extraction Solution (LGC Lucigen, Cat. QE09050) per manufacturer's protocol. Primers were designed around the target site within the gene of interest (e.g. TTR), and the genomic area of interest was amplified. Gene editing efficiency determination

[0298] Additional PCR was performed per the manufacturer's protocols (Illumina) to add chemistry for sequencing. The amplicons were sequenced on an Illumina NovaSeq 6000 instrument. The reads were aligned to a reference genome (e.g., the human reference genome (hg38) or the mouse reference genome (mm10)) after eliminating those having low quality scores. The resulting files containing the reads were mapped to the reference genome (BAM files), where reads that overlapped the target region of interest were selected and the number of wild type reads versus the number of reads which contain an insertion, substitution, or deletion was calculated. The editing efficiency is defined as the total number of sequence reads with insertions / deletions ("indels") or substitutions over the total number of sequence reads, including wild type. 153ny-2728093Attorney Ref.28767-20004.40 Biological Example B-1. in vitro mRNA delivery into cells EGFP mRNA delivery into cells

[0299] HEK 293T cells were seeded at 10000 cells / well in 100 μL DMEM supplemented with 10% (v / v) FBS and 1% (v / v) penicillin-streptomycin in black-walled 96-well plates. Cells were incubated 14-24 h at 37 ÛC (5% CO2) prior to transfection.

[0300] For transfection, the cells were washed with serum-free DMEM before treatment. The commercial transfection reagents, such as Lipofectamine™ 2000 and jetMESSENGER, were used as positive controls and prepared in serum-free DMEM per the manufacturer’s instructions. Polymer / mRNA polyplex was prepared as described above at a N / P ratio of 25. The solution was then diluted with serum-free DMEM to a final dose of 40 ng mRNA per well, all conditions in at least triplicate. The detailed formulations parameters are summarized in Table B-1. Table B-1154ny-2728093Attorney Ref.28767-20004.40

[0301] Cells were incubated with treatment for 24 h at 37 °C (5% CO2). The GFP fluorescence signals of each group were measured with a microscope and the images are shown in FIG.1. As shown in FIG.1, polymers Polymer No.9, Polymer No.11, Polymer No.7, Polymer No.8, Polymer No.13, Polymer No.43, and Polymer No.45 significantly increased mRNA transfection efficiency and expression level, while polymers Polymer No.4, Polymer No.35, Polymer No.25, Polymer No.19, Polymer No.27, and Polymer No.39 did not significantly alter the mRNA transfection efficiency or expression level. Furthermore, polymers with higher greasy lipid content (e.g., C9-C18alkyl), such as Polymer No.7, Polymer No.13, Polymer No.43, and Polymer No.45 exhibited more significant increase in mRNA transfection efficiency compared to the polymers with relatively lower or no greasy lipid content, such as Polymer No.9, Polymer No.35, and Polymer No.4 and polymers with more hydrophilic end groups such as Polymer No. 25. With a same greasy lipid structure and similar greasy lipid content, the polymer modified with didodecylamine at the chain end shows significantly higher transfection efficient than that of dodecylamine, as demonstrated by, for example, comparing Polymer No.11 with Polymer No. 27). This results clearly demonstrated that polymers with greasy lipids attached to chain ends (chain-end modifications) and dangling from the polymer backbone (random copolymers having greasy lipid side chains) can induce more efficient delivery of mRNA into cells. Additionally, increasing greasy lipid content in the polymer to some extent further improves transfection efficiency. 155ny-2728093Attorney Ref.28767-20004.40 Biological Example B-2. General procedures for in vivo mRNA delivery Animal

[0302] All animal experiments were consistent with local, state, and federal regulations as applicable. Food and water were supplied ad libitum. Female BALB / c mice (Charles River, UK) 6í8 weeks of age were placed into groups (n = 3) and housed in a fully acclimatized room. Polymer / mRNA complex formulation

[0303] Polymer / Fluc mRNA (Trilink L-7602) complexes were formulated as described below using 5 μg Fluc mRNA (1 μg / μL solution in pH 7.4 PBS) in a total formulation volume of 200 μL per mouse. Complex were mixed for 20 s, diluted by 2X PBS (pH 7.4) before i.v. injection into each of three BALB / c mice through tail vein. After various timepoints (3, 6, 12, 16 and 24 h), 100 ^L of 30 mg / mL D-luciferin prepared in 1X PBS was injected intraperitoneally, and luminescence was measured using a IVIS Lumina X5 imager (Perkin Elmer) and analyzed using LivingImage software (PerkinElmer). Mice were immediately sacrificed after various timepoints (3, 6, 12, 16 and 24 h). All major organs (brain, heart, lungs, liver, spleen, stomach, intestines, kidneys, and skeletal muscle) from two mice of each group were immediately imaged ex vivo.

[0304] Polymer samples were prepared in 5 μg / μL stock solution in H2O. The transporter stock solutions were stored at -20 ^ before use. To a 1.5 mL microcentrifuge tube was added indicated amount of water followed by 20 μL Fluc mRNA (1 μg / μL solution in pH 7.4 PBS) at room temperature. To this was added indicated amount of transporter stock solution. The solution was mixed for 20 s and diluted by 400 ^L 2X PBS (pH 7.4), giving a total volume of 800 μL. The solution was mixed thoroughly.200 μL of the solution was injected intravenously into each of three female BALB / c mice. Negative control formulation

[0305] The negative control was prepared as the following procedure. To a 1.5 mL microcentrifuge tube was added 380 ^L water and 20 μL Fluc mRNA (1 μg / μL solution in pH 7.4 PBS) at room temperature. The solution was mixed for 20 s and diluted by 400 ^L 2X PBS (pH 7.4), giving a total volume of 800 μL. The solution was mixed thoroughly.200 μL of the solution was injected intravenously into each of three female BALB / c mice. 156ny-2728093Attorney Ref.28767-20004.40 Biological Example B-3. In vivo mRNA delivery Study Design

[0306] To understand the effect of the polymers described herein on in vivo mRNA delivery efficiency, ten of the thirteen polymers tested in Example B-1 were selected and further tested in vivo. The experimental design is summarized in Table B-2. Table B-2abrain, heart, lungs, liver, stomach, spleen, kidneys, skeletal muscle, and intestines.bserves as negative control

[0307] 6-week-old female Balb / c mice were used in the in vivo study (36 animals in total). Polymer / Fluc mRNA (Trilink L-7602) complexes were formulated as shown in Table B-3. In 157ny-2728093Attorney Ref.28767-20004.40 each group, 5 μg Fluc mRNA in a total formulation volume of 200 μL was administered to each of three BALB / c mice through tail vein by i.v. injection. After 6 and 16 h of treatment, 100 ^L of 30 mg / mL D-luciferin prepared in 1× PBS was injected intraperitoneally, and the whole-body luminescence of the treated mouse was measured using an IVIS Lumina X5 imager (Perkin Elmer) and analyzed using LivingImage software (PerkinElmer). Mice were immediately sacrificed after 16 h. All major organs (brain, heart, lungs, liver, spleen, stomach, intestines, kidneys, and skeletal muscle) from two mice of each group were immediately imaged ex vivo. Table B-3aserves as negative control 158ny-2728093Attorney Ref.28767-20004.40 Results

[0308] The total luminescence of the animals treated with the polymer / mRNA complexes or the negative control in Table B-3 (Groups 1-11) is summarized in FIG.2A and FIG.2B. As shown in FIG.2A and FIG.2B, in most groups the signals were higher at 6 hours and went down a few folds at the 16-hour timepoint. Polymer No.13, Polymer No.43 and Polymer No.45 produced the brightest luminescence signals in vivo, which indicated significantly improved mRNA delivery efficiency compared to the pure mRNA negative control. Polymer No.7 and Polymer No.8 also showed brighter luminescence signals in vivo compared to the negative control, which also indicated improved mRNA delivery efficiency induced by the polymer transporters. Polymers with relatively low or no greasy lipid content (e.g., C9-C18alkyl), such as Polymer No. 9, Polymer No.11, Polymer No.35, and Polymer No.4, and polymers with more hydrophilic end groups such as Polymer No.25, all exhibited low or undetectable luminescence signal, which suggested that increasing greasy lipid content in polymer improved the polymer’s ability to transport mRNA in vivo.

[0309] Surprisingly, obvious accumulation of luminescence signals at certain organs were observed for some of the polymer transporters with various greasy lipid contents. The ex vivo imaging can further prove the organ and tissue selectivity of mRNA delivery. A summary of luminescence in different organs versus polymers used for mRNA delivery is shown in FIG.3. As indicated by FIG.3, polymers with various levels of greasy lipid contents, including Polymer No.7, Polymer No.13, Polymer No.43, and Polymer No.45, all exhibited certain level of organ selectivity for mRNA delivery. The level of selectivity varied with the structural formulae and greasy lipid contents of the polymer transporters.

[0310] The whole-body luminescence images of the mice treated with Polymer No.45 / Fluc mRNA are shown in FIG.4A, and the quantification results are summarized in FIG.4B and FIG.4C. As demonstrated in FIG.4A, lung and spleen of the treated mice clearly showed different levels of brightness, which indicated biodistribution and different levels of mRNA transfection. As shown in FIG.4B, the whole-body total luminescence of the mice treated with Polymer No.45 / Fluc mRNA complex was two orders of magnitude higher than the negative control, and as shown in FIG.4C, the luminescence of the spleen of the treated mice was more than an order of magnitude higher than that of the liver, which further elaborated the organ selectivity and extrahepatic targeting of the Polymer No.45 / Fluc mRNA for mRNA delivery. 159ny-2728093Attorney Ref.28767-20004.40

[0311] The whole-body luminescence images of the mice treated with Polymer No.43 / Fluc mRNA are shown in FIG.5A, and the quantification results are summarized in FIG.5B and FIG.5C. As demonstrated in FIG.5A, lung and spleen of the treated mice clearly showed different levels of brightness, which indicated biodistribution and different levels of mRNA transfection. As shown in FIG.5B, the whole-body total luminescence of the mice treated with Polymer No.43 / Fluc mRNA complex was two orders of magnitude higher than the negative control, and as shown in FIG.5C, the luminescence of the spleen of the treated mice was more than an order of magnitude higher than that of the liver, which further elaborated the organ selectivity and extrahepatic targeting of the Polymer No.43 / Fluc mRNA for mRNA delivery.

[0312] The whole-body luminescence images of the mice treated with Polymer No.13 / Fluc mRNA are shown in FIG.6A, and the quantification results are summarized in FIG.6B and FIG.6C. FIG.6A demonstrated the accumulation of luminescence at spleen of the treated mice, which indicated biodistribution and different levels of mRNA transfection. As shown in FIG. 6B, the whole-body total luminescence of the mice treated with Polymer No.13 / Fluc mRNA complex was about two orders of magnitude higher than the negative control, and as shown in FIG.6C, the luminescence of the spleen of the treated mice was more than an order of magnitude higher than that of the lung, and the signal from liver is almost undetectable, which further elaborated the organ selectivity and extrahepatic targeting of the Polymer No.13 / Fluc mRNA for mRNA delivery.

[0313] The whole-body luminescence images of the mice treated with Polymer No.7 / Fluc mRNA are shown in FIG.7A, and the quantification results are summarized in FIG.7B and FIG.7C. As demonstrated in FIG.7A, lung and spleen of the treated mice clearly showed different levels of brightness, which indicated biodistribution and different levels of mRNA transfection. As demonstrated in FIG.7B, the whole-body total luminescence of the mice treated with Polymer No.7 / Fluc mRNA complex was in the same order magnitude of the negative control. However, as shown in FIG.7C, the Polymer No.7 / Fluc mRNA complex exhibited lung selectivity and similar spleen selectivity, which was not observed in the negative control. This polymer / mRNA complex is spleen-lung bi-targeting. These results collectively demonstrated that by tuning lipid content and the hydrophobicity of the groups in the polymers, the mRNA delivery and transfection can be tuned, so as the targeting selectivity towards different organs. 160ny-2728093Attorney Ref.28767-20004.40 Biological Example B-4. Expanded in vivo study for mRNA delivery Study Design

[0314] To further explore the effect of the polymer transporters described herein on in vivo mRNA delivery efficiency and the organ selectivity, five polymers from Example B-3 and thirteen additional polymers were further studied. In addition, an early timepoint (t=3h) for in vivo imaging was added to examine the expression kinetics and an ex vivo imaging timepoint (t=6h) was added, where a brighter signal in the organic distribution could be observed. The detailed study design is summarized in Table B-4. For all groups, route of administration is intravenous injection, with a dose of 5 μg mRNA per animal and dose volume of 200 μL per animal. The necropsy time point and ex vivo imaging time point (numbers of animals) are 6 h (2 animals) and 12 h (1 animal) for all groups. The ex vivo imaging was carried out for brain, heart, lungs, liver, stomach, spleen, kidneys, skeletal muscle, and intestines. Table B-4161ny-2728093Attorney Ref.28767-20004.40aserves as negative controlbbrain, heart, lungs, liver, stomach, spleen, kidneys, skeletal muscle, and intestines. 162ny-2728093Attorney Ref.28767-20004.40

[0315] 8-week-old female Balb / c mice were used in the in vivo study (60 animals in total). Polymer / Fluc mRNA (Trilink L-7602) complexes were formulated as shown in Table B-5 and 5 μg Fluc mRNA in a total formulation volume of 200 μL was administered to each of three BALB / c mice through tail vein by i.v. injection. After various timepoints of treatment (3, 6, and 12 h for Group 1-6, 6 and 12 h for Group 7-19), 100 ^L of 30 mg / mL D-luciferin prepared in 1× PBS was injected intraperitoneally, and whole-body luminescence of the treated mouse was measured using a IVIS Lumina X5 imager (Perkin Elmer) and analyzed using LivingImage software (PerkinElmer). In each group, two mice were sacrificed after 6 h and one mouse was sacrificed after 12 h. All major organs (brain, heart, lungs, liver, spleen, stomach, intestines, kidneys, and skeletal muscle) were immediately imaged ex vivo. Table B-5163ny-2728093Attorney Ref.28767-20004.40aserves as negative control Results

[0316] The whole-body total luminescence imaging and quantification results for the negative control group (mRNA without polymer) are shown in FIG.8A and FIG.8B, which only had very low luminescence signals, suggesting the low level of mRNA in vivo delivery and expression without a polymer.

[0317] Quantification results for whole-body total luminescence and various organs / tissues of the mice treated with Polymer No.45 / Fluc mRNA are shown in FIG.9. As shown in FIG.9, luminescence signal was detected in spleen, lungs, liver, skeletal muscle, and heart. The expression level at spleen was about an order of magnitude higher than lungs, two orders of magnitude higher than liver, and more than two orders of magnitude higher than skeletal muscles and the negative control, indicating that Polymer No.45 / Fluc mRNA complex has superior delivery selectivity towards spleen. Surprisingly, luminescence signal was also observed in heart.

[0318] Quantification results for total luminescence and various organs / tissues in the mice treated with Polymer No.43 / Fluc mRNA and Polymer No.13 / Fluc mRNA are shown in FIG.10 and FIG.11, respectively. Similar as Polymer No.45 / Fluc mRNA, for Polymer No.43 / Fluc mRNA and Polymer No.13 / Fluc mRNA, luminescence signals were detected in spleen, lungs, liver, skeletal muscle, and heart. Highly targeted deliveries toward spleen were also observed.

[0319] Quantification results for whole-body total luminescence and various organs / tissues in the mice treated with Polymer No.7 / Fluc mRNA are shown in FIG.12A. Different from the 164ny-2728093Attorney Ref.28767-20004.40 polymers with relatively higher greasy lipid content, such as Polymer No.43, Polymer No.13, and Polymer No.45, the Polymer No.7 / Fluc mRNA complex led to similar expression levels in spleen and lungs, while much lower expression levels in liver and skeletal muscles, which suggests the bi-targeting character of the mRNA delivery achieved by Polymer No.7 / Fluc mRNA. As shown in FIG.12B, for Polymer No.8, which has the same structure but a different counteranion (Cl- rather than CF3COO-) compared to Polymer No.7, luminescence signal was only detected in spleen at the 6-hour timepoint. No specific signal was detected at 12 hours, suggesting the counterion for polymers and formulations also play a role in this targeted delivery process.

[0320] Polymers with different end groups were also tested in vivo. Changing C12H25end group to C4H9 (Polymer No.31), C6H13 (in Polymer No.19), branched C8H17 (Polymer No.21), unbranched C8H17 (Polymer No.33), C9H19 (Polymer No.39), or C18H37 (Polymer No.17) significantly decreases the delivery efficiency. For the polymer / mRNA complexes with these polymers, no specific signal was detected in spleen, liver, skeletal, or heart at any time points despite some localized higher expression level observed in stomach and / or intestine. However, surprisingly, moderate to strong luminescence signals were observed in the head of the tested mice. The whole-body luminescence imaging results for Polymer No.17 / Fluc mRNA, Polymer No.19 / Fluc mRNA, Polymer No.21 / Fluc mRNA, Polymer No.31 / Fluc mRNA, Polymer No. 33 / Fluc mRNA, and Polymer No.39 / Fluc mRNA complexes are shown in FIGs.13-18, respectively. As shown in FIGs.13-18, localized and significantly brighter signals were observed in head, which suggests that the delivery process might have entered brain of the mice and have the potential to cross the blood-brain barrier.

[0321] Polymer No.41, which had amino-modified end groups, did not lead to any significantly increased expression level in any organs or tissues, including head, at any time points. Similarly, polymers Polymer No.29, Polymer No.27, and Polymer No.39, which only have one greasy lipid chain in each end group, did not lead to significantly increased expression level in any organs or tissues, including head, at any time points, despite some localized weak signals in stomach. These observations further prove the crucial role of greasy lipid (e.g., C9-C18 alkyl) in the mRNA transporting and delivery performance of the polymers.

[0322] Polymer with end groups comprising unsaturated greasy lipid chains (e.g., C9-C18alkenyl), for example, polymer Polymer No.37, was also tested. For mice treated with Polymer 165ny-2728093Attorney Ref.28767-20004.40 No.37 / Fluc mRNA complex, no specific signal was detected in any organs at any timepoints, but some localized and relatively strong signals were observed in GI track, including small intestines and stomach. This localized GI track signal was also observed in mice treated with Polymer No.14 / mRNA complex.

[0323] In summary, the in vivo results showed direct correlation with in vitro results for most polymer / mRNA complexes. For the biodistribution, Polymer No.45, Polymer No.43 and Polymer No.13 are capable of delivering Fluc mRNA to spleen, lung, liver, and skeletal muscles with over 90% spleen targeting. Polymer No.8 shows 100% spleen targeting. Polymer No.7 and Polymer No.14 show over 40% spleen targeting.

[0324] Furthermore, homopolymers and random copolymers with greasy lipid (e.g., C9-C18alkyl) amine side chains and / or end groups described herein facilitate the mRNA delivery and expression and are efficient mRNA transporters. The chain end capping reagent can be primary or secondary amine, linear or branched amine, saturated or unsaturated (containing alkene) amine, and the type and content of the greasy lipid (e.g., C9-C18 alkyl) can significantly affect the delivery efficiency and organ / tissue selectivity. Biological Example B-5. Expanded in vitro mRNA delivery into cells

[0325] To explore the optimal greasy lipid content (e.g., C9-C18 alkyl) for efficient mRNA delivery, seven additional polymers with more finely tuned lipid content were further tested in vitro, following similar procedures and formulations as detailed in Example B-1, with the commercially available mRNA transporter JetMESSENGER as the positive control. The greasy lipid contents (e.g., C12alkyl) of the tested polymers are shown in Table B-6. Table B-6166ny-2728093Attorney Ref.28767-20004.40

[0326] The results are shown in FIG.19A. As indicated by FIG.19A increasing greasy lipid content (e.g., C12 alkyl) in the polymer to some extend can improve transfection efficiency. Compared to the commercially available mRNA transporter, JetMESSENGER, Polymer No.80, Polymer No.81, and Polymer No.82 show a little bit higher EGFP mRNA transfection efficiency; Polymer No.79, Polymer No.80, and Polymer No.81 show higher GFP signals on average. Flow cytometry results are shown in FIG.19B and FIG.19C. JetMESSENGER is a commercially available reagent and was used as positive control. As shown in FIG.19B and FIG.19C, Polymer No.80, Polymer No.81, and Polymer No.82 show over 92% transfection efficiency, which is better than JetMESSENGER. Mean GFP signals of Polymer No.79, Polymer No.80, and Polymer No.81 are significantly higher than JetMESSENGER.

[0327] All these in vitro and in vivo results collectively demonstrate that by changing the lipid structure, total lipid content, and the hydrophobicity of the groups in the polymers, the transporters have different delivery targets. By changing the formulation, the targeting site and delivery efficiency can be finely tuned. By changing the counterion of the polymer, the target site can be tuned. For the polymer transporters tested herein, the target site can be an organ, tissue, or cell. Example B-6. Nanoparticle stability in different buffers

[0328] The stability of selected polymer / mRNA nanoparticles was tested. Polymer No.43 / EGFP mRNA nanoparticles were kept at room temperature for 24 h. The samples were diluted with water or 1X PBS buffer under either an acidic or basic pH condition, and the sizes of the nanoparticles were measured by DLS. The results are shown in FIG.20A, FIG.20B, and FIG. 20C. As shown in FIG.20A, FIG.20B, and FIG.20C, Polymer No.43 / EGFP mRNA nanoparticles could maintain the size, PDI, and surface charge in basic water (pH 8.1) for 24 h. Example B-7. Preparation of Polymer / mRNA Compositions and Effects of Buffer

[0329] Polymer / mRNA Compositions prepared by Method 1 in Example S-9 and Method 2 in Example S-9 were further tested for particle size and size distribution. Further evaluated were effects of buffer on the particle size and size distribution. The size, PDI, zeta potential of 167ny-2728093Attorney Ref.28767-20004.40 Polymer No.45 / Fluc mRNA formulated at N / P of 25 and 10 in water or a pH 5.0 acetate buffer are shown in Table B-7-1. Table B-7-1. Size, PDI, zeta potential of Polymer No.45 / Fluc mRNA formulated at N / P of 25

[0330] As shown in Table B-7-1, Compared to preparation Method 1, Method 2 provided more consistent particles sizes but higher surface charges. The trends did not change when switching the formulation buffer from water to a pH 5.0 acetate buffer.

[0331] The influence of formulation buffer was further evaluated in vitro by transfecting Fluc mRNA into HEK 293T cells. The nanoparticles were formulated using Polymer No.45 with Fluc mRNA at N / P ratio of 10 and a mRNA dose of 60 ng per well (96-well plate). As shown in FIG. 21, the nanoparticle exhibited consistent transfection performance when formulated in water, 10 mM HEPES (pH 7.8), and 10 mM Acetate (pH 5.0), and the signal slightly decreased in the PBS (pH 7.4) group. Example B-8. Counteranion effect

[0332] Polymer No.43 and Polymer No.172 share the same polymer structure but comprise different counteranions. The former comprises a TFA counteranion while the latter comprises a Cl- counteranion. The nanocomplexes were prepared using the two polymers with Fluc mRNA at N / P ratio of 25 in water following Method 2 in Example S-9. Their physical properties are shown in Table B-8-1. Compared to Cl- counteranion, TFA counteranion gave smaller particle size, more consistent PDI, and lower zeta potential.

[0333] Potency test for delivering Fluc mRNA at N / P ratio of 25 was also conducted using the same nanocomplexes compositions and HEK 293T cells. As shown in FIG.22, better transfection performance was seen when TFA was the counteranion. Table B-8-1. Counteranion effects (TFA vs Cl) on nanocomplex size, PDI, and zeta potential.168ny-2728093Attorney Ref.28767-20004.40Example B-9. In Vitro mRNA Delivery Potency of Selected Polymers

[0334] The polymer potency was evaluated by delivery of EGFP mRNA into HEK 293T cells. The compositions were prepared following Table B-9-1. The results are shown in FIG.23. Polymers with greasier lipid (e.g., lipid with longer hydrocarbon chains and / or alkene moieties) showed increased transfection efficiency and EGFP mRNA expression level. For example, with similar lipid content, the signal of oleyl random copolymer (Polymer No.96) was higher than that of the dodecyl (Polymer No.81) and the nonyl one (Polymer No.98). And the signal increased with the increase of lipid content, for polymers having the same structural composition, at least demonstrated by comparing Polymer No 96 vs 97, Polymer No.98 vs 99, and Polymer No.81 vs 80. Table B-9-1. Formulation table of Polymer / EGFP mRNA at N / P of 25.

[0335] The polymer performances were also evaluated by Fluc mRNA transfection in HEK 293T cells. The nanocomplexes were prepared following Table B-9-2 and Table B-9-3. The 169ny-2728093Attorney Ref.28767-20004.40 results are shown in FIG.24A and FIG.24B. Polymers with greasier lipid (e.g., lipid with longer hydrocarbon chains and / or alkene moieties) showed higher luciferase mRNA expression level. For example, with similar lipid content, the luminescence signal of oleyl random copolymer (Polymer No.97) was higher than the dodecyl (Polymer No.43) and the isoamyl one (Polymer No.99) as shown in FIG.24A. Despite both having the same number of atoms in their side chains, Polymer No.43, which has a linear C12side chain, outperformed Polymer No.157, which has a branched C12side chain.170ny-2728093Attorney Ref.28767-20004.40Example B-10. In Vitro Gene Editing of Selected Polymers

[0336] Polymer No.43 and No.45 were tested in vitro for gene editing efficacy. The polymer / RNA complexes were formulated following the general procedure at N / P ratio of 25. The gene cargos were a mixture of Cas9 mRNA and sgRNA with various weight ratio from 0.1 to 79 and a fixed total RNA dose of 10 ng / well (96-well plates).

[0337] As shown in FIG.25A and FIG.25B, Polymer No.43 and 45 could effectively deliver Cas9 mRNA and sgRNA in a single nanoparticle. The system allows gene editing in Huh7 cells with a wide range of Cas9 mRNA : sgRNA ratio (from 0.1 to 79 as shown in FIG.25A). High genome editing efficacies were seen between 0.5 to 9 (Cas9 mRNA : sgRNA) and were used for the following dose response studies. With a fixed ratio of 9:1 and 4:1 (Cas9 mRNA : sgRNA), both Polymer No.43 and Polymer No.45 outperformed the commercially available transfection reagent, RNAiMAX. The gene editing efficiency increased with the total RNA dose and could achieve 96% at 40 ng RNA. 171ny-2728093Attorney Ref.28767-20004.40

[0338] Gene editing efficiency in Huh7 cells for transfection of Cas9 mRNA (in a plasmid for mammalian cell expression) with either chemically synthesized sgRNA or a second plasmid expressing sgRNA at N / P ratio of 25 in 100 μL of final medium volume was further summarized in Table B-10-1. Table B-10-1

[0339] In addition to RNA delivery, Polymer No.43 and 45 can also deliver DNA in the form of plasmids. In the example as shown in Table B-10-1, gene editing in cultured cell lines could be achieved by delivery of either one or two plasmids. For the one-plasmid system, one plasmid expressed Cas9 protein while sgRNA was chemically synthesized. The max gene editing efficiency was achieved at 60 ng of total DNA per well.

[0340] For the two-plasmids system, one plasmid expressed Cas9 protein while the other expressed sgRNA. The max gene editing efficiency was achieved at 36 ng of total DNA and RNA per well.

[0341] For both systems, the editing performance of Polymer No.43 and No.45 outperformed a commercial transfection reagent (fugene) under the same conditions. 172ny-2728093Attorney Ref.28767-20004.40 Example B-11. Effect of PEG on polymer / RNA nanoparticle stability and in vitro gene editing efficiency

[0342] Nanoparticles (Polymer / RNA) with addition of 0%, 1%, and 3% PEG (% (v / v) of 25 mg / ml DMG-PEG2000 stock relative to the total volume of the formulation) at N / P ratio of 25 were prepared and stored over 120 h at room temperature. The RNA was a mixture of Cas9 mRNA and sgRNA at a w / w ratio of 1:1. The sample was diluted with 1X PBS 30 times for DLS measurements. The results are shown in FIG.26A and FIG.26B.

[0343] The gene editing efficiency (in percentage) in Huh7 cells for transfection of Cas9-mRNA and sgRNA using of Polymer No.43 with or without 1% DMG-PEG-2000 at N / P ratio of 5 or 25 was further measured, and the results were summarized in Table B-11-1. The RNA was a mixture of Cas9 mRNA and chemically synthesized sgRNA at w / w ratio of 2:1. Table B-11-1

[0344] As demonstrated in FIG.26A and FIG.26B, adding 1% or 3% PEG allowed for greater stability in particle size and PDI over an extended period compared to nanoparticles containing only polymer materials. Under the same storage conditions, the control group for both Polymer No.43 and Polymer No.45 without PEG (0% PEG) exhibited a noticeable increase in nanoparticle size and PDI with increasing time of storage at room temperature. In contrast, nanoparticles protected with 1% or 3% PEG showed no significant change in particle size over a period of 120 hours, and the PDI remained below 0.2. Therefore, the addition of PEG allowed polymer nanoparticles to maintain their initial properties more effectively, enhancing the physical stability of the nanoparticles. Table B-11-1 further shows that under otherwise similar conditions, adding PEG increases the gene editing efficiency in vitro. Similarly, compositions with N / P ratio of 5 also showed significant improvements in gene editing efficacy with PEG added. 173ny-2728093Attorney Ref.28767-20004.40 Example B-12. Evaluation of safety in mice

[0345] CD-1 Mice (females aged approximately 10 weeks) were administrated with a mixture of two nanoparticle compositions, 43 / / 45(Cas9 / sgRNA), prepared using Polymer No.43 and Polymer No.45, respectively, and Cas9 / sgRNA. The gene cargos were a mixture of Cas9 mRNA and sgRNA (C188) at a 3:1 weight ratio,...

Claims

Attorney Ref.28767-20004.40 CLAIMS 1. A cationic polymer comprising n unit(s) of a first repeating unit of Formula (Ia) and m unit(s) of a second repeating unit of Formula (IIa):or a salt thereof, wherein L1, L2, L3, L4, L5, L6, L7and L8are each independently -O-, -NH-, optionally substituted C1-C12 alkylene, optionally substituted C2-C12 alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6 cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9 is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H, optionally substituted C1-C12alkyl, or a protecting group; R6is optionally substituted C3-C20 alkyl or optionally substituted C3-C20 alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end- capped by at least one capping group selected from the group consisting of optionally substituted C3-C18alkyl, optionally substituted C3-C18alkenyl and a peptide. 179ny-2728093Attorney Ref.28767-20004.40 2. The cationic polymer of claim 1, or a salt thereof, wherein R6is C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH- (C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle.

3. The cationic polymer of claim 1 or 2, comprising n unit(s) of a first repeating unit of Formula (I) and m unit(s) of a second repeating unit of Formula (II):wherein L1, L2, L3, L4, L5, L6, L7and L8are each independently -O-, -NH-, optionally substituted C1-C12 alkylene, optionally substituted C2-C12 alkenylene, optionally substituted C2-C12 alkynylene, optionally substituted C3-C6cycloalkylene, optionally substituted 3 to 8 membered heterocyclylene, optionally substituted C6-C12arylene, or optionally substituted 5 to 10 membered heteroarylene; L9 is a bond or a bifunctional linker capable of forming a chemical bond with the nitrogen and R5; R1, R2, R3and R4are each independently H, optionally substituted C1-C12 alkyl, optionally substituted C2-C12 alkenyl, or optionally substituted C2-C12 alkynyl; R5is H, -ORa, -COORa, or NRaRb, wherein Raand Rbare each independently H or optionally substituted C1-C12 alkyl; R6is C3-C18 alkyl or C3-C18 alkenyl; n is an integer from 0 to 500; and m is an integer from 0 to 500; 180ny-2728093Attorney Ref.28767-20004.40 provided that at least one of m and n is not 0, and when m or n is 0, the cationic polymer is end- capped by at least one capping group selected from the group consisting of C3-C18 alkyl, C3-C18 alkenyl and a peptide.

4. The cationic polymer of any one of claims 1-3, wherein L1-L8 are ethylene.

5. The cationic polymer of any one of claims 1-4, wherein L9is C1-C6alkylene, C2-C6PEGylated linker, or a peptide linker.

6. The cationic polymer of claim 5, wherein L9is propylene.

7. The cationic polymer of any one of claims 1-6, wherein R5is NRaRb.

8. The cationic polymer of any one of claims 1-7, wherein R1, R2, R3, and R4are H.

9. The cationic polymer of any one of claims 1-8, wherein R6is C9-C18alkyl or C9-C18alkenyl.

10. The cationic polymer of claim 9, wherein R6is C12-C18 alkyl.

11. The cationic polymer of any one of claims 1-10, wherein n is an integer from 1 to 100.

12. The cationic polymer of any one of claims 1-11, wherein m is an integer from 1 to 100.

13. The cationic polymer of any one of claims 1-12, wherein the ratio of n to m is in a range of about 0.3 to about 0.

8.

14. The cationic polymer of any one of claims 1-13, wherein m is 0 or n is 0, and the cationic polymer is a homopolymer; or m is an integer from 1 to 20, n is an integer from 1 to 20, and the cationic polymer is a block copolymer, or a random copolymer. 181ny-2728093Attorney Ref.28767-20004.40 15. The cationic polymer of any one of claims 1-14, wherein the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18 alkenyl or a peptide;optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide; provided that, when EG1is NRARB, thenleast one of RA, RB, RD, and REis optionally substituted C1-C18alkyl, optionally substituted C3-C18alkenyl, or a peptide; and 182ny-2728093Attorney Ref.28767-20004.40 when EG1is SRC, thenleast one of RCand RFis optionally substituted C1-C18 alkyl, optionally substituted C3-C18 alkenyl, or a peptide.

16. The cationic polymer of claim 15, or a salt thereof, wherein RD, RE, and RFare each independently H, C1-C20 alkyl or C3-C20 alkenyl, each of which is unsubstituted, or substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6- membered heterocycle.

17. The cationic polymer of any one of claims 1-16, wherein the cationic polymer further comprises two end groups EG1and EG2, wherein end group EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide;C3-C18alkyl, C3-C18alkenyl or a peptide; provided that, 183ny-2728093Attorney Ref.28767-20004.40alkyl, C3-C18 alkenyl, or a peptide; and when EG1is SRC, then least one oCf R and RFis C3-C18 alkyl, C3-C18 alkenyl, or a peptide.

18. The cationic polymer of claim 1, comprising a structural unit of Formula (A)(A), wherein n is an integer from 1 to 500; m is an integer from 1 to 500; and wherein each of the n unit(s) of the first repeating unit and each of the m unit(s) of the second repeating unit are connected in a random sequence; and wherein the first repeating unit and the second repeating unit are as defined in any of the preceding claims.

19. The cationic polymer of claim 18, being a polymer of Formula (Aa)wherein RAis H or C12H25; RBis C12H25; RDis H, C12H25; and REis C12H25, C12-C18alkenyl, or C1-C8alkyl substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), - 184ny-2728093Attorney Ref.28767-20004.40 NH(C1-C20 alkyl), -NH(C6-C14 cycloalkyl), -C(O)NH-(C1-C20 alkyl), -NH(C1-C20 alkyl-OH), or 5- to 6-membered heterocycle.

20. The cationic polymer of claim 18 or 19, being a polymer of Formula (A-1)(A-1) wherein RAis H or C12H25; RBis C12H25; RDis H or C12H25; and REis C12H25.

21. The cationic polymer of claim 20, wherein RAis H; RBis C12H25; RDis H; and REis C12H25, C12-C18 alkenyl, or C1-C8 alkyl substituted with one or more independently selected phenyl, -O-(C1-C20alkyl), -NH(C1-C20alkyl), -NH(C6-C14cycloalkyl), -C(O)NH-(C1-C20alkyl), -NH(C1-C20alkyl-OH), or 5- to 6-membered heterocycle.

22. The cationic polymer of any one of claims 18-21, wherein RAis H; RBis C12H25; RDis H; and REis C12H25.

23. The cationic polymer of any one of claims 18-22, wherein the first repeating unit is of Formula (I-1) and the second repeating unit is of Formula (II-1),wherein L9, R5, and R6are as defined in any of the preceding claims.

24. The cationic polymer of any one of claims 18-23, wherein the first repeating unit is of Formula (I-2) and the second repeating unit is of Formula (II-2), 185ny-2728093Attorney Ref.28767-20004.4025. The cationic polymer of any one of claims 18-24, wherein the ratio of n to m is about 0.3 to about 0.

8.

26. The cationic polymer of any one of claims 1-18, n is 0 and wherein the cationic polymer comprises a Formula (B)wherein m is an integer from 1 to 500; and wherein L5, R3, L6, L7, R4, L8, and R6are as defined in any one of claims 1-31.

27. The cationic polymer of claim 26, wherein the cationic polymer has Formula (B-1)28. The cationic polymer of claim 26 or 27, wherein the cationic polymer is of Formula (B-2)(B-2), wherein m is an integer from 1 to 100. 186ny-2728093Attorney Ref.28767-20004.40 29. The cationic polymer of any one of claims 26-28, wherein m is about 10 to 100.

30. The cationic polymer of any one of claims 1-18, wherein m is 0, and the cationic polymer is of Formula (C)wherein EG1is NRARBor SRC, wherein RA, RB, and RCare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, provided that RAand RBare not both H; wherein EG2iswherein RD, RE, and RFare each independently H, C3-C18alkyl, C3-C18alkenyl or a peptide, provided that RDand REare not both H; n is an integer from 1 to 500; and wherein L1, R1, L2, L3, R2, and L4 are as defined in claim 1.

31. The cationic polymer of claim 30, being a polymer of Formula (C-2)(C-2), wherein RA, RB, RD, and REare each independently H, C3-C18alkyl, or C3-C18alkenyl, provided that RAand RBare not both H, and RDand REare not both H. 187ny-2728093Attorney Ref.28767-20004.40 32. The cationic polymer of claim 31, wherein RA, RB, RCand RDare each independently selected C3-C18alkyl.

33. The cationic polymer of claim 32, wherein the C3-C18 alkyl is C12H25.

34. The cationic polymer of any one of claims 30-33, wherein n is an integer from 1 to 100.

35. The cationic polymer of claim 1, or a salt thereof, selected from the group consisting of polymer in Table 1.

36. The cationic polymer of claim 1, selected from the group consisting of polymer No.5, No.6, No.7, No.8, No.9, No.10, No.11, No.12, No.13, No.14, No.16, No.17, No.18, No.19, No.20, No.21, No.22, No.23, No.24, No.25, No.26, No.27, No.28, No.29, No.30, No. 31, No.32, No.33, No.34, No.35, No.36, No.37, No.38, No.39, No.40, No.41, No.42, No.43, No.44, No.45, No.70, No.71, No.72, No.73, No.74, No.75, No.76, No.77, No. 78, No.79, No.80, No.81, No.82, No.83, No.90, No.91, No.92, No.93, No.94, No.95, No.96, No.97, No.98, No.99, No.100, No.101, No.146, No.147, No.148, No.149, No. 150, No.151, No.152, No.153, No.154, No 155, No.156, No.157, No.158, No.159, No. 160, No.161, No.162, No.163, No.164, No.165, No.172, and No.173 in Table 1.

37. The cationic polymer of any one of claims 1-3, or a salt thereof, wherein the polymer is Polymer No.43 or Polymer No.45 in Table 1.

38. The cationic polymer of any one of claims 1-37, further comprising an anion.

39. The cationic polymer of claim 38, wherein the anion is trifluoroacetate or chloride.

40. A complex comprising the cationic polymer of any of claims 1-39, and a nucleic acid non- covalently bound to the cationic polymer. 188ny-2728093Attorney Ref.28767-20004.40 41. The complex of claim 40, wherein the nucleic acid is selected from the group consisting of messenger RNA (mRNA), small interference RNA (siRNA), short hairpin RNA (shRNA), micro RNA (miRNA), self-amplifying mRNA (saRNA), transactivating RNA (tracrRNA), guide RNA (gRNA), gene editing including CRISPR RNA (crRNA), RNA component in CRISPR, DNA component in CRISPR, plasmid DNA (pDNA), minicircle DNA, circular DNA (cDNA), single-stranded DNA (ssDNA), single-stranded circular DNA (circDNA), and genomic DNA (gDNA).

42. The complex of claim 40, comprising i) a first nucleic acid encoding a nuclease, and / or ii) a guide RNA, or a second nucleic acid encoding a guide RNA.

43. The complex of any one of claims 40-42, wherein the N / P ratio is about 3:1 to about 25:

1.

44. A nanoparticle composition comprising a plurality of the complexes of any of claims 40-43.

45. The nanoparticle composition of claim 44, wherein the average particle size of the nanoparticles is about 50 nm to 500 nm.

46. The nanoparticle composition of claim 44 or 45, further comprising PEG.

47. A pharmaceutical composition comprising a plurality of the complexes of any of claims 40- 43, or the nanoparticle composition of any one of claims 44-46, and a pharmaceutical excipient.

48. A method of introducing a nucleic acid into a cell, wherein the method comprises contacting the cell with a plurality of the complexes of any of claims 40-43 or the nanoparticle composition of any one of claims 44-46, or the pharmaceutical composition of claim 47.

49. A method of delivering a nucleic acid into a target organ and / or tissue of a subject in need thereof, wherein the method comprises administering to the subject a plurality of the 189ny-2728093Attorney Ref.28767-20004.40 complexes of any of claims 40-43 or the nanoparticle composition of any one of claims 44- 46, or the pharmaceutical composition of claim 47.

50. The method of claim 49, wherein the target organ is selected from the group consisting of brain, heart, lungs, liver, spleen, stomach, intestines, kidneys and skeletal muscles.

51. The method of claim 49, wherein the target tissue is in the eye. 190ny-2728093

Citation Information

Patent Citations

  • sgRNA and method for specifically activating human RSPO2 gene with CRISPR-Cas9 and application thereof

    US11015193B2

  • Polymeric composition

    WO2021069920A1